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General introduction
1
Worldwide, life-expectancy is increasing and populations are aging.1 This will lead to 
an increased prevalence of age-related diseases. Peripheral neuropathy is one of such 
diseases. However, despite the high frequency of occurrence and the impact on the 
individual patient, epidemiological data on peripheral neuropathies in scarce and public 
awareness is limited.
Peripheral neuropathy encompasses a spectrum of clinical syndromes that result 
in injury to axons or the myelin sheath of nerves of the peripheral nervous system. In 
general, this peripheral nerve injury leads to sensory disturbances, such as numbness 
and tingling or prickling sensations, often accompanied by neuropathic pain and motor 
symptoms, such as cramps, muscle wasting and especially muscle weakness. Peripheral 
neuropathy comprises radiculopathies, mononeuropathies, multifocal neuropathies 
and polyneuropathies. The most prominent symptoms and signs depend on the type 
and location of the neuropathy (Figure 1).
Ocular nerve palsy
Radial nerve compression
         Site of compression:
            - Spiral groove
Median nerve compression
         Sites of compression:
            - Pronator teres muscles
            - Carpal tunnel
Ulnar nerve compression 
         Sites of compression:
            - Cubital tunnel
            - Guyon’s canal
Meralgia paraesthetica
         Site of compression:
            - Inguinal ligament
Common peroneal nerve compression
         Site of compression:
            - Fibula head
Posterior tibial nerve compression
         Site of compression:
            - Tarsal tunnel
Facial nerve palsy
Length-dependent polyneuropathy:
chronic (idiopathic) axonal 
polyneuropathies, associated with 
diabetes, toxins, nutritional deficiencies
Mononeuropathies Polyneuropathies
Proximal predominant weakness:
Guillain-Barré syndrome, porphyria 
and chronic inflammatory 
demyelinating polyneuropathy 
(CIDP)
Figure 1. overview of peripheral neuropathies
(Hanewinckel et al. Handbook of Clinical Neurology: Neuroepidemiology, 2016)
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This thesis focusses on chronic polyneuropathy, which is the most common age-related 
disorder of the peripheral nervous system. Chronic polyneuropathy is typically charac-
terized by a gradual onset (over more than six weeks) of mostly sensory symptoms that 
usually start distally in the feet. As the disease progresses, generally over the course 
of months to years, these symptoms often ascend into the legs and also appear in 
the hands, leading to a symmetrical stocking and glove-like distribution of symptoms 
(Figure 1). Besides numbness, pain and paresthesia, patients often experience foot 
drop due to distal muscle weakness, unsteadiness in walking due to sensory ataxia and 
sometimes also symptoms of autonomic dysfunction, such as impotence, constipation 
and orthostatic hypotension. These symptoms of peripheral nerve dysfunction can lead 
to severe mobility problems and a reduced quality of life.2-4
Neurological examination of a patient with polyneuropathy usually shows decreased 
or absent sensation of touch, pin prick and vibration, reduced proprioception, decreased 
or absent tendon reflexes, and mild to moderate muscle weakness, all with a proximal 
to distal gradient. In clinical practice, the diagnosis of chronic polyneuropathy is made 
based on the combination of symptoms and signs, which is often complemented with 
nerve conduction studies. In case of an axonal polyneuropathy (which is the most fre-
quent form of polyneuropathy) these typically show a decline in nerve action potential 
amplitudes in both sensory and motor nerves, especially in distal parts of the limbs 
(Table 1 and Figure 2).5, 6
The described phenotype is that of the most common type of chronic polyneuropathy. 
This length-dependent polyneuropathy results from irreversible axonal degeneration of 
peripheral nerves. Polyneuropathy can also present more acutely with more prominent 
muscle weakness due to immune-mediated demyelination of peripheral nerves (Table 1 
table 1. Typical clinical and electrophysiological findings in axonal and demyelinating polyneuropathies
type symptoms signs nerve conduction studies
Axonal 
polyneuropathy
Usually slowly progressive, 
distal symmetric sensory-
predominant symptoms 
(numbness, tingling, pain). 
Muscle weakness occurs but 
often is relatively mild
Reduced or absent sensation 
of touch, vibration, pinprick, 
reduced or absent distal 
(Achilles) tendon reflexes, 
distal muscle weakness, 
sensory ataxia
Distal amplitudes: decreased
Distal latency: normal
Conduction velocity: normal
Conduction block: absent
Temporal dispersion: absent
Demyelinating 
polyneuropathy
More often proximal, 
primarily motor symptoms 
with mild to very severe 
muscle weakness. Usually 
mild sensory symptoms. 
Often a more acute onset 
and a more progressive or a 
relapsing course (in CIDP)
Proximal (or distal) muscle 
weakness, mild sensory 
deficits, absent tendon 
reflexes, sometimes cranial 
nerve deficits
Distal amplitudes: normal
Distal latency: prolonged
Conduction velocity: slowed
Conduction block: present
Temporal dispersion: present
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and Figure 2). The clinical features of a demyelinating polyneuropathy can range from 
a very acute, potentially life-threatening disorder with severe muscle weakness as oc-
curs in Guillain-Barré syndrome (acute inflammatory demyelinating polyneuropathy or 
AIDP), to a more chronic relapsing-remitting or slowly progressive neuropathy with also 
prominent proximal weakness as is observed in chronic inflammatory demyelinating 
polyneuropathy or CIDP (see also Figure 1).7, 8 The prevalence and incidence of demy-
elinating polyneuropathies is much lower than chronic axonal polyneuropathies. In 
contrast to axonal degeneration, demyelination however can be reversible, and patients 
with a demyelinating polyneuropathy usually respond to treatment. Unfortunately, 
treatment of chronic axonal polyneuropathy currently is mainly symptomatic, with a 
focus on physiotherapy, rehabilitation and treatment of neuropathic pain.
Chronic axonal polyneuropathy is one of the most commonly encountered diseases in 
neurological practice and is associated with significant morbidity, and even mortality.10 
Yet, the exact prevalence and incidence is unknown. Based on general practitioner and 
hospital registries, it is estimated that approximately 4% of elderly people suffer from 
A
2. Demyelinating polyneuropathy
3. Axonal polyneuropathy
1. Normal nerve conduction
Distal
Distal
Distal
Proximal
Proximal
B
Proximal
Latency
Amplitude
Duration
Prolonged latency and slowed 
velocity
Figure 2. demyelinating and axonal polyneuropathy (adapted from van Doorn et al.9). Panel A shows 
the two different types of polyneuropathy: demyelinating (destruction of the myelin sheath surrounding 
the axon) and axonal (degeneration of the axon itself ) polyneuropathy. Panel B shows the typical nerve 
conduction findings in these neuropathies. B1 shows normal nerve conduction studies. B2 shows the char-
acteristics in demyelinating neuropathy: prolonged distal latency, slowed conduction velocity, temporal 
dispersion (longer duration and lower amplitude of the action potential on proximal stimulation) and con-
duction block (drop in amplitude when comparing proximal to distal stimulation). B3 shows the character-
istics in axonal polyneuropathy: reduced distal and proximal action potential amplitudes.
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14
polyneuropathy, with an estimated 77 new cases per 100 000 persons per year.11, 12 How-
ever, due to underreporting and underdetection, the true burden of polyneuropathy is 
likely underestimated in these studies.
Chronic polyneuropathy is a heterogeneous disease with over a hundred putative causes 
or risk factors.13 These causes and risk factors have emerged from hospital-based studies 
and include diabetes mellitus, vitamin deficiencies, toxic factors (alcohol, chemotherapy 
and other drugs), end-stage kidney disease, hereditary factors, and immune-mediated 
factors, among others. Aside from symptomatic treatment, removing any toxic fac-
tors and treating vitamin deficiencies or underlying diseases if these are present is 
appropriate. However, despite an extensive diagnostic work-up the cause of chronic 
polyneuropathy remains unexplained in 25-30% of cases.14 These patients are generally 
diagnosed with chronic idiopathic axonal polyneuropathy (CIAP).15, 16
Diabetes mellitus is considered to be the most important known risk factor for 
polyneuropathy. About one third of all chronic polyneuropathy cases is attributed to 
diabetes.14 However, it is remarkable that only half of all diabetics develop polyneu-
ropathy, suggesting that additional factors must be involved.17 Accumulating evidence 
suggests that dyslipidemia, obesity, hypertension and other cardiovascular risk factors 
play an important role in the pathophysiology of micro- and macrovascular complica-
tions of diabetes, such as polyneuropathy.17-20 Similarly, these factors have increasingly 
been associated with CIAP in recent uncontrolled and case-controlled studies.14, 15, 21, 22 
Axonal degeneration currently is irreversible and therefore curative options do not (yet) 
exists. This underlines the relevance to identify modifiable risk factors that can serve 
as a target for therapeutic and potential preventive strategies. If vascular or metabolic 
factors indeed increase the risk of polyneuropathy, optimal treatment of these factors 
may, in part, prevent the occurrence or progression of polyneuropathy. Along with a 
more comprehensive investigation of these vascular and metabolic factors, the search 
for other potential risk factors must also continue, to further elucidate the etiology of 
chronic polyneuropathy and especially CIAP. Ideally, potential risk factors need to be 
investigated in population-based settings to overcome methodological limitations of 
hospital-based studies, the most important being selection bias.
Unfortunately, the absence of a simple gold standard test for the diagnosis of poly-
neuropathy makes it a quite challenging disease to investigate in population-based 
research settings. Preferably, the diagnosis should be based on medical history, full 
neurological examination and nerve conduction studies, similar to clinical neurological 
practice.5 This complex diagnostic procedure however is costly and time-consuming, 
and difficult to implement in large cohort studies utilizing an in-person screening. 
This probably explains why large population-based cohort studies focused on poly-
neuropathy are lacking. Other, simplified methods have been developed to screen for 
15
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polyneuropathy in high-risk patients, but there are several downsides of these simplified 
methods, which are discussed extensively in the next chapter.
Despite these complexities, we were able to implement an extensive in-person 
screening for polyneuropathy in a population-based study. This screening consists 
of an assessment of symptoms using a questionnaire, an assessment of signs with a 
short neurological examination of the legs, and also a short non-invasive nerve con-
duction protocol. The results of all individual participants are subsequently discussed 
by an expert panel. This screening provides information about important clinical and 
electrophysiological parameters to be able to diagnose chronic axonal polyneuropathy. 
The development and usage of this screening protocol in a population-based study is 
further detailed throughout this thesis.
sCoPe And outline oF tHesis
The overall aim of this thesis is to extend the epidemiological knowledge on chronic 
axonal polyneuropathy and on chronic idiopathic axonal polyneuropathy (CIAP) in 
particular. More specifically, the aims of the studies described in this thesis are:
1. To develop a sensitive screening protocol for chronic polyneuropathy that can be 
utilized in the general population.
2. To describe the prevalence of chronic polyneuropathy and especially CIAP in the 
general population.
3. To investigate the association of prediabetes, metabolic syndrome and its separate 
components with polyneuropathy and peripheral nerve function.
4. To investigate the effects of age, height, weight, and several metabolic factors on 
peripheral nerve function in persons yet without polyneuropathy.
5. To investigate to what extent polyneuropathy affects daily functioning, gait patterns 
and the risk of falls.
The research of most studies in this thesis is embedded within the epidemiological 
framework of the Rotterdam Study, a large prospective population-based cohort study 
that aims to investigate prevalence, incidence and determinants of various chronic dis-
eases in the elderly.23 Until the work described in this thesis, the main neurological focus 
of the study has been on cerebrovascular and neurodegenerative diseases, like stroke, 
dementia and Parkinson’s disease. In 2013, an extensive in-person screening protocol for 
polyneuropathy has been added to the core protocol of the Rotterdam Study. Details of 
this screening procedure are described in chapter 3.2.
Chapter 1
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In Chapter 2 of this thesis, polyneuropathy screening methods that can be applied 
in research settings are described. In Chapter 2.1 several questionnaires and scoring 
systems that have previously been developed with the aim to identify patients with 
polyneuropathy in high-risk populations, such as diabetics or patients receiving che-
motherapy, are summarized. Chapter 2.2 delineates which neuropathic symptoms are 
most informative for the diagnosis of polyneuropathy. The development of new, simple 
questionnaire that can help to distinguish persons with polyneuropathy from persons 
without polyneuropathy is also described in this chapter.
Chapter 3 comprises studies that describe the prevalence of polyneuropathy in the 
general population. In Chapter 3.1 data are reviewed from previous studies that esti-
mated the prevalence of polyneuropathy in the general population. Limitations of these 
studies are also discussed in this chapter. Next, the overall and age- and sex-specific 
prevalence of polyneuropathy in the population-based Rotterdam Study are presented 
in Chapter 3.2. Putative causes and the proportion of idiopathic cases, as well as the 
underreported nature of polyneuropathy are also addressed in this chapter.
In Chapter 4 potential risk factors for polyneuropathy are explored. In Chapter 
4.1 the association of prediabetes and metabolic syndrome with polyneuropathy and 
peripheral nerve function is examined. Early effects of age, height and several metabolic 
factors, like obesity, kidney disease, and liver dysfunction on peripheral nerve function 
in persons yet without polyneuropathy are discussed in Chapter 4.2.
Chapter 5 is dedicated to the impact of polyneuropathy and related disorders on 
daily life. Chapter 5.1 focusses on the association between polyneuropathy and impair-
ment in activities of daily living, gait and falls. In Chapter 5.2 gait patterns of persons 
with diabetes are investigated.
Finally, in Chapter 6 the main findings of this thesis are summarized. Additionally, 
methodological considerations concerning the performed studies and the clinical im-
plications of the main findings are discussed in this chapter.
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AbstRACt
Epidemiological studies that investigate the occurrence and determinants of chronic 
length-dependent polyneuropathy are scarce. Population-based studies on polyneu-
ropathy require a valid and reliable screening protocol with both good sensitivity and 
specificity. Several questionnaires and scoring scales have been developed for the 
detection of polyneuropathy, grading the severity of the disease or evaluating the clini-
cal course during follow-up. This review summarizes the aims and content of existing 
diagnostic polyneuropathy screening tools in order to help future studies decide which 
scale to use for screening in specific situations. We searched the PubMed database and 
identified 27 scales, 13 are based on symptoms alone, 8 on neurological signs alone, and 
6 on a combination of symptoms and signs. Scales that combine questions concerning 
symptoms and a neurological examination with a focus on sensory alterations seem 
to have the best discriminatory power. However, all scoring scales were developed for 
and investigated in pre-specified patient populations. Therefore, the generalizability of 
specific findings to the general population may be limited. We also discuss other limita-
tions of existing scales. Future studies are required to determine which clinimetrically 
well-developed scales are preferred for use in population-based studies.
23
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2
intRoduCtion
Polyneuropathy is a common disorder in the general population and is even more com-
mon in diabetics and in elderly.1, 2 Patients with polyneuropathy present with tingling 
sensations or pins and needles, numbness, weakness and pain, often starting in the 
lower legs and feet. Much research is being performed to identify pathways that can 
contribute to the development of polyneuropathy. As these pathways become more ap-
parent, early detection of symptoms of the disease becomes even more crucial. Avoid-
ing special products, drugs or environmental situations, but also intervening early in the 
pathological process may decrease progression of symptoms and associated morbidity. 
Polyneuropathy may be difficult to diagnose early on, since onset is insidious. Validated 
assessment scales may aid in diagnosis. Therefore, sensitive, specific and preferably also 
easy to perform assessment scales would be very helpful.
To detect chronic, length-dependent and often mild forms of polyneuropathy, several 
scoring systems for neurological symptoms and signs have been developed. Some in-
vestigators report reasonable sensitivity and specificity for screening questionnaires3, 4, 
while others conclude that the identification of neuropathic symptoms alone has little 
diagnostic value.5, 6 Diagnosing polyneuropathy at an early stage requires an assessment 
tool that is able to detect mild polyneuropathy in low-risk populations with a high sensi-
tivity. Such a tool would also be useful for epidemiological studies into polyneuropathy. 
A recent review article concluded that there is a paucity of up-to-date epidemiological 
data on polyneuropathy.2 Further field studies are required to obtain more data on 
epidemiological characteristics of polyneuropathy. For future studies an overview of 
existing scoring systems that can be used to diagnose chronic polyneuropathy can be 
very helpful. This article provides such an overview.
metHods
On November 12, 2015, we searched the PubMed database for studies in which scoring 
scales or questionnaires were used to detect or follow the course of polyneuropathy 
symptoms and/or signs. We searched using the terms ‘polyneuropathy’ and ‘neuropathy’, 
in combination with the terms ‘questionnaire’, ‘scoring scale’, ‘score’, ‘scored symptoms’, 
or ‘screening tool’, and limited the search to publication about humans in the English 
language. The search yielded 2951 publications. Titles and abstracts were scanned to 
identify articles in which scales were used suitable for the detection of chronic poly-
neuropathy, herewith referring to length-dependent, predominantly distal, symmetrical 
polyneuropathy, which is the most common subtype. Acute, small-fiber or predomi-
nantly autonomic polyneuropathies do not fall under the scope of this review. We subse-
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quently searched for the publication that first described the specific scales, if these were 
not already included in the search. We selected scales that combined symptoms and/or 
signs into a screening tool for the detection of polyneuropathy, but also tools primarily 
used for the follow-up of symptoms and severity of polyneuropathy, since these may 
also be useful for epidemiological studies. Studies that only investigated the correla-
tion between a single examination or apparatus and a reference test and studies that 
only used advanced techniques to detect polyneuropathy (e.g. only nerve conduction 
studies, biothesiometer, confocal microscopy) were not considered. Additionally, we did 
not include single tests (e.g. monofilament or vibration sense) into this review. Scales 
that were primarily developed to detect or characterize neuropathic pain (e.g. McGill 
Pain questionnaire, Douleur Neuropathique (DN4), Leeds assessment of Neuropathic 
Symptoms and Signs) were not included, nor were scales assessing the consequences 
of polyneuropathy, such as quality of life scales and disability scales (like the Overall 
Neuropathy Limitation Scale and the Rasch-built Overall Disability Scale), since we were 
primarily interested in methods that can be used to diagnose polyneuropathy.
Results
We identified 27 different questionnaires or composite scores that were used to screen for 
polyneuropathy. Of these 27 scales, 13 were solely based on symptoms, 6 on a combina-
tion of symptoms and signs, and 8 on signs alone (some in combination with additional 
tests, see Table 1). Most scales were primarily designed for the detection and grading of 
polyneuropathy, the remaining scales were constructed to longitudinally evaluate the 
severity of neuropathy. However, since the original development of the scales, several 
diagnostic scales have also been used for longitudinal assessment and vice versa. An 
overview of scoring systems and questionnaires with their specific purpose is listed in 
Table 1. More specific information about the contents of each questionnaire and the test 
characteristics is shown in Table 2. The components of the neurological examination 
included in different scales are shown in Table 3.
Polyneuropathy scales using only symptoms
One of the first and most frequently used scales for the assessment of peripheral nerve 
disorders is the Neuropathy Symptom Score (NSS). This scale was developed to detect 
and grade the severity of peripheral neuropathy in diabetic patients.7 The NSS includes 
weakness of bulbar and limb muscles, negative sensory symptoms, positive sensory 
symptoms and autonomic symptoms. Each item is scored with 1 point if present. In the 
original scale 1 or more points was considered abnormal, but multiple adaptations of 
the scoring system have been published.8-11 NSS significantly associated with neuro-
25
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2
logical examination scores, neuropathological abnormality of the sural nerve and with 
multiple parameters of nerve conduction.12, 13 NSS is often used in combination with a 
scored neurological examination, the Neurological Disability Score (NDS, later named 
the Neurological Impairment Score, NIS).7, 14 Administration is time-consuming, should 
preferentially be done by neurologists, and is therefore less useful for screening large 
amounts of patients in a primary care setting. Moreover, reproducibility is not optimal.15
The same research group also developed the Neuropathy Symptom Profile (NSP), a 
self-administered questionnaire that can be used for the characterization of neuropa-
thy16, and the Neuropathy Symptoms and Change score (NSC), which is performed by 
a neurologist to measure the number, the severity and the change in neuropathic 
symptoms since a previous time point.14 An advantage of these extensive scales is that 
the questionnaires can be read by a computer that converts the responses into specific 
scores.17, 18 These questionnaires are quite long and can take up to 45 minutes to fin-
ish. These scales are probably better suited to monitor progression of polyneuropathy, 
especially the NSC, rather than contribute to make the diagnosis of polyneuropathy.
In order to provide a faster screening tool for diabetic polyneuropathy, the Diabetic 
Neuropathy Symptom score (DNS) was developed.19 This four-item questionnaire was 
developed by an expert panel consisting of a neurologist, a diabetologist, a vascular 
internist and a rehabilitation physician and includes symptoms of unsteadiness in walk-
ing, neuropathic pain, paresthesia and numbness. The DNS was validated against the 
NSS, monofilaments, vibration thresholds, nerve conduction studies and the Diabetic 
Neuropathy Examination (DNE) score20, 21, which is a sensitive, easy to perform physical 
examination score for polyneuropathy. Reasonably good test characteristics and high 
reproducibility were reported. However, since specificity is not optimal, which will result 
in a large number of false positive subjects, the DNS should be complemented with 
other tests or scores.21
Several other validated but less widely used questionnaires have been developed. 
Examples include the Type 2 Diabetes Symptom Checklist22 and the Neuropathy Total 
Symptom Score-623, which were designed to detect or to follow complications of diabe-
tes; the Subjective Peripheral Neuropathy Screen24 and the Brief Peripheral Neuropathy 
Screen25, which were developed to detect neuropathy in patients with HIV; the Total 
Symptom Score26, which was developed to evaluate treatment effects in clinical trials. 
Several other researchers created a list of polyneuropathy related questions based on 
their personal experience and review of the literature.3, 4, 27, 28 Table 2 provides more de-
tails about all questionnaires. There are also several scales available that assess toxicity 
of chemotherapeutic agents. Scales that cover multiple aspects of side effects, with a 
brief neurotoxicity subscale are not reviewed here, but can be found in another review.29 
Some scales were specifically designed for neuropathy, such as the Chemotherapy-In-
duced Peripheral Neuropathy Assessment Tool (CIPNAT)30, the Chemotherapy-Induced 
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Peripheral Neuropathy-20 (CIPN20)31, 32 and the Chemotherapy Induced Neurotoxicity 
Questionnaire (CINQ).33, 34 These scales are included in Table 1 and 2.
Polyneuropathy scales using symptoms and signs
A frequently used tool that combines symptoms and signs is the Michigan Neuropathy 
Screening Instrument (MNSI). The MNSI was developed in order to simplify and adapt 
previously established diagnostic criteria for (diabetic) polyneuropathy, mainly for epi-
demiological screening purposes.35 The aim was to design a simple instrument, which 
can be used to rapidly screen a large number of patients with widely available tech-
niques. The MNSI contains a questionnaire, adapted from the NSP, and a clinical part, 
which consists of a short neurological examination involving foot inspection, testing of 
vibration sensation and grading of reflexes. The MNSI can serve as a first step in screen-
ing of a large number of patients in routine clinical settings. When this initial screening is 
positive, patients can be referred for further studies. For this purpose the Michigan Dia-
betic Neuropathy Score (MDNS) was introduced, which includes more physical exami-
nation tests and nerve conduction studies.35 The clinical examination part of the MNSI 
had reasonably high sensitivity and specificity, 80% and 95% respectively, whereas the 
questionnaire alone was not able to distinguish diabetic patients with polyneuropathy 
from those without polyneuropathy (sensitivity 13% and specificity 99%) and did not 
correlate with examination scores, vibration thresholds, or nerve conduction studies. 
However, lowering the cut-off to define abnormality improved the questionnaire and 
resulted in a sensitivity of 40% and specificity of 92%. Optimal test characteristics for the 
questionnaire part and the exam part combined were a sensitivity of 48% and a specific-
ity of 93%.36 The clinical part of the MNSI has been used throughout other studies.37-39 
These studies concluded that this examination tool is a rapid, reproducible and reliable 
test to screen for peripheral diabetic neuropathy.
Another scale that combines symptoms and signs to screen for the presence and 
grade the severity of diabetic polyneuropathy is the Toronto Clinical Scoring System 
(TCSS, later named the Toronto Clinical Neuropathy Score, TCNS). The TCSS puts em-
phasis on sensory symptoms and deficits.40 The TCSS was developed by neurologists 
and diabetologists and validated against electrophysiological criteria and morphology 
of sural nerve biopsies. Initially, the TCSS included reflex testing, but these were elimi-
nated in a modified version (mTCNS), to improve sensitivity to early pathophysiological 
changes of polyneuropathy.41 The mTCNS included sensory symptoms and pinprick, 
temperature, vibration, light touch and position sense.
A more extensive composite scale that combines symptoms and a neurological ex-
amination with additional test into a total score is the Total Neuropathy Score© (TNS©), 
developed to monitor changes in peripheral nerve function during and after treatment 
with chemotherapy.42-47 Apart from symptoms and signs, the original TNS© includes a 
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combination of quantitative sensory testing and nerve conduction studies, but several 
adapted versions appeared, including the TNSc, a clinical version with only symptoms 
and signs and the TNSr, a reduced version of the TNS© without quantitative sensory test-
ing.46, 48-50 The use of the TNS© and modifications of it has been extended to hereditary, 
diabetic and HIV associated neuropathies. The TNS© has been validated against the 
NSS and the NIS in patients with diabetes and Charcot-Marie-Tooth disease. Inter- and 
intra-rater reliability was very high and the TNS© correlated very good with the NSS and 
NIS.44 The TNS© may be useful to longitudinally assess progression of polyneuropathy 
or response to treatment. However, summing all components (symptoms, signs and 
nerve conduction or QST abnormalities) into a total score suggests equal weight of each 
component in the score, which might not reflect reality.
Polyneuropathy scales using only signs
The NSS was first developed in combination with the Neuropathy Disability Score (NDS), 
a score designed to measure deficits of the peripheral nervous system.7 The NDS in-
cludes examination of cranial nerves, muscle strength of upper and lower extremities, 
tendon reflexes, and multiple modalities of sensation on the index finger and the big 
toe. The NDS is significantly associated with the NSS, neuropathological abnormalities in 
the sural nerve and several nerve conduction parameters.12 The NDS was renamed into 
the Neurological Impairment Score (NIS) after eliminating tests not directly related to 
polyneuropathy, which in turn was modified into the NIS-LL to specifically address distal 
diabetic polyneuropathy in the lower limbs.14 The latter was also expanded with a range 
of additional examinations (vibration thresholds, nerve conduction studies, NIS-LL+7 
tests).17 The NDS and NIS are weighted towards motor deficits. Application may there-
fore be less useful in patients with (early) symptoms of chronic axonal polyneuropathies 
or otherwise predominantly sensory neuropathies.51
The extensive NDS was reduced into the 8-item Diabetic Neuropathy Examination 
(DNE)20, which only evaluates items that were considered as clinically relevant (unilat-
eral muscle strength for extension of the knee and dorsiflexion of the foot, ankle reflex, 
pinprick on the index finger and big toe and vibration, touch and position sense on the 
big toe), in order to obtain a more accurate and easily manageable scoring system. The 
DNE is a relatively fast tool, taking only 5 minutes to apply. The DNE has been validated 
against monofilaments and quantitative sensory testing of vibration thresholds, has 
good reproducibility and is strongly related to autonomic function testing and nerve 
conduction studies.20, 21
Because several scales that (mainly) quantify motor deficits were already available, 
but no scales specifically addressing sensory deficits existed for patients with inflamma-
tory neuropathies, the inflammatory neuropathy cause and treatment (INCAT) sensory 
sumscore (ISS) was created.52 This scale includes pinprick and vibration sense on the 
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arms and legs, evaluating presence of a proximal gradient and two-point discrimination 
on the index finger. The scale is validated with a disability sumscore, Nine-Hole Peg Test 
and a 10-Meter Walking test and is mainly used as outcome measure to grade the sever-
ity of sensory deficits in patients with inflammatory neuropathies.
To focus more on early signs of polyneuropathy, the Utah Early Neuropathy Scale 
(UENS) was developed.53 In this scale the focus is more on pinprick sensibility than 
on muscle weakness (only extension of the big toe). Vibration and position sense are 
included as well as ankle reflexes. The UENS was developed to detect neuropathy in 
patients with diabetes and prediabetes. Although sensory signs are emphasized in this 
scale, there was still a good correlation with the more motor performance-based NIS-LL 
and MDNS. Moreover, there was a better correlation between UENS and nerve conduc-
tion studies, QST and intraepidermal nerve fiber density than there was between the 
NIS-LL and MDNS with these tests. The diagnostic sensitivity of the UENS was also higher 
than that of the MDNS and the NIS-LL. An advantage of the UENS is that loss of pinprick 
is mapped by anatomical distribution, making it possible to study change in severity 
over time.
Recently, the Early Neuropathy Scale (ENS) was developed with the same rationale 
as the UENS.54 The ENS includes multiple sensory tests (monofilament testing, vibration 
testing with a Rydel-Seiffer tuning fork, pin perception on the hallux and cold percep-
tion on the dorsum of the foot) and ankle reflexes. The ENS was validated against nerve 
conduction studies and intraepidermal nerve fiber density. Sensitivity and specificity 
were investigated using the definition published by the Toronto Diabetic Neuropathy 
Expert Group as gold standard55 and were 83% and 97% respectively.
Components and characteristics of all discussed scales for the quantification of the 
neurological examination are listed in Table 3.
disCussion
We aimed to identify and summarize existing assessment scales that can be used for 
the diagnosis of chronic, length-dependent polyneuropathy in epidemiological studies. 
Other subtypes of polyneuropathy, such as acute inflammatory neuropathies, chronic 
demyelinating neuropathies with proximal weakness, small-fiber neuropathies or pre-
dominantly autonomic neuropathies probably require an alternative approach. Many 
different scales have been developed to screen for the presence or to grade the severity 
of a polyneuropathy. Most have been validated and showed reasonable correlations and 
discriminatory characteristics. However, several of the scoring systems are complex and 
time consuming. Some include a complete neurological examination or multiple ad-
vanced investigations or combine assessment at both levels of disability (impairments) 
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and functioning (participation). For population studies or other studies investigating a 
large number of people, it is important that the screening tool is fast, simple, highly re-
producible and highly sensitive. If no further confirmatory investigations are performed 
after the initial screening, specificity also needs to be optimal.
We evaluated existing scales, and not single tests, for their possible usefulness to 
screen for the presence of a polyneuropathy. Therefore, we excluded studies that only 
used one test, such as monofilaments, vibration sense or nerve conduction studies. For 
screening studies, especially when aiming to describe the frequency of polyneuropathy 
in the unselected general population, a high sensitivity is important in order not to 
miss any cases. Studies have shown that this is often not optimal for single test, such as 
monofilament or tuning fork examination.56-58 Moreover, distal sensory loss can also be 
found in healthy people without other signs of polyneuropathy, especially in elderly.59 
Therefore, using single tests as screening instrument may lead to a substantial propor-
tion of false-negative and false-positive cases. Test characteristics like sensitivity and 
specificity of the different scales that combine several items are reported to be reason-
able in most studies. However, when interpreting these characteristics, one must take 
into account in which population they have been tested, how participants were sampled 
and which reference test was used. Evaluating a test in a strictly selected population may 
lead to optimistic test characteristics, referred to as spectrum bias or spectrum varia-
tion.60 Using only patients with severe disease as cases will yield an optimistic sensitivity 
and using only fully healthy controls will yield an optimistic specificity. Results of the 
test characteristics may be valid, but not generalizable to other populations, limiting 
the applicability of the test in clinical practice.60, 61 The choice of the reference test can 
also bias the diagnostic accuracy of a test. This is referred to as inappropriate reference 
standard bias.60 Diagnostic accuracy of the test under observation is calculated under 
the assumption that the reference test is 100% sensitive and specific. In polyneuropathy 
there is no such gold standard test: all reference tests that are used in the discussed 
studies are imperfect, possibly resulting in biased results. Moreover, different reference 
tests will yield different test characteristics for the same index tests.60, 61 Additionally, 
filling in a simple score may not be a guarantee for accurate screening data, because 
reproducibility and intra- and inter-rater agreement of scoring symptoms and signs can 
vary considerably.62 It is important to keep these issues in mind when interpreting the 
test characteristics of the discussed screening instruments.
Another issue with several of the discussed scales is that they are composed of dif-
ferent components that are assigned with a (random) score, which are subsequently 
summed into a total score. Not all components that form the total score in a scale may 
be clinically relevant and assigning equal weights to summed components assumes 
that the total score is linear, which is not likely.63 Several of the discussed scales are also 
used as outcome measures in longitudinal studies. Recently, a more modern clinimetric 
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approach, using Rasch-analysis, has been applied to outcome measures, largely fixing 
these limitations.63-65 The Rasch Overall Disability Scale (RODS) is an example of such an 
outcome measurement, which can be used to assess disability in patients with inflam-
matory neuropathy. In deciding which scale to use, that includes scales to diagnose 
polyneuropathy, these limitations should be taken into account.
Most of the scales are validated against other scales, nerve conduction studies or 
a clinical diagnosis, but a direct comparison between all these scales is not available. 
One study recently compared seven of the evaluated scoring scales (NDS, NIS-LL, MNDS, 
modified TCNS, clinical TNS©, UENS, ENS) in a population of patients with impaired 
glucose tolerance.54 In this study the modified version of the TCNS (mTCNS) had the best 
discriminative ability, followed by the clinical version of the TNS© (TNSc), for detection 
of polyneuropathy in general, as well as for large and small fiber neuropathy subgroups 
separately. All seven scales in this study correlated with peroneal nerve motor conduc-
tion velocity and vibration detection thresholds, while none of the scales correlated 
with cold detection thresholds or intraepidermal nerve fiber density. The mTCNS was 
the only scale that did not correlate with sural nerve action potential amplitudes. The 
mTCNS and the TNSc were the only scales tested in this study that also include questions 
on symptoms of polyneuropathy.54 These findings suggest that, while the presence of 
symptoms of polyneuropathy alone is considered to be not suitable for screening pur-
poses, information about sensory complaints may have additional diagnostic relevance. 
Therefore, it seems advisable that future polyneuropathy screening studies incorporate 
both symptoms and signs into the screening protocol. Furthermore, the examination 
part must emphasize sensory deficits, especially when investigating persons that may 
only have minor symptoms of polyneuropathy. In many scales, several components are 
present that are usually mainly affected in advanced stages of polyneuropathy. Early 
signs are often underrepresented or overshadowed by impairment of muscle strength 
or reflexes, leading to a low sensitivity to detect polyneuropathy in an early stage of 
disease. Of course, this largely depends on the specific subtype of polyneuropathy be-
ing under investigation.
Assessment scales can help to detect the presence of chronic polyneuropathy. It is 
important to realize that most of the scales being discussed are developed for and inves-
tigated in specific, high-risk patient groups, such as patients with diabetes or patients 
who received chemotherapy. In epidemiological studies, valid, reliable and fast screen-
ing instruments are essential. Most existing scales have several limitations that are not 
easily overcome. Therefore, future studies are required to create clinimetrically correct 
screening instruments that can be used to determine the presence of polyneuropathy 
in large, low-risk population studies.
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AbstRACt
objective: To evaluate the diagnostic value of individual symptoms of chronic polyneu-
ropathy and to construct and validate a simple screening questionnaire that can help to 
diagnose polyneuropathy in low-risk patient groups.
methods: In a multi-step procedure, we initially compiled a twelve-item question-
naire concerning symptoms of polyneuropathy. The questionnaire was completed by 
117 polyneuropathy patients and 188 controls (headache, transient ischemic attack, 
multiple sclerosis). We calculated the sensitivity, specificity and likelihood ratios of 
each individual symptom. Next, we used stepwise multivariable logistic regression to 
create a compact model that could discriminate cases from controls with only the most 
informative symptoms. Based on the regression coefficients of this compact model, we 
subsequently developed a simple scoring system (the Erasmus Polyneuropathy Symp-
tom Score, E-PSS) and carried out external validation in a population of 140 cases with 
chronic idiopathic axonal polyneuropathy and 96 controls without polyneuropathy. We 
assessed performance of the E-PSS with discrimination (area under the curve, AUC) and 
calibration analyses.
Results: Numb and tingling feet were most frequently reported by polyneuropathy 
patients and had the highest sensitivity. Feeling as if walking on cotton wool and al-
lodynia had the highest specificity. Multivariable logistic regression yielded a model that 
contained these four symptoms, complemented with balance problems and tingling 
hands. Based on regression analysis, the E-PSS was created with a score ranging from 0 
to 14. This polyneuropathy symptom score had a good performance (AUC 0.92) in the 
derivation set and proved to be valid in the external population (AUC 0.95).
Conclusion: A simple, validated polyneuropathy symptom score (E-PSS) that takes into 
account the individual value and frequency of six different symptoms can be helpful as 
screening instrument in clinical practice and for future studies on polyneuropathy.
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intRoduCtion
Patients with chronic axonal polyneuropathy can suffer from tingling sensations, numb-
ness, weakness and invalidating pain, most frequently in the lower legs and feet.1 These 
symptoms are well known and are used in clinical practice and in several screening 
protocols for polyneuropathy, such as the Michigan Neuropathy Screening Instrument 
and the Diabetic Neuropathy Symptom score.2, 3 Some studies report that neuropathic 
symptoms correlate well with neurological signs or nerve conduction studies and can 
be adequately used for screening, while other publications state that symptoms alone 
are not useful for discrimination purposes, because they have poor diagnostic accuracy 
in detecting the presence of a (diabetic) polyneuropathy.2-8 Sensitivity and specificity of 
questionnaires differ widely across studies, ranging from very low (<50%), to relatively 
high (around 90%).2-4, 6, 7, 9, 10
Most questionnaires were specifically developed to screen high-risk populations, 
for example patients with diabetes, or patients receiving chemotherapy. No symptom 
questionnaires for chronic polyneuropathy have been developed and properly validated 
for screening of a lower-risk population.10 Such a questionnaire would be very useful 
in a primary care setting or outpatient clinic and for chronic polyneuropathy-related 
research. Most questionnaires include several nonspecific symptoms such as cramps or 
muscle pain, and apply equal weights to all symptoms. However, it is unlikely that all 
symptoms are equally informative. Furthermore, when a specific symptom is constantly 
present this may be more informative than when the same symptom only occurs in-
termittently. Taking these factors into account might improve the accuracy and clinical 
usefulness of screening questionnaires.
We extensively interviewed in a predefined standardized manner patients with poly-
neuropathy and controls without polyneuropathy about the presence of neuropathic 
symptoms, to investigate which symptoms are most common and which are most infor-
mative in the diagnostic process. We aimed to create and validate a short questionnaire 
that can be used in various settings to help discriminating persons with polyneuropathy 
from persons without polyneuropathy.
metHods
study participants
Persons who were diagnosed with polyneuropathy at the neurological outpatient clinic 
of the Erasmus University Medical Center Rotterdam between 2012 and 2014 were po-
tentially eligible for the study. Polyneuropathy was diagnosed after thorough interview 
of the patients, combined with extensive neurological examination and confirmed with 
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nerve conduction studies according to the Dutch national Guideline on Polyneuropa-
thy.11 We contacted 213 patients with diabetic or idiopathic polyneuropathy by mail, 
inviting them to participate in the current study.
Controls were selected from the same neurological outpatient clinic. Patients who 
visited the outpatient clinic between 2012 and 2014 with headache, having no other 
neurological abnormalities and a normal neurological examination, served as control 
group. In a later stage, the control group was expanded with patients who had experi-
enced a transient ischemic attack, as these persons were expected to be more similar to 
polyneuropathy cases with respect to age. We additionally included a group of patients 
with a recent diagnosis of multiple sclerosis with an expanded disability status scale < 4. 
This control group was added because these patients might have symptoms that could 
resemble symptoms of polyneuropathy. By extending the control groups we aimed to 
improve the clinical utility, specifically concerning the specificity of the questionnaire. 
All controls underwent a full neurological examination at the time of their visit. Controls 
with distal, sensory or motor deficits or bilaterally impaired tendon reflexes were not eli-
gible. Additionally, persons with other neurological diseases or severe systemic diseases 
that are associated with polyneuropathy were not eligible.
We validated the final version of the questionnaire in an external population that 
consisted of 140 patients diagnosed with chronic idiopathic axonal polyneuropathy 
(CIAP) at the University Medical Center Utrecht, the Netherlands.12 The partner of each 
of these patients, if present, was asked to act as control. Partners were suitable as control 
when they had no self-reported polyneuropathy. There were no other selection criteria. 
Therefore, this control group can be considered as a random sample of the same source 
population. In total, 102 partners returned a completed questionnaire, 6 of whom had a 
self-reported polyneuropathy and were excluded. The final control group in this valida-
tion population consisted of 96 controls.
development of the questionnaire
The development of the questionnaire was a multi-staged process (see Figure 1).
Initially, we compiled a list of questions based on previous known polyneuropathy 
questionnaires, advice of neuromuscular specialists in the field of polyneuropathy and 
personal experience.4, 13
First stage. The first version of the questionnaire included ten questions assessing 
the presence of numb feet, tingling feet, muscle cramps, weakness in the legs during 
standing or walking, feeling as if walking on foam or cotton wool, tightness of the legs, 
burning feet, muscle pain, restless legs, and difficulty opening jars. This first version of 
the questionnaire was sent to 213 cases and 245 headache controls.
Second stage. We modified the questionnaire based on preliminary analyses of the 
returned questionnaires, which showed that restless legs and difficulty opening jars had 
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both poor sensitivity and poor specificity. These questions were replaced by a question 
assessing the presence of allodynia (are your feet too sensitive to touch?) and a question 
assessing the presence of stabbing or shooting pain in the legs.2, 9, 14, 15 In this stage, 
we additionally included an inquiry about the five most bothersome polyneuropathy-
related symptoms cases experienced. This second version was sent to all respondents of 
the first version.
Response: 
117 cases (72%) 
44 headache controls (48%) 
99 TIA controls (61%) 
45 MS controls (63%) 
Sent to: 
163 cases 
91 headache controls 
161 TIA controls 
72 MS controls 
Stage 4: 
Final analyses and 
development of the Erasmus 
Polyneuropathy Symptom 
Score (E-PSS) 
Sent to:
163 cases 
91 headache controls 
Response:
140 cases (86%) 
58 headache controls (64%) 
Response: 
163 cases (77%) 
91 headache controls (36%) 
Sent to:
213 cases 
245 headache controls 
Stage 1: 
Compilation of a list of  
common neuropathic 
symptoms, based on 
literature and expert opinion 
Stage 2: 
Modifications: 
1. Replacement of non-
informative symptoms  
2. Inquiry about the most 
bothersome neuropathic 
symptoms (cases only) 
Stage 3: 
Modifications: 
1. Addition of most 
bothersome symptoms 
2. Inclusion of a frequency 
measure 
Figure 1. multi-staged development of the questionnaire. The development of the final score was a 
multi-staged process that involved several preliminary analyses and patient input. Modifications were 
made to the questionnaire accordingly.
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Third stage. We again modified the questionnaire by including two not previously 
listed symptoms that were often reported by the polyneuropathy patients: balance 
problems and tingling sensations in both hands. We also included a frequency measure 
in this version (never, sometimes, and (almost) continuously). The third version of the 
questionnaire consisted of twelve questions evaluating the presence of symptoms 
during the last three months. Eleven questions covered sensory and motor symptoms 
in the feet: numbness, tingling sensations, balance problems, cramps, weakness, walk-
ing on cotton wool, tightness, burning, muscle pain, allodynia, and stabbing pain, and 
one question concerned tingling sensations of both hands. This version was sent to all 
respondents of the first version. Moreover, in this stage the control group was expanded 
with patients who experienced a transient ischemic attack (n=161) or were diagnosed 
with multiple sclerosis (n=72).
Final stage. The results of the third version of the questionnaire and the develop-
ment and validation of the final Erasmus Polyneuropathy Symptom Score (E-PSS) are 
described in the remainder of this article.
This study was approved by the medical ethics committee of the Erasmus MC Uni-
versity Rotterdam, the Netherlands. The validation study was approved by the medical 
ethics committee of the University Medical Center Utrecht.
statistical analysis
Sensitivity, specificity, positive likelihood ratio and negative likelihood ratio of spe-
cific symptoms were calculated with standard two by two tables (symptoms present 
or absent), using the clinical diagnosis as gold standard. Sensitivity was calculated as 
the probability of having the specific symptom in the presence of polyneuropathy 
and specificity as the probability of not having the specific symptom in the absence of 
polyneuropathy. Positive likelihood ratio was calculated as the ratio between the prob-
ability of having the symptom given the presence of the polyneuropathy (sensitivity) 
and the probability of having the symptom given the absence of the polyneuropathy 
(1-specificity). Negative likelihood was calculated as the ratio between the probability 
of not having the symptom given the presence of the polyneuropathy (1-sensitivity) and 
the probability of not having the symptom given the absence of the polyneuropathy 
(specificity). A positive likelihood ratio above 1 and a negative likelihood ratio below 1 
indicate an informative test and the further away from 1, the more informative the test. 
Specificity, and likelihood ratios were recalculated while restricting the control group to 
patients with multiple sclerosis to investigate whether symptoms can also differentiate 
polyneuropathy patients from controls in a more clinical setting of suspected patients. 
Presence of symptoms among cases and controls was compared using chi-square tests.
Multivariable logistic regression analysis was used to determine which symptoms 
were independently associated with the presence of polyneuropathy. We subsequently 
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used backward stepwise selection to achieve a compact model, leaving only the most 
important symptoms in the model, using a p-value cut-off of 0.1. Based on the regression 
coefficients of this multivariable model we created a scoring system to make the ques-
tionnaire clinically useful. The performance of this final scoring system was quantified 
with respect to discrimination (area under the receiver operating characteristics curve, 
AUC) for the control group in total and for each of the control groups separately. Internal 
validity was assessed by bootstrapping (using 1000 bootstrap samples), to estimate the 
over-optimism of the model.16 The model was further validated in an external popula-
tion with CIAP patients and controls. Calibration of predictions was assessed graphically 
by plotting observed frequencies against predicted probabilities. Statistical analyses 
were carried out using the SPSS statistical package, version 21 for Windows (IBM Corp., 
Armonk, NY) and R statistical software.
Results
In total, 117 of the 163 (71.8%) polyneuropathy patients and 188 controls (58.0%) re-
turned the third version of the questionnaire. The control group comprised 44 headache 
patients (response rate 48.4%), 45 multiple sclerosis patients (response rate 63.4%), and 
99 transient ischemic attack patients (response rate 61.5%). Polyneuropathy patients 
were on average older than control patients (70.0 years, compared to 59.7 years), and 
59.8% of cases were men, compared to 48.4% of controls (see Table 1).
All polyneuropathy patients were symptomatic, 92.3% reported at least five of the 
twelve symptoms and 93.2% experienced at least one symptom almost continuously. All 
patients had either tingling feet, numb feet, balance problems or a “walking on cotton 
wool” feeling of the feet. The most commonly reported symptoms were numbness of the 
feet (present in 87.2%; 62.4% experienced this symptom (almost) continuously), tingling 
feet (present in 84.6%; 46.2% continuously), and balance problems (present in 82.9%; 
53.0% continuously). Figure 2 shows the frequency of all symptoms among cases and 
controls. All symptoms were significantly more present in cases than in controls. Cramps, 
balance problems, weakness and muscle pain were the most commonly reported 
table 1. Characteristics of the study populations
Cases Controls
Polyneuropathy
(n=117)
Headache
(n=44)
Transient ischemic 
attack (n=99)
Multiple 
sclerosis (n=45)
Total
(n= 188)
Age 70.0 (10.6) 50.1 (12.6) 65.6 (11.2) 43.7 (11.3) 56.7 (15.0)
Male sex 70 (59.8) 14 (31.8) 64 (64.6) 13 (28.9) 91 (48.4)
Values represent age in years (standard deviation) and number (percentage) of male individuals
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symptoms among controls. When comparing the presence of symptoms between cases 
and controls in each of the control groups separately, we found no significant differ-
ence in the occurrence of cramps, muscle pain and tingling hands between cases and 
headache controls and of balance problems between cases and controls with multiple 
sclerosis. All symptoms were significantly more present in polyneuropathy cases than in 
transient ischemic attack controls (Supplementary Figure 1).
The presence of numbness, tingling feet, and balance problems had the highest 
sensitivity (87%, 85% and 83% respectively) and allodynia and cotton wool feeling of 
the feet had the highest specificity (90% and 77% respectively). The most informative 
symptoms, if present, were allodynia (LR 6.07) and cotton wool feeling of the feet (LR 
3.14), indicating that the presence of these symptoms greatly increases the probability 
of the presence of a polyneuropathy. The most informative symptoms, if absent, were 
numb feet (LR 0.19) and tingling feet (LR 0.26) indicating that the presence of polyneu-
ropathy is much less likely if these symptoms are not present. Cramps and muscle pain 
were the least informative symptoms (Supplementary table 1).
0% 20% 40% 60% 80% 100%
Tingling hands
Stabbing pain
Allodynia
Muscle pain
Burning
Tightness
Cotton wool feeling
Weakness
Cramps
Balance problems
Tingling feet
Numbness
Tingling hands
Stabbing pain
Allodynia
Muscle pain
Burning
Tightness
Cotton wool feeling
Weakness
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Balance problems
Tingling feet
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B
Figure 2. Frequency of symptoms in cases (A) and in controls (b). Black bars indicate the percentage of 
(almost) continuously occurring symptoms, light grey bars indicate the percentage of sometimes occurring 
symptoms and dark gray bars indicate the percentage of never occurring symptoms.
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Multivariable logistic regression showed that numb feet, cotton wool feeling of the 
feet and balance problems were most strongly associated with polyneuropathy, espe-
cially when these were continuously present. Backward stepwise selection resulted in a 
reduced model that included six symptoms: tingling feet, numb feet, cotton wool feeling 
of the feet, allodynia of the feet, balance problems and tingling hands (Table 2). Based 
on the regression coefficients of the six symptoms in the reduced model, we developed 
the Erasmus Polyneuropathy Symptom Score, E-PSS (Table 3). This score ranges from 0 
to 14, with a maximum of 3 points for numb feet, 1 point for tingling feet, 2 points for 
allodynia, 4 points for cotton wool feeling, 3 points for balance problems, and 1 point 
for tingling hands, depending on the frequency of occurrence of these symptoms. The 
discriminative ability and calibration of the E-PSS using the total control group was very 
good (AUC 0.92, which did not change after bootstrapping). Applying the model to 
each of the control groups separately yielded an AUC of 0.92 for controls with headache, 
0.95 for controls with a transient ischemic attack and 0.87 for controls with multiple 
sclerosis. The E-PSS was further tested in the independent validation set of 140 patients 
with chronic idiopathic axonal polyneuropathy (mean age 68.7 years) and 96 controls 
table 2. Final multivariable logistic regression of the symptom questionnaire
symptom Response odds ratio (95% confidence interval)
Numb feet Never 1.00
Sometimes 2.71 (1.00;7.35)
(almost) continuously 5.92 (1.99;17.60)
Tingling feet Never 1.00
Sometimes 2.93 (1.12;7.70)
(almost) continuously 1.58 (0.48;5.24)
Allodynia of the feet Never 1.00
Sometimes 4.04 (1.55;10.52)
(almost) continuously 2.76 (0.75;10.08)
Cotton wool of the feet Never 1.00
Sometimes 0.85 (0.36;2.04)
(almost) continuously 8.48 (2.75;26.21)
Balance problems Never 1.00
Sometimes 0.95 (0.39;2.35)
(almost) continuously 5.38 (1.94;14.92)
Tingling hands Never 1.00
Sometimes 0.44 (0.19;1.01)
(almost) continuously 2.32 (0.65;8.27)
Values represent odds ratios with 95% confidence intervals for the prediction of having polyneuropathy. 
Variables shown originate from logistic regression models applying backward selection of variables to re-
duce the original model containing all twelve symptoms of the questionnaire
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without neuropathy (mean age 70.1 years), where it showed equally good performance 
(AUC 0.98) and reasonable calibration (Supplementary Figure 2).
Table 4 shows the sensitivity, specificity and percentage of correctly classified partici-
pants corresponding to different cut-offs of this score, calculated for both the derivation 
and the validation population.
disCussion
In this case-control study, numbness and tingling of the feet were the most often en-
countered symptoms in patients with polyneuropathy. The absence of these symptoms 
greatly reduces the probability of the presence of polyneuropathy. Presence of a feeling 
like walking on cotton wool and allodynia of the feet greatly increase the probability of 
the presence of a polyneuropathy. Based on a multivariable logistic regression model, 
these four symptoms, together with balance problems and tingling sensations in the 
hands, were included in a newly developed, accurate and validated scoring system that 
can help discriminate persons with polyneuropathy from persons without polyneuropa-
table 3. The Erasmus Polyneuropathy Symptom Score (E-PSS)
during the last 3 months, did you experience: Responses score
Numbness of the feet never 0
sometimes 1
(almost) continuously 3
Tingling or prickling sensations in your feet never 0
sometimes 1
(almost) continuously 1
A painful feeling when your feet are touched never 0
sometimes 2
(almost) continuously 1
A feeling as if you are walking on cotton wool never 0
sometimes 0
(almost) continuously 4
Balance problems during standing or walking never 0
sometimes 0
(almost) continuously 3
Tingling sensations in your hands never 0
sometimes 0
(almost) continuously 1
Polyneuropathy symptom score 0-14
Points given to each symptom category, based on the multivariable logistic regression coefficients
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thy. Due to the simplicity and very limited time-consuming nature of the E-PSS, it may 
also serve as a useful tool for screening purposes in both clinical and research settings.
We showed that numbness and tingling sensations in the feet were most frequently 
present in patients with polyneuropathy, yielding a high sensitivity of these symptoms. 
However, specificity of these symptoms was poor, especially when compared to controls 
with multiple sclerosis. In contrast, specificity of allodynia of the feet was very high, 
while this symptom was not very sensitive, a finding corroborated by others.14 These 
findings show that although individual symptoms provide important information, they 
may not be suitable for screening purposes, since this would yield a large amount of 
false-positives or false-negatives.7 Combining several symptoms in a screening protocol 
may therefore be more useful.
Several questionnaires combining multiple symptoms have been reported.10 Most 
of these questionnaires were developed for high-risk patient groups, such as patients 
with diabetes or patients receiving chemotherapy. Additionally, most were based on 
literature, or on expert opinion, without consulting patients and without a developmen-
tal process that comprised several preliminary analyses and modifications to improve 
the questionnaire. Importantly, in most questionnaires an equal score is given to the 
presence of each symptom. However, we showed that not all symptoms are equally in-
table 4. Sensitivity, specificity and percentage of correctly classified participants of the Erasmus Polyneu-
ropathy Symptom Score (E-PSS)
Cut-off
derivation set Validation set
Sensitivity
(%)
Specificity
(%)
Correctly
classified (%)
Sensitivity
(%)
Specificity
(%)
Correctly
classified (%)
≥1 98.3 49.7 68.4 99.3 88.4 94.9
≥2 95.7 65.8 77.3 98.6 95.8 97.4
≥3 88.9 78.1 82.2 94.2 95.8 94.9
≥4 88.0 83.4 85.2 89.2 95.8 91.9
≥5 78.6 91.4 86.5 79.1 97.9 86.8
≥6 70.1 93.6 84.5 72.7 97.9 82.9
≥7 64.1 95.2 83.2 68.3 97.9 80.3
≥8 57.3 95.2 80.6 61.2 97.9 76.1
≥9 45.3 97.9 77.6 43.9 98.9 66.2
≥10 39.3 98.4 75.7 35.3 98.9 61.1
≥11 28.2 98.4 71.4 25.2 100 55.6
≥12 18.8 100 68.8 18.7 100 51.7
≥13 11.1 100 65.8 9.4 100 46.2
≥14 4.3 100 63.2 3.6 100 42.7
Sensitivity, specificity and percentage of correctly classified participants were calculated at different cut-
offs of the Erasmus Polyneuropathy Symptom Score
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formative, so assigning the same weight to for example the presence of muscle cramps 
as to presence of allodynia seems not appropriate. Given these limitations of previous 
questionnaires, we created the new E-PSS.
We showed that the E-PSS is highly accurate in discriminating patients from controls. 
Therefore, this score may be a useful tool to identify persons with a polyneuropathy 
in primary care, outpatient clinics, as well as research settings. Depending on the aim 
(determining the presence of polyneuropathy in a symptomatic patient, or screening of 
a population in a research setting) the performance of the model will differ and different 
cut-off scores may be required as positivity criterion. For application in neurology outpa-
tient clinics, the setting in which we created the E-PSS, and perhaps also in primary care, 
the E-PSS can be used to estimate the likelihood of polyneuropathy in symptomatic 
patients. However, it must be realized that the E-PSS can only be used as a screening 
tool. Additional clinical investigation and preferably also nerve conduction studies are 
required to definitely assess whether a particular person has polyneuropathy. In research 
settings the E-PSS can be employed to screen persons for a polyneuropathy, for example 
in population-based settings. In this case, a low cut-off score is necessary to have a high 
sensitivity. However, further studies are required to assess the performance of the E-PSS 
in large population-based samples.
A limitation of our study is that we used relatively small control groups. Furthermore, 
cases and controls differed with regard to sex and age (with exception of the TIA controls). 
It is possible that certain symptoms are more prevalent in higher age, independent of 
the presence of polyneuropathy. We may therefore have overestimated the diagnostic 
value of these symptoms. However, given the good performance of the model in the 
external population, where the age of cases and controls is more comparable, this over-
estimation is probably minimal.
In summary, we created the new, externally validated, highly accurate symptom-
weighed Erasmus Polyneuropathy Symptom Score (E-PSS), which may serve as a useful 
tool in clinical practice and for future studies.
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supplementary table 1. Sensitivity, specificity and likelihood ratios for neuropathic symptoms
symptom Controls sensitivity specificity lR+ lR-
Numb feet All 87% 69% 2.78 0.19
MS only - 49% 1.71 0.26
Tingling feet All 85% 60% 2.12 0.26
MS only - 44% 1.52 0.35
Balance problems All 83% 52% 1.71 0.33
MS only - 24% 1.10 0.70
Cramps All 80% 39% 1.31 0.51
MS only - 56% 1.81 0.35
Weakness All 79% 56% 1.78 0.38
MS only - 44% 1.42 0.48
Cotton wool feet All 72% 77% 3.14 0.37
MS only - 69% 2.31 0.41
Tightness of feet All 72% 75% 2.86 0.38
MS only - 64% 2.01 0.44
Burning feet All 71% 70% 2.34 0.42
MS only - 64% 2.00 0.45
Muscle pain All 63% 59% 1.52 0.63
MS only - 60% 1.58 0.61
Allodynia feet All 58% 90% 6.07 0.46
MS only - 96% 13.07 0.44
Stabbing pain All 57% 77% 2.50 0.55
MS only - 78% 2.58 0.55
Tingling hands All 53% 66% 1.57 0.71
MS only - 67% 1.59 0.71
Sensitivity and specificity were calculated using the two by two tables. Positive likelihood ratio (LR+) and 
negative likelihood ratio (LR-) were subsequently calculating using the sensitivity and specificity of each 
symptom
MS: multiple sclerosis; LR: likelihood ratio
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supplementary figure 1. Frequency of symptoms in cases and in different control groups. Black bars 
indicate the percentage of (almost) continuously occurring symptoms, light grey bars indicate the per-
centage of sometimes occurring symptoms and dark gray bars indicate the percentage of never occurring 
symptoms.
PNP: polyneuropathy, MS: multiple sclerosis; H: headache; TIA: transient ischemic attack
Chapter 2.2
58
supplementary figure 2. Calibration plots of the Polyneuropathy symptom score in the derivation 
set (A) and in the validation set (b). The dashed straight line from (0,0) to (1,1) indicate perfect calibra-
tion, the dotted line the calibration of the actual model, and the bias-corrected solid line the calibration 
after bootstrapping. The calibration of the model is very good in the derivation set, but underestimates the 
actual probability in the validation set.
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AbstRACt
Polyneuropathy is a disabling condition of the peripheral nerves, characterized by 
symmetrical distal numbness and paresthesia, often accompanied with pain and 
weakness. Although the disease is often encountered in neurological clinics and is well 
known by physicians, incidence and prevalence rates are not well known. We searched 
EMBASE, Medline, Web-of-science, Cochrane, PubMed Publisher, and Google Scholar, for 
population-based studies investigating the prevalence of polyneuropathy and its risk 
factors. Out of 5119 papers, we identified 29 eligible studies, consisting of 11 door-to-
door survey studies, 7 case-control studies and 11 cohort/database studies. Prevalence 
of polyneuropathy across these studies varies substantially. This can partly be explained 
by differences in assessment protocols and study populations. The overall prevalence of 
polyneuropathy in the general population seems around 1% and rises to up to 7% in the 
elderly. Polyneuropathy seemed more common in Western countries than in developing 
countries and there are indications that females are more often affected than males. Risk 
factor profiles differ across countries. In developing countries communicable diseases, 
like leprosy, are more common causes of neuropathy, whereas in Western countries 
especially diabetes, alcohol overconsumption, cytostatic drugs and cardiovascular 
disease are more commonly associated with polyneuropathy. In all studies a substantial 
proportion of polyneuropathy cases (20-30%) remains idiopathic. Most of these stud-
ies have been performed over 15 years ago. More recent evidence suggests that the 
prevalence of polyneuropathy in the general population has increased over the years. 
Future research is necessary to confirm this increase in prevalence and to identify new 
and potentially modifiable risk factors.
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intRoduCtion
Polyneuropathy is a peripheral neuropathy characterized by symmetrical sensory 
symptoms, such as numbness, paresthesia and pain, and muscle weakness, which are 
predominantly located in the distal parts of arms and legs. Polyneuropathy is a disabling 
disease and has a negative impact on a person’s quality of life.1 Although it is assumed 
that polyneuropathy affects a considerable proportion of the population, the exact 
prevalence and incidence of the disease are not well known. Elderly probably are at 
higher risk to develop polyneuropathy2, and are thus at higher risk for associated falls 
and related injuries. Since an increasing proportion of the population is over 50 years of 
age, especially in developed countries, it is important to recognize the disease and to 
screen for treatable causes. Information about the frequency of the disease and its risk 
factors is therefore crucial.
Over 100 different causes of polyneuropathy have been identified, with diabetes as 
most important risk factor.2-6 Guidelines have been developed to distinguish between 
these different causes.6-9 Differentiation into acquired versus inherited, chronic versus 
acute and axonal versus demyelinating variants helps the diagnostic process in clinical 
practice. Most polyneuropathies have a progressive phase over months or years and 
have predominantly axonal characteristics with reduced sensory and motor nerve ac-
tion potential amplitudes on electrophysiological examination.2 However, even when 
diagnostic guidelines in patients with a slowly progressive axonal neuropathy are strictly 
applied, no cause can be identified in about 20-30% of patients. These patients are often 
diagnosed with chronic idiopathic axonal neuropathy (CIAP).10
The aim of this review is to summarize the literature about the epidemiology of poly-
neuropathy and to obtain more information about differences across populations and 
between age groups. The review provides an overview of studies that investigated the 
prevalence and incidence of polyneuropathy and its associated risk factors.
metHods
literature search
On January 8, 2015 (date last searched), we comprehensively searched the literature, us-
ing electronic medical databases (EMBASE, Medline, Web-of-science, Cochrane, PubMed 
Publisher and Google Scholar), to identify published studies reporting the prevalence 
or incidence of polyneuropathy in the general population. Our search strategy included 
a combination of terms about the disease of interest (polyneuropathy, peripheral neu-
ropathy) and about epidemiology (epidemiology, prevalence, incidence). The specific 
search terms for each database can be found in the supplement. The search was limited 
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to publications in the English language. We did not use a limitation for publication date. 
We initially selected publications that reported prevalence or incidence of peripheral 
neuropathy or polyneuropathy based on title and abstract. Studies that only investi-
gated specific patients groups without a control group, for example only patients with 
diabetes, and studies that only investigated specific neuropathies, such as autonomic 
neuropathy, optic neuropathy, or mononeuropathy were not included. Studies about 
peripheral neuropathy were only included if the prevalence of polyneuropathy was also 
specified. When multiple articles from the same study were identified, the most recent 
or most comprehensive report was selected for this review. Our literature search was 
complemented by reviewing the reference lists of the identified articles, in order to 
gather other important publications that were missed with our search terms.
In addition to the prevalence of polyneuropathy in general, we further discuss some 
important risk factors for polyneuropathy and the prevalence of chronic idiopathic 
polyneuropathy. For this part of the review we also used hospital-based studies that 
specified risk factors like diabetes or intoxications. Therefore, we searched Medline for 
additional reports on frequency of different subtypes of polyneuropathy. We used the 
following search term: (neuropathy OR polyneuropathy OR neuropathies OR polyneu-
ropathies) AND (workup OR diagnostic investigation OR cryptogenic OR idiopathic OR 
unspecified OR unclassified OR undetermined) and used the same limitations for this 
search as we did for the first one.
data collection
The following information was extracted from the selected studies: study size; geographi-
cal location (country); age distribution of the study population; screening protocol used; 
crude and, if available, standardized prevalence rates; age- and sex specific prevalence 
rates; incidence rates; cause-specific prevalence and, if possible, relative risks or odds 
ratios for risk factors of polyneuropathy.
Results
Our search yielded 5119 articles, of which 3065 were original articles. After excluding 
articles based on title or abstract, and after reading the full-text of the remaining ar-
ticles, 28 studies remained. We included one additional reference that was identified 
after reviewing the reference lists of the selected articles. In total, 29 population-based 
studies that reported on the frequency of polyneuropathy were included in the review 
(Figure  1). Twenty-eight studies reported the prevalence, but only three reported the 
incidence of polyneuropathy. One study only investigated the incidence of polyneu-
ropathy. The studies were divided into three categories, based on study design: eleven 
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door-to-door survey studies11-21, seven case-control studies22-28 and eleven cohort stud-
ies (seven cohort studies and four database studies).29-39
door-to-door survey studies (table 1)
The World Health Organization (WHO) developed a protocol to study the epidemiol-
ogy of major neurological disorders, which was specifically designed for developing 
countries where financial and medical resources are limited.40 This protocol consists of 
two stages. In the first stage, a questionnaire to determine the presence of neurological 
symptoms and a brief examination to detect major neurological dysfunction are admin-
istered to the entire study population. This stage is often carried out by non-medical 
personnel (teachers, students, social workers) under supervision of a nurse or a neurolo-
gist. In screen-positive participants a neurologist performs a neurological examination 
to document the presence and type of the neurological disorder. The protocol includes 
screening for headache, epilepsy, stroke and peripheral neuropathy, among others. 
Peripheral neuropathy in this protocol includes mononeuropathies, radiculopathy and 
polyneuropathy. Only studies that specified the frequency of polyneuropathy cases 
were included in this review.
Records identified 
through databases  
(n = 5119) 
Records after 
duplicates removed 
(n = 3065) 
Records given full text 
assessment 
(n = 59) 
Records excluded based 
on title and abstract 
(n = 3006) 
Studies included 
(n = 29) 
Records identified 
through reference lists 
(n = 1) 
Full-text articles 
excluded 
(n = 31) 
 
- Background papers  
- Pilot studies  
- Multiple papers from one 
study 
- Various neuropathies, 
without specification 
‘polyneuropathy’ 
Records screened 
(n = 3065) 
Figure 1. selection of 29 studies that reported on the epidemiology of polyneuropathy.
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table 1. Door-to-door survey studies reporting prevalence of polyneuropathy
study and 
study period
study
size
Age of 
the study 
population
Assessment protocol
Prevalence of 
polyneuropathy
Prevalence of 
polyneuropathy 
related causes 
(per 1000)
Cruz11
Ecuador
1982
1113 All ages 
included;
>50 years: 18%
WHO protocola Crude: 9.0 per 
1000
osuntokun12
Nigeria
1982-1983
18954 All ages 
included;
>50 years: 11%
WHO protocol Crude: 2.5 per 
1000
1.9 tropical
0.4 idiopathic
0.1 diabetic
0.1 hereditary
0.1 nutritional
gutierrez-del-
olmo13
Spain
1984
961 All ages 
included;
>50 years: 30%
WHO protocolb Crude: 7.3 per 
1000
3.1 idiopathic
2.1 diabetic
2.1 alcoholic
longe14
Nigeria
1986
2925 All ages 
included;
>50 years: 10%
WHO protocol Crude: 1.4 per 
1000
bharucha15
India
1985
14010 All ages 
included;
>50 years: 44%
Adapted WHO protocol Crude: 7.1 per 
1000
3.7 diabetic
2.1 idiopathic
0.4 toxic
0.3 inflammatory
0.1 hereditary
Al Rajeh16
Saudi Arabia
1989
22630 All ages 
included;
>50 years: 4%
Adapted WHO protocol Crude: 0.8 per 
1000
savettieri17
Italy
1993
14540 All ages 
included;
>40 years: 40%
Adapted WHO protocol Crude: 7% screen 
positivec
2.1 diabetic
lor18
Malaysia
100 Only subjects 
>65 years 
included
Bilateral distal symptoms 
and/or bilateral loss of 
pinprick or joint position 
sensation
Crude: 200 per 
1000
kandil19
Egypt
1997
42223 All ages 
included;
>50 years: 10%
Adapted WHO protocol Crude: 8.3 per 
1000
6.5 diabetic
0.9 idiopathic
0.5 metabolicd
0.2 inflammatory
0.1 hereditary
kruja20
Albania
2006-2008
9869 All ages 
included;
>50 years: 31%
≥2 symptoms + bilateral 
impairment of strength 
and/or sensation and/or 
reflexes with symmetrical 
distributione
Crude: 32.5 per 
1000
Adjustedf: 23.6 
per 1000
dewhurst21
Tanzania
2009-2010
2232 Only subjects 
>70 years 
included
Self-developed two-
phased screening tool. 
First phase based on 
questionnaire. Diagnosis 
according to WHO 
definition
Crude: 18.8 per 
1000
Adjustedf: 18.6 
per 1000
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Crude point prevalence of polyneuropathy in studies using this, or a similar protocol, 
ranged from 0.8 to 32.5 per 1000 (0.1-3.3%) persons across all ages.11-17, 19, 20 When only 
elderly are studied, prevalence ranges from 18.8 to 200 per 1000 persons (1.9-20%).18, 21 
There is a large variation in reported rates, but also in age distribution across different 
study populations, study area and study protocol (Table 1). Studies that report a low 
prevalence of polyneuropathy (0.8-2.5 per 1000) originate from African and Middle 
Eastern countries, such as Nigeria12, 14, and Saudi Arabia.16 In these studies only 4-11% 
of the population is over the age of 50 years. In contrast, in European countries such 
as Spain13, where polyneuropathy affects 7.3 per 1000 people, and in Albania20, where 
polyneuropathy is reported in 32.5 per 1000 people, around 30% is over 50 years of age. 
However, the latter study used a different assessment protocol and was performed 20 
years after most of the other studies (Table 1).
Only two studies standardized the reported prevalence rates to a reference popula-
tion.20, 21 Adjusting the prevalence to the WHO world standard population resulted in an 
adjusted prevalence of 23.6 per 1000 (crude 32.5 per 1000) in Albania20 and of 18.6 per 
1000 (crude 18.8 per 1000) in Tanzania.21
Case-control studies (table 2)
Seven reports compared the prevalence of polyneuropathy in patients with diabetes 
or prediabetes to a non-diabetic population-based sample of controls (Table 2).22-28 In 
four of these studies, persons known with diabetes or impaired glycemia were identified 
from medical databases and invited to participate in the study.22, 23, 25, 28 A random sample 
of controls was selected from the same community22, 25, 28 or practice23 and matched to 
the diabetes patients on age22, 23, 25, 28, sex22, 23, 28 and ethnicity.22 The three remaining case-
control studies included participants from population-based surveys, where diabetes 
was assessed by self-report24, 27 or by an oral glucose tolerance test.26 Controls were 
randomly sampled from those without diabetes. Controls were categorized into (new) 
diabetes, impaired glucose tolerance, impaired fasting glucose or normal glycemia ac-
cording to the results of an oral glucose tolerance test in four studies.22, 26-28
Survey studies reporting prevalence of polyneuropathy. If reported, prevalence of polyneuropathy sub-
types is also shown.
a WHO protocol: door-to-door survey screening with a questionnaire and short examination, followed by a 
more comprehensive neurological examination performed by a neurologist to detect neurological disor-
ders when initial screening is positive.
b Protocol not specified, most likely WHO protocol
c Screening for all neuropathies, but only prevalence of diabetic neuropathy reported
d Including hypothyroidism, uremic and hepatic neuropathy
e Same protocol as Beghi et al.29 (possible polyneuropathy criterion). Screening based on questionnaire, 
neurologist diagnosed polyneuropathy according to given definition
f Age-standardized to the WHO world standard population
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These studies reported a crude prevalence of polyneuropathy in 7-42% of patients 
with (newly diagnosed or known) diabetes, in 6-13% of patients with prediabetes and 
in 2-13% of controls. The main aim of these studies is to show whether prevalence of 
polyneuropathy varies across different stages of glycemic impairment and to determine 
which determinants are associated with polyneuropathy. Assessment methods, exclu-
sion criteria and polyneuropathy definitions across these studies differ substantially 
(Table 2).
Cohort studies (table 3)
Three cohort studies also compared the prevalence of polyneuropathy in individuals 
with diabetes to individuals without diabetes.36-38 However, in these studies all members 
from a specific community were invited before stratification on diabetes status, giving 
the opportunity to also assess prevalence of polyneuropathy in the whole population. 
In a study conducted in Canada, an adult population with a very high prevalence of 
diabetes (29%) was investigated and an overall crude neuropathy prevalence of 7% was 
reported.36 Neuropathy was defined as loss of monofilament sensation at one or more 
sites on the feet in order to obtain a highly sensitive, but not very specific, screening 
tool. The two other studies were performed in China.37, 38 Polyneuropathy was present in 
13% of adults of the She ethnic minority group of China37 and in 4% of the Han Chinese 
population over 25 years of age, free of renal failure or type 1 diabetes.38 These studies 
used scoring systems (Toronto Clinical Neuropathy Scoring System and Neuropathy 
Symptom Score with Neuropathy Deficit Score respectively) to evaluate the presence of 
polyneuropathy (Table 3).
In an effort to give a more precise population prevalence estimate of polyneuropathy, 
a large study in two Italian regions was conducted from 1990 to 1993. In this study 4191 
subjects of 55 years and older, seen in General Practitioners’ office consultations for any 
reason, were investigated as a reflection of the general population.29 Participants were 
screened with a 7-point yes/no screening questionnaire (muscle cramps, restless legs, 
burning feet, muscle pain, problems with object handling, impairment in standing and 
gait, and paresthesia). The questionnaire was pretested and validated in a hospital set-
ting before initiation of the study. In this validation study sensitivity and specificity were 
78% and 82% respectively, using a cut-off of two positive answers. After two or more 
positive answers on the questionnaire, participants were examined by a neurologist for 
signs of polyneuropathy. Possible polyneuropathy (defined as neuropathic symptoms 
with bilateral impairment in at least one of the following modalities: strength, sensation 
or deep tendon reflexes) was present in 7.3% of participants and probable polyneu-
ropathy (symptoms and at least two abnormal modalities) in 3.6% of participants. The 
age- and sex-adjusted prevalence rates for the two regions (adjusted to the 1990 Italian 
population) were 3.6% for Varese and 3.3% for San Giovanni Rotondo.
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In the Italian Longitudinal Study on Aging (ILSA), a population-based cohort study, 
the prevalence of polyneuropathy was also investigated (Table 3).35 Participants were 
randomly included from eight municipalities, based on population registries (704 
participants per municipality, 88 males and 88 females per 5-year age group; range 65 
to 84 years). The polyneuropathy screening procedure consisted of an interview about 
symptoms (“have you ever had the feeling of burning pain and/or numbness, or par-
esthesia in the feet or legs”), a previous neuropathy diagnosis (“has a doctor ever told 
you that you suffer from neuropathy of the legs”) and drug treatments and of a brief 
neurological examination (heel gait, ankle tendon reflexes and touch and pain sensa-
tion), administered by a clinical investigator. Individuals with a self-reported diagnosis, 
at least one symptom, or at least one abnormal test on the examination underwent a 
clinical work up, which consisted of an evaluation of the medical history, an extensive 
neurological examination and a review of medical records. Nerve conduction studies 
and laboratory investigations were not part of the study protocol, but information about 
these measurements was extracted from medical records if available. The screening 
procedure had a sensitivity of 94.7% and a specificity of 70% in a pilot study of 20 cases 
and 20 controls. The ILSA study reported an adjusted prevalence of 7.0% among 4500 
participants aged 65-84.35 Three years after the baseline investigation, 2845 participants 
were screened for a second time with the same case-finding procedure. This yielded an 
incidence rate of 7.9 per 1000 person-years.
Other studies that are listed in Table 3 include four database studies.30-32, 39 Two da-
tabase studies used hospital registries to identify patients with polyneuropathy from a 
specific community.32, 39 The other two additionally used medical records and notes from 
general practices.30, 31 The diagnosis of polyneuropathy was based on the clinical picture, 
complemented with EMG according to local guidelines. In one study, no polyneuropathy 
definition was reported.30 With this database approach, only registered cases are used to 
calculate prevalence or incidence rates, taking the whole population of the community 
as the denominator. The last two studies described in Table 3 include one general practi-
tioner study assessing elderly with a less strict definition of polyneuropathy (at least one 
bilateral peripheral neurological deficit)33, and one study investigating only idiopathic 
polyneuropathy in Gulf war veterans.34
Age and sex-specific prevalence across all studies
Studies that reported age-specific prevalence rates consistently showed a 
higher polyneuropathy prevalence in higher age categories of the studied popula-
tion.12, 15, 17, 19, 20, 27, 29, 35, 38, 39 Crude sex-specific prevalence rates are less consistent; most 
authors reported a higher prevalence in females, with a ratio of 1.5-2:1.15, 17, 19, 20, 35, 36 Two 
of these studies reported age-standardized, sex-specific prevalence rates and showed 
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3
that this female predominance is not confounded by age.20, 35 Other studies found no 
difference27, 38, or a slight opposite result with a female:male ratio of about 1:1.4.22, 39
Risk factors for chronic polyneuropathy
Several diseases and factors have been associated with polyneuropathy. Since polyneu-
ropathy probably is a multifactorial disease, it is not entirely appropriate to attribute the 
development of polyneuropathy to only one factor. These factors should be considered 
as component causes, and not as one sufficient cause. For instance, not all patients with 
diabetes or alcoholism will develop polyneuropathy, so multiple (known and unknown) 
component causes probably contribute to the development of the disease.41 In clinical 
practice often one factor or disease, such as diabetes or alcohol abuse, is considered 
as a main (sufficient) cause of polyneuropathy in an individual. Some of the aforemen-
tioned survey studies sub-classified polyneuropathy according to these different causes. 
Tropical neuropathies like leprosy are common causes of polyneuropathy in develop-
ing countries such as Nigeria, whereas diabetes is more common in countries or study 
populations with a higher socio-economic status like Italy, the Netherlands and Spain 
(Table 1 and 3). However, there is not much population-based data available.
Several investigators studied causes of polyneuropathy in hospital settings (Table 
4).32, 39, 42-48 In all of these studies, diabetes is the most common cause of polyneuropathy, 
accounting for 18-49% of all cases. Other known important causes of polyneuropathy 
include alcohol abuse, toxic agents, such as chemotherapeutic drugs, nutritional 
deficiencies, immune-mediated causes and hereditary factors. Despite laboratory 
investigations, the cause in patients with a chronic axonal polyneuropathy cannot be 
identified in 12-49%. Although there are probably some differences in the etiology of 
these polyneuropathy subtypes, it is likely that they share multiple common etiological 
factors. Investigation of risk factors in specific subtypes is therefore also important for 
polyneuropathy in general. Some of the most common conditions related to polyneu-
ropathy and chronic idiopathic axonal polyneuropathy will be discussed briefly.
Diabetic polyneuropathy
Prevalence of diabetes is 6.4% worldwide and this number is expected to rise the next 
decades.49 Diabetes can lead to several types of peripheral neuropathy, such as distal 
symmetric polyneuropathy, autonomic neuropathy, mononeuropathy and non-com-
pressive radiculopathy. Polyneuropathy is the most common presentation.50 The Italian 
General Practitioner Study Group reported a relative risk of polyneuropathy associated 
with diabetes of 8.8 (95% confidence interval 6.1-12.8).51 Polyneuropathy occurs in up to 
50% of patients with diabetes and diabetes accounts for 18-49% of all polyneuropathy 
cases (Table 3). Sensory symptoms are usually more prominent than motor involvement 
and neuropathic pain is a common disabling symptom, occurring in 40-60% of patients 
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3
with diabetic neuropathy.50 Diabetic polyneuropathy has an axonal subtype in most 
cases. Treatment is mainly symptomatic. Potential modifiable risk factors associated 
with neuropathy in patients with diabetes include dyslipidemia, hypertension and obe-
sity.50, 52-56 Whether these factors also contribute to the development of polyneuropathy 
in non-diabetic subjects remains to be verified.
Alcoholic polyneuropathy
Polyneuropathy is reported to be present in 13-66% of chronic alcoholics, depending on 
diagnostic criteria used to diagnose neuropathy.57, 58 The relative risk of polyneuropathy 
in chronic alcoholics is estimated at 3.9 (95% confidence interval 1.5-9.0).51 There has 
been debate whether neuropathy in alcoholics occurs due to direct toxic effects of etha-
nol, due to a secondary thiamine deficiency or due to a failure of tissues to utilize thia-
mine in the presence of alcohol.57, 58 Both alcoholic neuropathy and thiamine-deficiency 
neuropathy are mainly of the axonal type and are usually characterized by (painful) 
sensory disturbance and weakness in the distal parts of the lower extremities. Auto-
nomic dysfunction often occurs. There is accumulating evidence that there are differ-
ences in the clinical phenotype between alcoholic neuropathy and thiamine-deficiency 
neuropathy. Pure alcoholic neuropathy without accompanying thiamine deficiency 
mainly affects small fibers, leading to slowly progressive sensory-dominant symptoms, 
neuropathic pain and impaired superficial sensation, whereas thiamine-deficiency neu-
ropathy predominantly affects large fibers, leading to a more progressive, or even acute, 
polyneuropathy with predominantly motor symptoms.57, 58 Since alcohol abuse often 
coexists with nutritional deficiencies, combined small and large fiber polyneuropathies 
are frequently found. Treatment, other than alcohol cessation and improvement of 
nutritional intake, is symptomatic.
Hereditary polyneuropathy
Hereditary motor and sensory neuropathy, also called Charcot-Marie-Tooth disease 
(CMT) is the most common form of inherited peripheral neuropathy. CMT has an esti-
mated prevalence of 40-82 per 100 000 people.59, 60 Mutations in genes encoding major 
structural proteins of myelin, axonal transport and mitochondrial metabolism have 
been described.60 These gene mutations ultimately lead to slowly progressive weakness, 
wasting and sensory symptoms in distal body parts, starting at the feet. These patients 
usually have high arches, hammer toes and weakness and wasting of intrinsic muscles 
of the feet that will progress in the lower legs in later stages of the disease. There are 
demyelinating (CMT1, CMT3 and CMT4), axonal (CMT2) and mixed or intermediate 
(CMTX and dominant intermediate CMT) types of CMT. Age of onset, severity and type 
of symptoms, family history, presence of other neurological signs (such as involvement 
of the central nervous system), and especially nerve conduction studies can give clues 
Chapter 3.1
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to determine the specific subtype and possibly involved genes. No specific treatment is 
currently available.59
Inflammatory neuropathies
Inflammatory neuropathies are reported in 2-16% of all polyneuropathy cases depend-
ing on the clinical setting of the study (Table 4). Inflammatory neuropathies can present 
as a rapidly progressive sensorimotor polyneuropathy with a nadir within 4 weeks, 
known as the Guillain-Barre syndrome61 and as a more chronic, relapsing-remitting 
or gradually progressive polyneuropathy that develops over a period of more than 8 
weeks, as in chronic inflammatory demyelinating polyradiculoneuropathy (CIDP).62
CIDP is the most common chronic acquired demyelinating polyneuropathy. Preva-
lence rates vary between 1 and 7 per 100 000 people, but this may be an underestima-
tion since the clinical presentation can be rather diverse, leading to under diagnosis.62 
CIDP likely has an autoimmune origin and is a treatable disorder. Patients can be treated 
with intravenous immunoglobulins, steroids or plasma exchange.62, 63
Other causes
There are many more factors, such as vitamin B1 or B12 deficiency, paraproteins, con-
nective tissue disorders (systemic lupus erythematosus, Sjögren’s syndrome) and toxic 
agents (like chemotherapy) that are associated with polyneuropathy. When patients 
over the age of 50 have a slowly progressive symmetrical axonal polyneuropathy and no 
cause can be established, these individuals are usually diagnosed as chronic idiopathic 
axonal polyneuropathy (CIAP).64-68
Chronic idiopathic axonal polyneuropathy
CIAP occurs in 12-49% of polyneuropathy cases (Table 4), depending on the clinical 
setting (secondary versus tertiary center, or referral center for specific diseases). Precise 
population-based prevalence estimates are lacking. A recent population-based data-
base study from the Netherlands reported that 26% of incident polyneuropathy cases 
were idiopathic. An incidence rate of 30.3/100 000 person-years for persons 40 years or 
older was found.39
CIAP is characterized by an insidious onset of symptoms usually starting in the sixth 
decade or later, and seems to affect males more than females.10, 39, 64, 69 Symptoms are 
predominantly sensory, characterized by distal loss of sensation (pain, numbness and 
tingling), with or without weakness. The legs are more affected than the arms and 
distribution is usually symmetrical. The disease is slowly progressive and most patients 
remain ambulatory with mild to moderate disability, but all patients experience a 
reduced quality of life. Neurological examination shows decreased or loss of vibration 
sense, diminished perception of pain and light touch in a stocking like distribution and 
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ankle reflexes are often absent.64, 70 Electrophysiological examination shows features of 
an axonal polyneuropathy, usually with reduced or absent sensory nerve action poten-
tials of the sural nerves and decreased amplitudes of the peroneal compound motor 
action potential.64, 70 Quantitative sensory testing may show abnormal temperature and 
vibration thresholds.70 Diagnostic criteria have been developed to improve recognition 
and diagnosis of CIAP.70
CIAP probably constitutes of a heterogeneous group of conditions. Current research 
suggests a role for the metabolic syndrome, which includes impaired glucose tolerance, 
dyslipidemia, hypertension and obesity.65 Studies showed that the metabolic syndrome 
is an independent risk factors for macro- and microvascular complications such as 
retinopathy, nephropathy and neuropathy in patients with diabetes.54, 71, 72 Studies also 
showed that the metabolic syndrome is more prevalent in patients with CIAP.65, 73 Im-
paired glucose metabolism probably is the most important factor attributing to the de-
velopment of polyneuropathy, although results are not entirely consistent. Independent 
associations with dyslipidemia and obesity have also been reported.22, 27, 28, 65, 68, 73-80 It is 
likely however that yet undiscovered factors also contribute to the development of CIAP.
disCussion
We identified 29 population-based studies that investigated the epidemiology of poly-
neuropathy. There is a large variation in reported prevalence rates across these studies 
(0.1-12.6% across all ages, 1.9-30.9% in elderly), which is probably due to the diversity 
in assessment protocols, definition of polyneuropathy, study populations and study de-
signs. Many studies rely on a two-step screening protocol. Participants are screened with 
a questionnaire, sometimes in combination with a short neurological examination, and 
only screen-positive participants are examined by a trained physician, usually a neurolo-
gist. In order to get a valid estimate of the prevalence of a disease, this first stage should 
identify all cases as screen-positive (sensitivity should be 100%). A low number of screen 
positive participants without disease (high specificity) is also preferred, especially when 
resources and time are limited. Studies that do not use a two-step approach, but only 
use symptoms or signs, or a combination of both into a component score as diagnostic 
protocol need to be both sensitive and specific in order to obtain a valid estimate of the 
prevalence.
Most information is derived from door-to-door survey studies. An advantage of these 
studies is that similar research protocols have been used in large study populations 
and that the diagnostics can be done with relatively few resources. These studies give 
insight in the epidemiology of several neurological disorders, but may underestimate 
the prevalence of polyneuropathy, since subclinical polyneuropathy can be missed and 
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refusal to participate in the study may give rise to selection bias. As these studies were 
not primarily focused on polyneuropathy and did not include an extensive neuropathy 
work-up, including nerve conduction studies, the results highly depend on the sensi-
tivity of the screening procedure in the first stage, which is often not optimal. Despite 
this, most studies report a high sensitivity for the entire screening protocol. Overall, 
prevalence of polyneuropathy in door-to-door survey studies from developed countries 
seems higher than in studies performed in developing countries. This may partly be 
explained by a larger proportion of elderly people included in studies from developed 
countries. Standardizing prevalence to the same reference population is helpful to 
investigate this confounding effect of age, but unfortunately not many studies have 
standardized their prevalence rates. Other reasons for this variation can be differences 
in genetic, socioeconomic and environmental factors and differences in prevalence of 
associated risk factors for neuropathy. For example, alcohol consumption is considered 
to be less common in most developing countries81, and prevalence of diabetes is lower, 
especially in Africa.49
The case-control studies that were identified were primarily focused on determining 
an association between diabetes, prediabetes and neuropathy. Although these case-
control studies give an estimate of the occurrence of non-diabetic polyneuropathy 
in controls, they are not suitable to give a population prevalence of polyneuropathy, 
because the distribution of cases and controls likely differs from the general population. 
Although three other studies included all inhabitants from a specific community before 
stratifying for diabetes, the assessment methods (with low sensitivity or low specific-
ity), exclusion criteria or low participation rate, indicate that the population prevalence 
estimates are most likely overestimated or biased.36-38
The four database studies that investigated the frequency of polyneuropathy prob-
ably all underestimate the true incidence or prevalence, since only previously diagnosed 
patients were identified in these studies. Symptomatic individuals who do not visit a 
doctor, asymptomatic individuals, and individuals not being referred to a hospital (in 
case of hospital-based database studies) because there is a clear cause for the com-
plaints (e.g. diabetes) are missed with this approach. The cohort study performed by 
the Italian General Practitioner Study Group was one of the first extensive community 
studies specifically designed to investigate polyneuropathy in an unselected elderly 
population. A ‘probable’ neuropathy was present in 4% and a ‘possible’ polyneuropathy 
was diagnosed in 7% of the participants who visited their general practitioner.29 The 
results found in this study might lack validity due to selection bias. On the one hand, 
patients who visit a general practitioner may be less healthy and at a higher risk for 
polyneuropathy, due to chronic diseases or medication use, leading to an overestimated 
prevalence rate. On the other hand, some persons who have an increased risk to develop 
neuropathy, such as alcoholics or severely impaired patients, might be less likely to visit 
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a general practitioner, leading to an underestimation of the prevalence. An unselected 
sample of 93 patients from the same general practitioners was visited and assessed at 
home. In this small sample, probable polyneuropathy was present in 4.3%. This suggest a 
modest underestimation in the screened population (3.6%). However, prevalence might 
also be underestimated, because only symptomatic patients were included in the study 
and sensitivity of the screening instrument was only 78%. Moreover, nerve conduction 
studies were not performed.
The ILSA study reported a prevalence of polyneuropathy in persons over 65 years 
of age of 7%.35 Participants were randomly selected from database registries, probably 
leading to an unbiased and random sample of the general population. The case-finding 
procedure had a desirably high sensitivity and did not only rely on symptoms. This prob-
ably resulted in the most unbiased and reliable estimate of the prevalence of chronic 
polyneuropathy in the general elderly population. However, nerve conduction studies 
were not part of the study protocol and no polyneuropathy work-up, including labora-
tory investigations, was performed. Therefore, detailed information about causes and 
subtypes of polyneuropathy was not available.
Both these cohort studies reported a polyneuropathy prevalence of around 
7%29, 35,which is much higher than the rates found in the door-to-door surveys, which 
are close to 1%.13 In the two Italian cohorts only elderly were included and the screening 
protocols were primarily focused on the detection of polyneuropathy, whereas most 
survey studies screened for a variety of neurological disorders across all ages. This might 
explain the higher prevalence found in these cohort studies.
Almost all before mentioned studies, including the ILSA study, were performed fifteen 
to twenty years ago. Since that time, life-expectancy, the proportion of elderly in the 
population and prevalence of obesity and diabetes increased.49, 82 Perhaps this resulted 
in an increase in the incidence of polyneuropathy as well, which is also suggested by 
the results of the survey study performed in Albania from 2006 to 2008.20 This study 
reported a polyneuropathy prevalence of 3% in the total general population (including 
all age categories), using a similar screening method as the Italian General Practitioner 
Study Group. Whether polyneuropathy is truly more prevalent than it was 20 years ago 
has to be confirmed in properly designed, large population-based studies.
ConClusions And FutuRe diReCtions
Prevalence of polyneuropathy in the general population ranges from 1% to 3% and 
increases to 7% in the elderly. Prevalence seems to depend on socioeconomic status and 
the age distribution of the study population. In developing countries the prevalence is 
lower, which can possibly be explained by a smaller proportion of elderly in the popula-
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tion and by differences in the prevalence of polyneuropathy risk factors. Life-expectancy 
and prevalence of associated risk factors have increased in the last decades. Whether 
this resulted in more patients with polyneuropathy is yet unknown. There is a need for 
more, properly designed, large studies that investigate the prevalence and risk factors 
of polyneuropathy in the general population. A cohort study of a general, unselected 
population would be the most ideal study design to give an unbiased estimate of the 
prevalence and incidence of polyneuropathy. Population surveys may also be used, but 
in general, available data and case definitions in these studies are less detailed than in co-
hort studies. To assess risk factors for polyneuropathy, case-control studies may be more 
efficient than cohort studies, but may also be more prone to biases. Heterogeneity in 
polyneuropathy definitions in past studies makes comparison between studies difficult. 
To overcome this, future studies should use a similar definition and screening protocol 
for polyneuropathy. Unfortunately, a gold standard test for polyneuropathy does not 
exist. A combination of neuropathic symptoms, neuropathic signs and abnormal nerve 
conduction studies provides the most accurate diagnosis of polyneuropathy. Therefore 
investigating prevalence of polyneuropathy in a large population is challenging. Ideally, 
new studies should uniformly include all these three aspects.7 Standardizing results to a 
reference population is encouraged in order to ease comparison between studies.
Hopefully, future large prospective cohort studies that assess the presence of chronic 
diseases together with cardiovascular, metabolic, hereditary and lifestyle factors will 
also focus on disorders of the peripheral nervous system. These studies should also in-
corporate the assessment of polyneuropathy both cross-sectionally and longitudinally 
during follow-up over the years. This will hopefully give insight into new risk factors for 
this disabling condition.
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AbstRACt
objectives: To determine the prevalence of chronic polyneuropathy in an unselected 
community-dwelling population of middle-aged and elderly people.
methods: The current study was embedded in the prospective, population-based Rot-
terdam Study. Between June 2013 and October 2015, 1310 participants (mean age 70 
years, 55% female) were screened for the presence of polyneuropathy. This screening 
consisted of a questionnaire, neurological examination and nerve conduction studies. 
Polyneuropathy was diagnosed by a consensus panel that categorized participants into 
no, possible, probable or definite polyneuropathy, depending on the level of abnormal-
ity of the screening. Medical records were scrutinized to evaluate whether the disorder 
was diagnosed before and laboratory investigations were performed to determine the 
presence of associated risk factors.
Results: Prevalence of definite polyneuropathy was 5.5% (95% confidence interval 4.4-
6.9), age-standardized to the population of the Netherlands 4.0% (3.1-5.3). Prevalence 
was higher in males (6.7% compared to 4.5%) and increased with age. When combining 
probable and definite polyneuropathy, age-standardized prevalence was 9.4% (7.9-
11.1). Almost half of the polyneuropathies (49%) was newly diagnosed. The majority of 
polyneuropathies was idiopathic (46%). Diabetes, present in 31% of participants with 
polyneuropathy, was the most commonly found risk factor.
Conclusions: Prevalence of polyneuropathy in the general middle-aged and elderly 
population is at least 4%, and increases with age. Almost half of the cases was newly 
diagnosed, indicating that the presence of polyneuropathy is underreported or underdi-
agnosed. Currently, almost half of the polyneuropathies is idiopathic. Future prospective 
cohort studies should focus on identifying new determinants of polyneuropathy.
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intRoduCtion
Chronic polyneuropathy, or distal symmetric neuropathy, is a commonly seen disabling 
neurological disorder.1-6 Patients suffer from cumbersome sensory and motor symptoms 
that can lead to falls, amputations, impairment in daily activities and other comorbidity. 
Despite this, polyneuropathy remains an under acknowledged disorder in daily practice, 
both by patients and medical practitioners.1, 2, 7
There is little reliable population-based information about the frequency of chronic 
polyneuropathy available. The majority of previous studies used less than optimal 
screening methods and were performed almost two decades ago.5 More recent studies 
used medical databases of registered polyneuropathy cases1, 8, 9, which probably led to 
an underestimation of the prevalence, since polyneuropathy is often underreported.3 
Since life-expectancy and incidence of cardiovascular and metabolic diseases have 
increased the last decades, it is likely that prevalence of polyneuropathy has increased 
likewise, especially in a rapidly aging population.5, 10 However, extensive population-
based studies that study trends in the frequency of polyneuropathy, utilizing a full work-
up, including nerve conduction studies (NCS) and laboratory investigations to screen for 
putative causes do not exist.5
Therefore, we prospectively screened participants of the population-based Rotter-
dam Study to investigate the prevalence and risk factors of polyneuropathy in a middle-
aged and elderly population.
metHods
study population
This study was embedded in the prospective population-based Rotterdam Study, a 
cohort study in the Netherlands, that focuses on the epidemiology of chronic diseases in 
elderly.11 In 1990 and 2000, inhabitants aged 55 years and older living in a well-defined 
district of Rotterdam, a homogenous middle-class population, predominantly of Cauca-
sian origin, were invited to participate. In 2006, the study was extended with inhabitants 
aged 45 years and older. In total, 14926 participants (response rate 72%) participated in 
the Rotterdam Study. Every three to four years, all participants undergo a comprehen-
sive set of interviews and examinations.
From June 2013 onwards, polyneuropathy screening was included in the core proto-
col of the Rotterdam Study. The current study includes all participants that underwent 
the polyneuropathy screening between June 2013 and September 2015. During this 
period, 1544 participants were randomly invited. Ninety-three participants did not 
undergo the screening procedure, mainly due to logistic reasons in the initiation phase 
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of the study. Additionally, 141 participants were excluded because there was insufficient 
data collected to complete the diagnostic process. In total, 1310 people were included 
(Figure 1).
standard protocol approvals, registrations and patient consents
The Rotterdam Study has been approved by the Medical Ethics Committee of the Eras-
mus MC and by the Ministry of Health, Welfare and Sport of the Netherlands, implement-
ing the “Wet Bevolkingsonderzoek: ERGO (Population Studies Act: Rotterdam Study)”. All 
participants provided written informed consent to participate in the study and to obtain 
information from their treating physicians.
Polyneuropathy screening
We implemented a protocol to screen participants for polyneuropathy, comprising an 
in-person screening, self-report and review of medical records. In-person screening 
Sufficiently 
screened (n=1310) 
No PNP 
(n=909; 69%) 
Possible PNP 
(n=230; 18%) 
Probable PNP 
(n=99; 8%) 
Definite PNP 
(n=72; 6%) 
Positive by screening or self-report, requiring 
review of medical records (n=403) 
Invited (n=1544) 
Screened (n=1451) 
Consensus
Consensus
Figure 1. Flowchart of the study population and case-finding procedure. In total, 1544 participants 
were invited. After exclusion of participants that did not (completely) undergo the screening 1310 partici-
pants were included in the study. A consensus panel categorized participants based on the results of the 
screening (questionnaire, neurological examination, nerve conduction studies and self-report) and review 
of medical records. In two persons medical records were reviewed because of a self-reported diagnosis of 
polyneuropathy, while the rest of the screening was completely normal. Since no diagnosis of polyneu-
ropathy was found in their medical records, these persons were categorized as no polyneuropathy.
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comprised three components: a symptom questionnaire, a standardized neurological 
examination, and short non-invasive NCS. Items of the examination and NCS were 
chosen after consulting with experts worldwide in the field of polyneuropathy. The 
examinations were performed by carefully trained examiners and a high quality was 
ascertained by routine checks and repeated training.
Neuropathic symptoms were evaluated with a questionnaire that was based on previ-
ous studies.4, 12, 13 Participants were asked whether they bilaterally experienced tingling 
or prickling sensations, burning, cotton-wool feeling while walking, muscle cramps, 
muscle pain, stabbing pain, weakness, numbness, tightness, and allodynia in the legs 
or feet during the last three months. Answers included ‘never’, ‘sometimes’ and ‘(almost) 
continuously’.
The presence of neuropathic signs was assessed with a neurological examination of 
the legs. Examination involved bilateral assessment of tendon reflexes, several sensory 
modalities and muscle strength of the feet. Ankle and knee tendon reflexes were as-
sessed in seated position and scored as normal, reduced, or absent. Vibration sense 
was evaluated using a Rydel-Seiffer tuning fork, a graduated tuning fork that carries 
calibrated weights imprinted with a scale from 0 (minimum score) to 8 (maximum score), 
which can be used to determine vibration thresholds.14 Vibration thresholds were de-
termined at the hallux of both feet. Superficial pain sensation was evaluated using a 
disposable wooden pin. Stimulation was applied on the lower legs, starting on the knee 
and descending the anterior lower leg towards the big toe. When participants reported 
a numb feeling right from the start at the level of the knee, the examination was ex-
tended to a more proximal part of the leg. Sensation was scored as normal, abnormal 
distal of the toes, ankles, lower part of the lower leg, knee, or abnormal from above 
the knee. Muscle strength of the anterior tibial muscles was scored with the modified, 
Rasch-built Medical Research Council (MRC) grading scale.15 In this scale, the six options 
of the original MRC score have been reduced to 4 options: paralysis, severe weakness 
(>50% loss of strength), slight weakness (<50% loss of strength) and normal strength. 
Dorsiflexion of the feet was also tested by asking the participants to stand on their heels, 
using balance support if necessary.
NCS were performed using a Nicolet™ Viking Quest (Natus Medical Incorporated, 
San Carlos, California, USA). The sural sensory nerve was measured bilaterally and the 
peroneal motor nerve unilaterally. Together these nerves are considered the most sensi-
tive nerves to detect polyneuropathy.16 The distal peroneal nerve compound muscle 
action potential (CMAP) amplitude and distal motor latency (DML) were recorded at the 
extensor digitorum brevis muscle. Stimulation was applied to the anterior side of the 
ankle, 8 cm proximal to the recording electrode. CMAP baseline-peak amplitudes below 
1.1 mV and DML values above 6.5 ms were considered abnormal.17 Sural sensory nerve 
action potential (SNAP) amplitudes were measured bilaterally with a standard recording 
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electrode placed behind the lateral malleolus. Stimulation was applied on the posterior 
side of the calf, 14 cm proximal to the recording electrode. SNAP baseline-peak am-
plitudes below 4.0 μV were considered abnormal.18 Electrophysiology was performed 
using standard techniques of percutaneous supramaximal stimulation. The setting of 
our study did not allow extensive NCS in upper and lower extremities or invasive needle 
examination. NCS were performed at room temperature. Limb temperature was mea-
sured and documented, but maintaining the limb temperature above a certain degree 
was not possible in the current setting.
Case ascertainment and diagnostic work-up
Since there is no gold standard test for polyneuropathy, we discussed each individual 
participant case by case in an expert panel, using all collected information on symp-
toms, signs and NCS, to diagnose polyneuropathy. This panel was led by a neuromuscu-
lar specialist (PvD) and also included a neurophysiology specialist (JD) and a physician 
trained in epidemiology with a special interest in neuromuscular diseases (RH). In panel 
discussions, participants were categorized into “no”, “possible”, “probable” or “definite 
polyneuropathy”, depending on the perceived likelihood of the diagnosis.16 Participants 
were discussed until unanimity was reached.
Each screening component (questionnaire, examination and NCS) was evaluated 
separately, before establishing the overall conclusion. Like in clinical practice, the panel 
judged whether symptoms, as assessed with the questionnaire, matched symptoms of 
polyneuropathy (e.g. sometimes occurring tingling, cramps or muscle pain was judged 
to be within the spectrum of normal). The examination was deemed compatible with 
polyneuropathy when multiple items of the examination were abnormal; to be compat-
ible with usual neurological decision making, decreased tendon reflexes or vibration 
sensation alone was considered to be insufficient to be rated as abnormal. Furthermore, 
since polyneuropathy generally is a symmetrical disorder, the items of the examination 
were only considered compatible with polyneuropathy if both sides were abnormal, to 
avoid symptoms not caused by a polyneuropathy. As a result, asymmetric neuropathies, 
like mononeuritis multiplex, multifocal motor neuropathy and multifocal acquired 
demyelinating sensory and motor neuropathy may be missed. These disorders however 
are extremely rare in the general population.19 NCS were interpreted using published 
normal values17, 18, while taking limb temperature into consideration. Sural SNAP am-
plitudes were considered to be the most sensitive parameters. Bilateral abnormal sural 
SNAP amplitudes were considered reflective of polyneuropathy. When only a single sural 
nerve measurement was available (e.g. due to signal disturbance), the peroneal CMAP 
amplitude was used to assess abnormality. If both the sural SNAP amplitude and the 
peroneal CMAP amplitude were abnormal, results could also be considered compatible 
with polyneuropathy.
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Medical records of participants with one or more abnormal components of the screen-
ing were scrutinized to investigate whether participants were previously diagnosed 
with polyneuropathy. Records were also reviewed when participants self-reported a 
diagnosis of polyneuropathy. Participants who were previously diagnosed by a neurolo-
gist were categorized as definite polyneuropathy, irrespective of the results of the panel, 
since we consider a complete polyneuropathy work-up according to hospital guidelines 
executed by a neurologist superior to our screening. Definite polyneuropathy was also 
diagnosed when symptoms, signs and NCS were all abnormal. Occasionally, when NCS 
were unavailable but symptoms and signs were abundantly clear, participants could 
still be considered as having definite polyneuropathy when the panel was unanimously 
convinced of the certainty of this diagnosis. This occurred in 7 instances. When none of 
the components was abnormal, participants were categorized as no polyneuropathy. 
Participants who met neither the definite, nor the no polyneuropathy criterion, were 
categorized as possible or probable polyneuropathy, depending of the level of abnor-
mality. Typically, participants were categorized as possible polyneuropathy when one 
component was abnormal and as probable polyneuropathy when two components 
were abnormal. Participants with missing data in more than one component were 
excluded (n=141).
Participants with newly diagnosed definite polyneuropathy underwent extra blood 
sampling to screen for associated risk factors, such as vitamin deficiencies (B1, B12), pres-
ence of monoclonal gammopathies and thyroid dysfunction. Routine blood sampling 
of the Rotterdam Study included measurement of fasting glucose. Information about 
alcohol use (self-reported), and medication use was also collected. Diabetes was defined 
as a fasting glucose level >7.0 mmol/L, a non-fasting glucose level >11.1 mmol/L (when 
fasting data was not available) or use of anti-diabetic therapy. Medical records were 
reviewed for known causes of polyneuropathy in all definite polyneuropathy cases.
data analysis
Prevalence of polyneuropathy was calculated by dividing the number of cases by the 
total number of participants in the respective groups. We reported crude prevalence 
with confidence intervals (Wilson interval20), as well as age-standardized prevalence, 
standardized to the 2013 population of the Netherlands21, European Union22, WHO pop-
ulation23 and the 2010 Census population of the United States of America24, restricted to 
persons over 50 years of age. Age-standardization adjusts rates to take the age structure 
of the study population into account. Standardized prevalence was calculated using the 
direct method of standardization; 95% confidence intervals were calculated with the 
method described by Fay and Feuer25, using R version 3.2.1. Difference in prevalence 
between sexes (age-adjusted) and age decades (sex-adjusted) was tested with logistic 
regression using SPSS, version 21.
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Results
In total, 1310 participants were sufficiently screened for polyneuropathy (Table 1). This 
sample consisted of 55% females and 45% males. Mean age was 70 years (range 52-95 
years).
In total, 72 participants were diagnosed with definite polyneuropathy (Table 1 and 
Figure 1). The crude prevalence of polyneuropathy was 5.5% (95% Confidence Interval 
4.4-6.9). Age-standardized prevalence to the population of the Netherlands was 4.0% 
(3.1-5.3) and to the USA population 3.9% (2.9-5.2). Prevalence was slightly higher in males 
than in females (6.7% compared to 4.5%, p-value 0.09), and was higher in older people 
(p-trend <0.01). When applying a wider definition of polyneuropathy, which combined 
probable and definite polyneuropathy (see Table 1 and Figure 2), crude prevalence was 
13.1% (11.3-15.0).
In 49% of cases with definite polyneuropathy, this had not been previously rec-
ognized. This proportion was higher among females and subjects without diabetes 
(Table  2). Of those that were already diagnosed with a polyneuropathy, more than 
half (51%) responded negatively on the question “have you ever been diagnosed with 
polyneuropathy”.
table 1. Sex- and age specific prevalence of polyneuropathy
Population,
n
Prevalence of definite 
polyneuropathy,
% (95% CI)
Prevalence of probable and 
definite polyneuropathy,
% (95% C.I.)
Total sample 1310 5.5 (4.4-6.9) 13.1 (11.3-15.0)
Age-standardized
Dutch population 2013 4.0 (3.1-5.3) 9.4 (7.9-11.1)
European Union population 4.3 (3.3-5.6) 10.0 (8.5-11.8)
USA 2010 census population 3.9 (2.9-5.2) 9.0 (7.6-10.8)
WHO standard population 3.4 (2.5-4.7) 7.9 (6.5-9.6)
Stratified by sex
Males 595 6.7 (5.0-9.0) 14.6 (12.0-17.7)
Females 715 4.5 (3.2-6.3) 11.7 (9.6-14.3)
Stratified by age
50-60 250 1.2 (0.4-3.5) 2.4 (1.1-5.1)
60-70 439 3.9 (2.4-6.1) 8.0 (5.8-10.9)
70-80 341 4.4 (2.7-7.1) 12.6 (9.5-16.6)
>80 280 13.2 (9.7-17.7) 31.1 (25.9-36.7)
Sex- and age specific prevalence, with 95% confidence intervals, of definite and combined probable and 
definite polyneuropathy in participants of the Rotterdam Study. Crude as well as age-standardized preva-
lence is reported.
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table 2. Proportion of previously and newly diagnosed polyneuropathy cases
Previously diagnosed 
polyneuropathy, n (%)
newly diagnosed 
polyneuropathy, n (%)
total cases
n/n
Total sample 37 (51%) 35 (49%) 72/1310
Males 24 (60%) 16 (40%) 40/595
Females 13 (41%) 19 (59%) 32/715
<60 years 1 (33%) 2 (67%) 3/250
60-70 years 9 (53%) 8 (47%) 17/439
70-80 years 7 (47%) 8 (53%) 15/341
>80 years 20 (54%) 17 (46%) 37/280
Participants with type 2 diabetes 17 (77%) 5 (23%) 22/181
Participants without diabetes 20 (40%) 30 (60%) 50/1109*
Number and proportion of newly diagnosed and previously diagnosed cases of definite polyneuropathy 
per sex, age decade and diabetes status.
* Diabetes status was unknown in 20 participants without polyneuropathy
Figure 2. Prevalence of polyneuropathy per age decade. The figure shows the age-specific prevalence 
of polyneuropathy, using different polyneuropathy definitions (green squares: possible, probable and defi-
nite polyneuropathy combined; red triangles: probable and definite polyneuropathy combined; blue dots: 
definite polyneuropathy).
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Previously diagnosed polyneuropathies were mainly associated with diabetes, 
or were considered as chronic idiopathic axonal polyneuropathy (Table 3). Review of 
medical records and additional laboratory investigations in participants with newly 
diagnosed polyneuropathy revealed that in the majority no associated risk factor was 
present. Overall, 31% of participants with polyneuropathy had diabetes and in 46% of all 
polyneuropathy cases, no known risk factor was found. These cases can be considered as 
having idiopathic polyneuropathy (Table 3).
table 3. Potential causes in cases with definite polyneuropathy
Associated risk factor
Cases with a previous 
diagnosis (n=37), n (%)
Cases with a new diagnosis 
(n=35), n (%)
All cases
(n=72), n (%)
Diabetes 17 (46%) 5 (14%) 22 (31%)
Vitamin deficiencya 4 (11%) 6 (17%) 10 (14%)
Possible alcohol abuseb 2 (5%) 1 (3%) 3 (4%)
Toxic 3 (8%) 1 (3%) 4 (6%)
Hereditary 1 (3%) - 1 (1%)
Immune-mediatedc 4 (11%) 3 (9%) 7 (10%)
Thyroid dysfunction 2 (5%) 3 (9%) 5 (7%)
Renal failure 4 (11%) 1 (3%) 5 (7%)
Systemic diseased 2 (5%) - 2 (3%)
No risk factor present/CIAP 13 (35%) 20 (57%) 33 (46%)
Total 52 (141%) 40 (114%) 92 (128%)
Presence of risk factors in participants with definite polyneuropathy, based on review of medical records in 
all definite cases, and additional laboratory investigations in newly diagnosed cases. Multiple risk factors 
may be present in one participant, the total may thus exceed 100%. Participants are diagnosed with chronic 
idiopathic axonal polyneuropathy (CIAP) when no risk factors were identified. Participants did not undergo 
genetic testing, therefore hereditary neuropathies were not evaluated.
a Vitamin B12 deficiency, none of the cases had a B1 deficiency
b Alcohol use as possible risk factor was defined as >21 glasses per week (based on self-report)
c Immune mediated includes monoclonal gammopathies and inflammatory neuropathies
d Systemic disease includes vasculitis and connective tissue diseases
disCussion
The prevalence of polyneuropathy in our population-based study was 5.5%, which 
increased with age to 13% of persons over 80 years. In a substantial proportion of cases 
polyneuropathy was not previously diagnosed and of the participants with a previous 
diagnosis, a high proportion was unaware of having it. Approximately a third of par-
ticipants with polyneuropathy concomitantly had diabetes, while the vast majority of 
polyneuropathies could be considered as idiopathic.
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We screened participants with a protocol that included assessment of symptoms, 
a neurological examination and NCS. Previous studies included only symptomatic 
individuals or used less extensive screening methods, often consisting of only a single 
test, such as a monofilament.5 Unfortunately, there is no simple diagnostic test that has 
a high sensitivity and specificity for the diagnosis of polyneuropathy. Screening tools 
have been developed that can help detect polyneuropathy, like the Michigan Diabetic 
Neuropathy Screen26, Total Neuropathy Score27 and Toronto Clinical Neuropathy Score.28 
However, these tools were designed to screen high-risk patients, such as diabetics or 
patients receiving chemotherapy. We did not use these tools, since their sensitivity and 
specificity have not been evaluated in an unselected, low-risk population, like ours.29 
Moreover, as opposed to assigning scores to symptoms and signs, we discussed all col-
lected data from each participant in an expert panel to form an overall conclusion about 
polyneuropathy. With this approach we avoid making (arbitrary) cut-off points for the 
diagnosis. Additionally, in population-based research a consensus panel approach is as 
close to clinical practice as possible.
In our sample of middle-aged and elderly participants, we found a polyneuropathy 
prevalence of 5.5%. Age-standardized prevalence to the Dutch population and to 
the USA population was 4.0% and 3.9% respectively. In the USA, this relates to ap-
proximately 3.8 million persons over 50 years with polyneuropathy, with an additional 
5 million persons when probable cases are also included. Aging of the population and 
the rising prevalence of diabetes, the most important risk factor for polyneuropathy, 
will probably lead to even higher numbers in the future.30 Additionally, prevalence of 
prediabetes, obesity and metabolic syndrome, factors that have all been associated with 
polyneuropathy, is also reaching epidemic proportions.10 This will probably contribute 
to a further rise in polyneuropathy cases.
Our age-standardized prevalence of 4.0% is lower than 7.0% found in the Italian 
Longitudinal Study on Aging (ILSA), the most comprehensive study on polyneuropathy 
prevalence that had been performed to date.3 However, in this study polyneuropathy 
was clinically diagnosed without NCS. In our study the combination of probable and 
definite polyneuropathy would result in a standardized prevalence of 9.4%, which is 
perhaps better comparable. Importantly, similar to our study, a large proportion of cases 
in the ILSA was undiagnosed.3 Aside from bothersome symptoms, polyneuropathy is 
also related to sleep disturbance, depression, impairment in daily activities, fall-related 
injuries and even mortality.1, 7 This makes it an important health problem, posing a 
high burden on both individuals and society. Despite these disabling consequences, 
a substantial proportion of patients with polyneuropathy remains undiagnosed, and 
therefore probably not receiving appropriate treatment and education. Recognition, 
early detection and patient education of this common disorder is very important in 
order to prevent or treat comorbidity.
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In addition to the prevalence of polyneuropathy, we also investigated how often 
associated risk factors were present in patients with polyneuropathy. Currently, most 
information about the distribution of risk factors for polyneuropathy originates from 
hospital-based studies, where referral bias is a serious issue. In these studies, roughly a 
third of polyneuropathy cases is considered as idiopathic.5 In our study, this proportion 
was 46%. Aside from referral bias, this difference may be explained by the identification 
of milder forms of polyneuropathy, which are probably missed in hospital-based studies. 
However, detection of mild or early forms is crucial, since these are the patients that 
might benefit most from future interventions.
One of the strengths of our study is the population-based design of our study. An-
other important strength is the use of a polyneuropathy work-up that included NCS and 
review of medical records. To our knowledge, there are no other prospective population 
studies that included NCS. An advantage of population-based studies over clinical stud-
ies is the high external validity. However, we must note that our results may not directly 
translate to non-Caucasian populations. There are also other limitations to our study. 
First, there might have been some selection bias in our study population. We included 
relatively healthy individuals, since polyneuropathy was assessed in persons that visited 
the research center, which might have prevented persons with severe physical disabil-
ity to participate. Second, we used a questionnaire instead of a live interview, which 
might have resulted in some misclassification due to bilateral radiculopathy or focal 
neuropathies. Additionally, misclassification may occur in elderly due to occurrence of 
non-specific symptoms attributable to osteoarthritis or other locomotor problems, and 
due to a lack of normative data for vibration sensation, ankle reflexes, and NCS for the 
oldest old. Differentiating normal aging from pathology can therefore be difficult. As a 
result, the prevalence in elderly might be overestimated. However, it is reasonable to as-
sume that this misclassification is limited, because we combined symptoms, neurologi-
cal examination and NCS to come to the overall conclusion. Another limitation is that 
we did not preheat the legs of participants before performing NCS. Some participants 
with cold feet might have had artificially high amplitudes. Therefore, although we did 
take the temperature into account, some NCS might have been misclassified as normal 
while in normal temperature the amplitudes would have been below the threshold for 
abnormality. In this case, our prevalence might be slightly underestimated.
Our study showed that polyneuropathy is a common disorder, especially in elderly. 
Polyneuropathy is an important health problem since it is associated with several co-
morbidities. Polyneuropathy is underdiagnosed and deserves more public attention. 
Future studies are required to estimate risks attributable to associated diseases, but 
also to find new, potentially modifiable determinants involved in the development and 
progression of polyneuropathy.
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AbstRACt
objective: Diabetes mellitus is a known risk factor for polyneuropathy, but the role of 
prediabetes and metabolic syndrome remains unclear. We aimed to investigate the role 
of these factors in a community-dwelling middle-aged and elderly population.
methods: 1256 participants of the population-based Rotterdam Study (mean age 70.0, 
54.5% females) were screened for polyneuropathy with a questionnaire, neurological 
examination and nerve conduction studies. Data on type 2 diabetes and components 
of metabolic syndrome were also collected. Logistic regression was used to investigate 
associations of diabetes, prediabetes, and metabolic syndrome and its separate compo-
nents with polyneuropathy. Linear regression was used to investigate associations with 
nerve conduction parameters in participants without polyneuropathy.
Findings: Diabetes was associated with polyneuropathy (OR 3.01, 95% CI 1.60;5.65), 
while impaired fasting glucose was not (OR 1.55, 95% CI 0.70;3.44). Metabolic syndrome 
was associated with polyneuropathy (OR 1.92, 95% CI 1.09;3.38), with a stronger associa-
tion when more components of the syndrome were present. Analyzing separate com-
ponents of metabolic syndrome revealed associations for elevated waist circumference 
(OR 2.84, 95% CI 1.35;5.99) and elevated triglycerides (OR 2.01, 95% CI 1.11;3.62). Similar 
associations were found after excluding participants with diabetes. In participants with-
out polyneuropathy, metabolic syndrome associated with lower sural sensory nerve 
action potential amplitudes.
Conclusions: Metabolic syndrome, abdominal obesity and dyslipidemia, are strongly 
associated with polyneuropathy, irrespective of the presence of diabetes. Metabolic 
syndrome also associates with impaired nerve function in people without polyneuropa-
thy. Our study therefore suggests that cardiometabolic disturbances have an impact on 
peripheral nerve function that extends beyond clinically manifest disease.
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intRoduCtion
Diabetes mellitus is a major risk factor for polyneuropathy, a disabling condition that 
is associated with falls, fractures, ulcers and mortality.1 Impaired fasting glucose (IFG) 
and impaired glucose tolerance (IGT), together commonly called prediabetes, might 
also increase the risk of polyneuropathy.2 With the globally increasing prevalence of 
both diabetes and prediabetes, incidence of polyneuropathy and its consequences 
is also expected to increase.3 However, evidence supporting the association between 
prediabetes and neuropathy has so far been inconclusive. Several studies showed a 
higher prevalence of prediabetes in patients with idiopathic neuropathy compared to 
previously published prevalence numbers in the general population. However, since 
these studies did not include a control group, a true association cannot be inferred.4-8 
Results from studies that did investigate the association between prediabetes and neu-
ropathy using a control group have been inconsistent.9-15 The uncontrolled nature, often 
retrospective study design, lack of appropriate adjustments and potential referral bias 
of most of these studies have previously been indicated.16
More recently, attention has shifted from hyperglycemia as a single cause of poly-
neuropathy to a more multifactorial hypothesis suggesting an interaction of glucose 
metabolism with other metabolic factors.17, 18 Obesity, another global epidemic, is one 
of these factors. Hyperglycemia and obesity are central components of the metabolic 
syndrome (MetS).19 This syndrome comprises a combination of interrelated risk fac-
tors for cardiovascular diseases and diabetes and also includes high blood pressure, 
elevated triglycerides and reduced high-density lipoprotein cholesterol.19 Prevalence 
of MetS has also been rising and nowadays almost 50% of the US population meets 
the criteria. MetS is related to cardiovascular disease, neurodegenerative disease and 
cancer18 and several components of this syndrome have also been implicated in the 
development of neuropathy in patients with diabetes.20-23 A few case-control studies 
even suggested an association between MetS and idiopathic polyneuropathy12, 24, 25, but 
more well-developed, extensive epidemiological studies are necessary to confirm this 
association.17, 18, 26
Therefore, we investigated the association of prediabetes and MetS with chronic 
polyneuropathy in an unselected sample of community-dwelling middle-aged and 
elderly people.
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mAteRiAls And metHods
setting
The current study was part of the Rotterdam Study, a large prospective, population-
based cohort study in the Ommoord district of Rotterdam, the Netherlands.27 The study 
was initiated in 1990 when all inhabitants aged 55 years or older were invited to partici-
pate. There were no other eligibility criteria besides minimum age and postal code. The 
study was expanded in 2000 and 2006, this last time inviting all persons aged 45 years or 
older, living in the Ommoord district. Currently, 14926 participants have been enrolled 
in the Rotterdam Study. At baseline, and at follow-up every four years, participants 
undergo extensive interviews and examinations at home and at the research center. The 
Rotterdam Study has been approved by the Medical Ethics Committee of the Erasmus 
Medical Centre and by the Ministry of Health, Welfare and Sport of the Netherlands, 
implementing the “Wet Bevolkingsonderzoek: ERGO (Population Studies Act: Rotterdam 
Study)”. All participants provided written informed consent to participate in the study 
and to obtain information from their treating physicians.
Since June 2013, a polyneuropathy screening has been implemented in the core pro-
tocol of the Rotterdam Study. The current study includes all participants that have been 
invited for this assessment between June 2013 and October 2015. During this period, 
1544 participants were invited for the polyneuropathy screening. Of these participants, 
262 were excluded: 93 did not undergo the screening and 141 participants were not 
sufficiently screened, mainly due to logistic reasons (shortage of time to complete all ex-
aminations or due to a lack of personnel or on some occasions). Of the 1310 participants 
who were sufficiently screened, information on diabetes and MetS was present in 1256 
participants. These 1256 participants were included in the analyses.
Assessment of type 2 diabetes, prediabetes, and metabolic syndrome
Diabetes mellitus type 2 was diagnosed using serum glucose measurements performed 
at the research centre, data on medication use (through linkage with pharmacy dispens-
ing data), and general practitioners’ records. Participants with a fasting glucose ≥7.0 
mmol/L, a non-fasting glucose level ≥11.1 mmol/L (if fasting samples were not available), 
and participants that used anti-diabetic treatment were considered as having diabetes. 
Additionally, when participants were diagnosed with incident diabetes in between 
previous follow-up measurements of the Rotterdam Study, as identified through the 
link with the general practitioner records, participants were also considered as having 
diabetes.28 We defined impaired fasting glucose using the World Health Organization 
(WHO) 2006 criteria (fasting glucose level ≥6.1 mmol/L and <7.0 mmol/L, in the absence 
of diabetes).2 Glucose tolerance test were not performed, precluding the possibility to 
investigate the effect of impaired glucose tolerance.
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MetS was defined according to the harmonized criteria published in 2009.19 The 
presence of at least three of the following five components defined MetS: elevated 
waist circumference (≥94 cm for males, ≥80 cm for females), elevated triglycerides (≥1.7 
mmol/L, or drug treatment for elevated triglycerides), reduced high-density lipoprotein 
cholesterol (HDL-C; <1.0 mmol/L in males, <1.3 mmol/L in females, or specific treatment 
for reduced HDL-C), elevated blood pressure (systolic ≥130 mmHg and/or diastolic ≥85 
mmHg, and/or use of antihypertensive treatment) and elevated fasting glucose (≥5.6 
mmol/L, or use of glucose lowering medication). Medication use was assessed by self-
report and by going through the medication cabinets at the house of the participants 
during the home interview. Participants using lipid-lowering medication (the drugs that 
are mainly prescribed for lipid abnormalities in the Netherlands are statins) were con-
sidered to fulfil the triglyceride criterion, but not the HDL-C criterion, since statins only 
have a marginal effect on HDL-C. Specific drugs that are meant to raise HDL-C levels are 
very rarely prescribed in our population sample. Waist circumference, height, weight, and 
blood pressure (mean of two consecutive measurements) were measured at the research 
center. Information on glucose, cholesterol, and triglyceride levels was derived from blood 
samples taken as close to the polyneuropathy screening as possible. For 730 participants 
data on these cardiometabolic factors was collected on average two months before the 
polyneuropathy screening. In the remaining 526 participants evaluation of these factors 
took place at a previous visit (mean 4.9 years before polyneuropathy screening).
Polyneuropathy screening
Participants were screened for the presence of polyneuropathy with an in-person 
screening consisting of a symptom questionnaire, neurological examination and nerve 
conduction studies. The questionnaire consisted of sensory and motor symptoms of the 
legs or feet, like weakness, tingling, numbness, burning, allodynia, cramps, and pain. 
The neurological examination comprised assessment of vibration (Rydel-Seiffer tuning 
fork) on the hallux of both feet, pain sensation (wooden pin) on the lower legs, muscle 
strength for dorsiflexion of the feet (Rasch-MRC), and knee and ankle tendon reflexes. 
Nerve conduction studies were performed on the sural nerve bilaterally and on the pe-
roneal nerve unilaterally. The distal peroneal compound muscle action potential (CMAP) 
amplitude (mV, baseline-peak) and distal motor latency (ms) were recorded while 
stimulating 8 cm proximal to the recording electrode, which was placed on the extensor 
digitorum brevis muscle. The sural sensory nerve action potential (SNAP) amplitude (µV, 
baseline-peak) and sensory nerve conduction velocity (m/s) were measured by applying 
stimuli 14 cm proximal to the recording electrode, which was placed behind the lateral 
malleolus. Standard methods of supramaximal stimulation were applied. Examination 
took place at room temperature. Skin temperature was documented, but maintaining 
the temperature above a certain degree was not possible in the current setting.
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Medical records were scrutinized when participants scored abnormal on any of the 
three elements in the screening procedure (symptoms, signs, or abnormal nerve con-
duction parameters) to investigate whether participants received a previous specialist’s 
diagnosis of polyneuropathy. Participants could also self-report a previous diagnosis of 
polyneuropathy, which was subsequently checked in records. All collected data, both 
from the screening and medical records, from each individual participant was evaluated 
by an expert panel with extensive experience in diagnosing neuromuscular diseases. 
The panel consisted of an experienced neuromuscular specialist, a neurophysiology 
specialist and a medical doctor trained in epidemiology with a special interest in neu-
romuscular diseases. The panel categorized participants into no, possible, probable, 
and definite polyneuropathy, depending on the certainty of the diagnosis. Participants 
were discussed until unanimity was reached. When all three elements of the screening 
were abnormal participants were categorized as definite polyneuropathy, and when 
no elements were abnormal participants were categorized as no polyneuropathy. The 
remaining participants were categorized as possible and probable polyneuropathy, 
depending on the level of abnormality. Typically, one abnormal element or two slightly 
abnormal elements yielded a possible polyneuropathy categorization, and two abnor-
mal elements a probable categorization. All participants with a previous diagnosis of 
polyneuropathy made by a neurologist were categorized as definite polyneuropathy, 
since we consider a complete clinical work-up performed by a neurologist as superior 
to our screening. More details on the screening and diagnostic work-up can be found 
elsewhere.29
data analysis
Logistic regression analyses were performed to investigate the association of diabetes, 
prediabetes, continuous glucose levels and MetS with (categories of ) polyneuropathy. 
Analyses involving continuous glucose levels were performed using restricted cubic 
splines regression to assess potential non-linear associations. Analyses involving MetS 
were repeated after excluding participants with diabetes.
Additionally, linear regression analyses were used to investigate the association of 
diabetes, prediabetes, and MetS and its individual components with nerve conduction 
parameters. These analyses were performed in participants without polyneuropathy 
in order to investigate whether associations could already be found in the absence of 
polyneuropathy. For the sural nerve, the side with the highest SNAP amplitude and 
conduction velocity was used in the analyses.
All analyses were adjusted for age, sex, height and time between assessment of 
cardiometabolic factors and polyneuropathy screening. Logistic regression analyses in-
volving diabetes and prediabetes were additionally adjusted for weight, diastolic blood 
pressure, systolic blood pressure, blood pressure lowering medication, smoking, serum 
111
Metabolic syndrome and polyneuropathy
4
triglyceride level, serum HDL-cholesterol level and lipid lowering medication in a second 
model. Analyses involving components of MetS were additionally adjusted for the other 
components of the syndrome. Interaction terms for sex were explored in all models to 
investigate effect modification. Interaction between components of MetS in analyses 
involving these components was also investigated.
To further exclude the possibility that the time between polyneuropathy screening 
and assessment of cardiometabolic factors influenced the results, we performed a 
sensitivity analyses in which we repeated the logistic regression analyses into diabetes, 
impaired fasting glucose, and (components of ) MetS, restricted to the 730 participants 
with assessment of cardiometabolic factors on average 2 months before the polyneu-
ropathy screening.
Splines regression for continuous glucose levels was performed in R version 3.2.0, all 
other analyses were performed in SPSS statistical package, version 21 for Windows (IBM 
Corp., Armonk, NY),
Results
In total, 1256 participants were included in the analyses. The sample consisted of 685 
females (54.5%) and 571 males (45.5%), and the mean age was 70.0 years (see Table 1). 
Type 2 diabetes was present in 175 participants (13.9%) and IFG in 153 participants 
(12.2%). MetS was present in 659 participants (52.5%). Elevated waist circumference and 
elevated blood pressure were the most common components, present in 67.5% and 
78.0% of participants respectively. Sixty-four participants (5.1%) were diagnosed with 
a definite polyneuropathy, 92 (7.3%) with a probable polyneuropathy, and 218 (17.4%) 
with a possible polyneuropathy.
Diabetes was associated with definite polyneuropathy (odds ratio (OR) 3.01, 95% 
confidence interval (CI) 1.60;5.65, see Table 2). This association was mostly confined to 
males and slightly attenuated after adjusting for cardiovascular risk factors. We did not 
observe an association between IFG and polyneuropathy (OR 1.55, 95% CI 0.70;3.44). 
When investigating fasting glucose levels continuously, there was no association after 
exclusion of participants using anti-diabetic treatment. No associations were found with 
possible or probable polyneuropathy (Table 2).
MetS, defined as the presence of at least three out of five criteria, also associated 
with definite polyneuropathy (OR 1.92, 95% CI 1.09;3.38, Figure 1). This association was 
stronger when more components of the syndrome were present (at least four compo-
nents: OR 2.64, 95% 1.40;4.98 and all five components OR 3.23, 95% CI 1.22;8.55). Of the 
individual components, elevated waist circumference (OR 2.84, 95% CI 1.35;5.99) and 
elevated triglycerides (OR 2.01, 95% CI 1.11;3.62) were both related to definite polyneu-
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table 1. Population characteristics
Characteristic total population (n=1256)
Age, years 70.0 (10.0)
Females, n 685 (54.5)
Diabetes mellitus, n 175 (13.9)
Impaired fasting glucosea, n 153 (12.2)
Waist circumference, cm 92.4 (12.5)
Height, cm 169.8 (9.4)
Weight, kg 78.1 (13.7)
Serum triglycerides, mmol/L 1.4 (0.7)
Serum HDL cholesterol, mmol/L 1.5 (0.4)
Systolic blood pressure, mmHg 140.6 (21.3)
Diastolic blood pressure, mmHg 82.6 (10.7)
Serum glucose, mmol/L 5.8 (1.2)
Current smokers, n 189 (15.2)
Former smokers, n 656 (52.6)
Never smokers, n 401 (32.2)
MetSb, n 659 (52.5)
 Elevated waist circumference, n 848 (67.5)
 Elevated triglycerides, n 566 (45.1)
 Reduced HDL cholesterol, n 237 (18.9)
 Elevated blood pressure, n 980 (78.0)
 Elevated fasting glucose, n 617 (49.1)
Values represent number (%) or mean (SD).
a Fasting glucose ≥6.1 mmol/L and <7.0 mmol/L (WHO 2006 definition)
bMetS was defined according to the IDF 2009 criteria
MetS: metabolic syndrome; HDL: high-density lipoprotein
Figure 1. Association of number of mets components with polyneuropathy. Panel A shows the associa-
tion of MetS with polyneuropathy in the total study population. In panel B participants with diabetes have 
been excluded to investigate whether the association is also present in the non-diabetic population. Grey 
squares represent the presence of MetS (at least 3 components present). The white triangles and black dots 
represent the presence of at least 4 and 5 components respectively. All groups are compared to no MetS 
(<3 components). MetS: metabolic syndrome; PNP: polyneuropathy.
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ropathy (Table 3). Reduced HDL-C levels were associated with possible polyneuropathy 
(OR 1.50, 95% CI 1.01;2.24). A similar, although not significant effect estimate was found 
for probable, but not for definite polyneuropathy. After excluding participants with 
diabetes a similar pattern of associations, especially between elevated waist circumfer-
ence and definite polyneuropathy (OR 2.36, 95% CI 1.04;5.32), was found. There was 
no significant difference between genders in these analyses, nor was there significant 
interaction between different components of the syndrome.
Restricting the analyses to the 730 participants with assessment of cardiometa-
bolic factors on average two months before the polyneuropathy screening yielded even 
stronger associations, be it with wider confidence intervals (Supplementary Table 1). 
Diabetes (OR 5.98, 95% C.I. 2.11;16.93) strongly associated with definite polyneuropathy, 
as did the number of MetS components, elevated waist circumference and elevated 
triglycerides.
table 2. Association of diabetes mellitus and impaired fasting glucose with polyneuropathy
Possible 
polyneuropathy
OR (95% CI)
Probable 
polyneuropathy
OR (95% CI)
definite 
polyneuropathy
OR (95% CI)
total sample
 Diabetes Model 1 0.92 (0.58;1.46) 1.10 (0.57;2.14) 3.01 (1.60;5.65)a
Model 2 0.73 (0.44;1.21) 0.87 (0.43;1.77) 2.18 (1.09;4.34)a
 Impaired fasting glucose Model 1 1.03 (0.64;1.67) 0.81 (0.38;1.73) 1.55 (0.70;3.44)
Model 2 0.92 (0.56;1.51) 0.71 (0.33;1.56) 1.26 (0.54;2.91)
males
 Diabetes Model 1 0.74 (0.36;1.53) 1.54 (0.64;3.70) 6.04 (2.48;14.71)
Model 2 0.65 (0.30;1.39) 1.37 (0.54;3.51) 4.88 (1.82;13.10)
 Impaired fasting glucose Model 1 0.79 (0.39;1.62) 0.62 (0.21;1.89) 2.04 (0.70;5.94)
Model 2 0.77 (0.36;1.64) 0.61 (0.19;1.92) 1.62 (0.50;5.29)
Females
 Diabetes Model 1 1.08 (0.59;1.99) 0.66 (0.23;1.90) 1.22 (0.41;3.68)
Model 2 0.75 (0.38;1.50) 0.51 (0.16;1.57) 0.91 (0.28;2.95)
 Impaired fasting glucose Model 1 1.32 (0.68;2.54) 1.18 (0.41;3.40) 1.32 (0.37;4.78)
Model 2 1.09 (0.55;2.16) 1.03 (0.35;3.03) 1.16 (0.31;4.30)
Values represent odds ratios (95% confidence interval) of diabetes and impaired fasting glucose compared 
to normoglycemia
Model 1: adjusted for age, sex (only for the non-stratified analyses), height and time between assessment 
of cardiometabolic factors and polyneuropathy screening
Model 2: additionally adjusted for diastolic blood pressure, systolic blood pressure, antihypertensive treat-
ment, triglyceride level, HDL-cholesterol level, lipid lowering medication and smoking
a Significant sex interaction. HDL: high-density lipoprotein
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In individuals without clinical or neurophysiological suspicion on polyneuropathy, 
MetS was associated with lower sural SNAP amplitudes in both the total and the non-
diabetic population. Additionally, MetS related to lower peroneal CMAP amplitudes, but 
this association was present in males only (Table 4). When focusing on the separate com-
ponents of MetS, we found that elevated fasting glucose and reduced HDL-C related to a 
lower sural SNAP amplitude, especially in males, and that elevated waist circumference 
related to a lower peroneal CMAP amplitude in males only. There were no associations 
between any of the metabolic factors and peroneal distal latency or sural sensory nerve 
conduction velocity.
disCussion
In this population-based study, both diabetes and MetS were strongly associated with 
the presence of polyneuropathy. Elevated waist circumference and elevated triglycerides 
were the metabolic factors contributing the most to this association. We also showed 
that the effect of these factors is independent of the presence of diabetes. Although no 
association was found between IFG and polyneuropathy, an elevated fasting glucose 
was related to lower sural SNAP amplitudes in participants without polyneuropathy. Ad-
ditionally, we showed that MetS in participants without polyneuropathy related to lower 
sural SNAP amplitudes in males and females and to lower peroneal CMAP amplitudes in 
males.
The strong association between MetS and polyneuropathy has also been found in 
some other studies. These studies suggested an association of dyslipidemia or abdominal 
obesity with polyneuropathy in cohorts of patients with diabetes20-23 and in case-control 
studies of patients with idiopathic neuropathy.12, 24, 25, 30 A recent population-based study, 
table 3. Association of MetS components with polyneuropathy
Possible 
polyneuropathy
OR (95% CI)
Probable 
polyneuropathy
OR (95% CI)
definite 
polyneuropathy
OR (95% CI)
Elevated waist circumference 1.03 (0.72;1.47) 0.87 (0.52;1.46) 2.84 (1.35;5.99)
Elevated triglycerides 1.18 (0.85;1.65) 1.49 (0.91;2.46) 2.01 (1.11;3.62)
Reduced HDL cholesterol 1.50 (1.01;2.24) 1.58 (0.86;2.90) 1.21 (0.61;2.42)
Elevated blood pressure 0.93 (0.61;1.42) 0.71 (0.36;1.40) 1.43 (0.56;3.65)
Elevated fasting glucose 1.00 (0.72;1.38) 1.10 (0.68;1.79) 0.72 (0.41;1.29)
Adjusted for age, sex, height, time between assessment of cardiometabolic factors and polyneuropathy 
screening and all other components of MetS
No significant interactions with sex or between different components were found.
MetS: metabolic syndrome; HDL: high-density lipoprotein
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table 4. Association of MetS with nerve conduction parameters in males and females categorized as no 
polyneuropathy
Peroneal CmAP amplitude, mV sural snAP amplitude, µV
Males Females Males Females
glycemic state
  Diabetes -0.27 (-1.18;0.64) 0.01 (-0.80;0.82) -0.58 (-1.67;0.52) -1.18 (-2.89;0.53)
  Impaired fasting glucose -0.33 (-1.16;0.49) -0.11 (-1.02;0.79) -0.98 (-2.06;0.09) -1.40 (-3.14;0.33)
mets
Total sample
  ≥3 criteria of MetS -0.84 (-1.44;-0.23)b 0.44 (-0.06;0.94)b -0.99 (-1.75;-0.22) -1.24 (-2.28;-0.21)
  ≥4 criteria of MetS -0.92 (-1.68;-0.16)b 0.44 (-0.24;1.11)b -1.38 (-2.36;-0.40) -1.80 (-3.16;-0.44)
  5 criteria of MetS 0.25 (-1.20;1.71) 0.56 (-0.53;1.66) -1.72 (-3.61; 0.17) -0.51 (-2.92;1.90)
  Elevated waist 
circumferencea
-0.78 (-1.44;-0.13)b 0.03 (-0.55;0.61)b -0.42 (-1.24;0.40) -0.64 (-1.83;0.54)
  Elevated triglyceridesa 0.27 (-0.37;0.91) 0.46 (-0.08;0.99) -0.06 (-0.88;0.76) -0.18 (-1.28;0.92)
  Reduced HDL 
cholesterola
0.27 (-0.63;1.17) 0.11 (-0.55;0.77) -0.74 (-1.90;0.43) -0.40 (-1.78;0.98)
  Elevated blood pressurea 0.04 (-0.79;0.88) 0.03 (-0.57;0.62) -0.15 (-1.21;0.91) 0.49 (-0.72;1.71)
  Elevated fasting glucosea -0.48 (-1.12;0.16)b 0.17 (-0.35;0.68)b -0.90 (-1.71;-0.10) -0.71 (-1.77;0.36)
Participants without 
diabetes
  ≥3 criteria of MetS -0.94 (-1.60;-0.28)b 0.39 (-0.15;0.94)b -1.13 (-1.97;-0.30) -1.30 (-2.38;-0.23)
  ≥4 criteria of MetS -1.03 (-1.90;-0.17)b 0.48 (-0.31;1.27)b -1.84 (-2.92;-0.77) -2.11 (-3.58;-0.64)
  5 criteria of MetS 0.21 (-1.60;2.01) 0.37 (-1.38;2.11) -3.08 (-5.43;-0.74)b 0.94 (-2.56;4.43)b
  Elevated waist 
circumferencea
-0.74 (-1.46;-0.03)b 0.03 (-0.58;0.64)b -0.46 (-1.34;0.42) -0.57 (-1.78;0.64)
  Elevated triglyceridesa 0.36 (-0.34;1.06) 0.59 (0.02;1.16) -0.28 (-1.16;0.61) -0.26 (-1.39;0.88)
  Reduced HDL 
cholesterola
-0.11 (-1.15;0.93) 0.02 (-0.72;0.76) -1.41 (-2.72;-0.10) -0.43 (-1.93;1.07)
  Elevated blood pressurea 0.09 (-0.81;0.99) -0.11 (-0.75;0.52) 0.16 (-0.95;1.27) 0.20 (-1.06;1.46)
  Elevated fasting glucosea -0.50 (-1.20;0.19)b 0.26 (-0.31;0.82)b -0.93 (-1.78;-0.07) -0.60 (-1.73;0.53)
Values represent the difference in the specific nerve conduction parameters between participants with 
diabetes or impaired fasting glucose compared to participants with normoglycemia, or between presence 
of MetS or its components compared to absence of the syndrome or the specific component
Adjusted for age, height and time between assessment of cardiometabolic factors and polyneuropathy 
screening
Bold values are significant (p<0.05)
a Additionally adjusted for the other components of MetS
b Significant interaction by sex.
MetS: metabolic syndrome; HDL: high-density lipoprotein
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similar to ours, also showed an association of MetS with polyneuropathy, with a stronger 
association in the presence of more components. In contrast to our study, independent 
associations of specific MetS components were only found with secondary neuropathy 
outcomes, but not with the primary outcome, which was presence of polyneuropathy.31 
Our findings further contribute to the hypothesis that neuropathy in patients with dia-
betes is not only related to consequences of long-standing hyperglycemia, but is also 
influenced by the presence of other metabolic factors, especially abdominal obesity and 
dyslipidemia. We also showed that these factors likely are evenly important in persons 
without diabetes. Potential pathways through which these metabolic factors may lead 
to neuropathy include oxidative stress, possibly in combination with neuronal and 
axonal mitochondrial dysfunction, which can lead to nerve injury via chronic metabolic 
inflammation, insulin resistance and nerve ischemia.18
Our study is cross-sectional, which makes it difficult to draw firm conclusions about 
causality. It is possible that persons with polyneuropathy become less active, and con-
sequently gain weight and develop dyslipidemia. However, we showed that the associa-
tion with polyneuropathy got stronger when more components of MetS were present, 
suggesting a dose-response relation. Additionally, we found that MetS, elevated fasting 
glucose and dyslipidemia related to lower sural SNAP amplitudes in males and females 
without any suspicion on polyneuropathy and to lower peroneal CMAP amplitudes in 
males without polyneuropathy. Impaired function of these nerves, especially the SNAP 
amplitude of the sural nerves, is a fairly sensitive marker for axonal polyneuropathy.32 
Together these findings suggest that these metabolic factors increase the risk to 
develop polyneuropathy and not the other way around. Still, longitudinal studies are 
required to further strengthen this hypothesis. The observed differences between males 
and females in the association of diabetes, prediabetes and (components) of MetS with 
polyneuropathy and peripheral nerve function warrant further investigation.
Our study further showed that diabetes was associated with polyneuropathy. This 
is a well-established association which has been documented before.33 After adjusting 
for other cardiovascular risk factors, the association with polyneuropathy remained 
significant. This suggests that although other metabolic factors contribute to the patho-
physiology of polyneuropathy in patients with diabetes, consequences of prolonged 
hyperglycemia are probably most important. In contrast with some other studies, we 
did not find an association of polyneuropathy with IFG. Most studies that suggested an 
association between prediabetes and polyneuropathy lacked a control group4-8, or did 
not control for age, which is strongly related to both polyneuropathy and (pre)diabe-
tes.10, 34, 35 One controlled study did show an association of impaired glucose tolerance 
and neuropathy9, while the majority of controlled studies, especially the studies that 
took the confounding effect of age into account, found no association.11-13, 15, 25, 30, 31, 36 De-
spite these findings, prediabetes is still often considered a risk factor for polyneuropathy. 
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Our study does not support this assumption, but it is possible that we lacked sufficient 
power to show an effect. Moreover, we did not include impaired glucose tolerance into 
the definition of prediabetes, since oral glucose tolerance tests were not performed. Im-
paired glucose tolerance might be a better measure of prediabetes. Additionally, since 
we included an elderly population, with a mean age of 70 years, we cannot comment on 
the potential role of prediabetes earlier in life.
Our study is one of the very few studies that approaches the question if prediabetes 
and MetS are associated with polyneuropathy using a study design that includes an 
unselected sample of the middle-aged and elderly general population, without specific 
sampling techniques for cases or controls. Moreover, we used a rigorous definition of 
polyneuropathy, which is diagnosed with a protocol that largely resembles clinical prac-
tice and also includes nerve conduction studies. However, since we performed our study 
in a homogeneous, middle-aged to elderly population, we must note that our results 
may not directly translate to more heterogeneous, or younger populations. Our study 
also has other limitations. First, for some of the subgroup analyses samples were limited, 
yielding insufficient power to show small associations. Second, due to logistics of the 
study, in 526 participants the presence of diabetes and MetS was assessed approxi-
mately four years before the polyneuropathy screening. It is possible that participants 
developed incident (pre)diabetes during this period and lipid levels may have changed 
since the blood samples were collected. Therefore, we adjusted all analyses for the time 
between the assessment of cardiometabolic factors and the polyneuropathy screening 
to take this into account. Additionally, we performed a sensitivity analyses while exclud-
ing these 526 participants, which suggested that the results in the main analyses might 
even be an underestimation of the true effect. Third, we did not perform an oral glucose 
tolerance test. Possibly, post load hyperglycemia in the postprandial phase plays a key 
role in the pathogenesis of complications such as polyneuropathy.26 Finally, although 
our screening approach is as close to clinical practice as possible, it has not been 
validated and it is possible that some participants were misclassified as having poly-
neuropathy, while instead abnormality was due to focal neuropathies, radiculopathy, 
or non-specific symptoms attributable to osteoarthritis or other locomotor problems. 
This especially concerns the possible and probable polyneuropathy categories, which 
might explain the inconsistent findings in these groups. It is reasonable to assume that 
misclassification in the definite polyneuropathy category is very minimal, because we 
combined symptoms, neurological examination and NCS to make this categorization. 
The association with definite polyneuropathy thus provides an accurate estimate of the 
effect.
In conclusion, this population-based study showed that cardiometabolic distur-
bances, like abdominal obesity and dyslipidemia, are strongly related to the presence 
of polyneuropathy and impaired peripheral nerve function in participants without poly-
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neuropathy, irrespective of the presence of diabetes. Therefore, screening and optimal 
control of these risk factors may be warranted. Whether this also reduces neuropathic 
symptoms, or may even prevent the development or progression of polyneuropathy 
needs to be further evaluated in longitudinal studies.
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supplementary table 1. Sensitivity analyses in 730 participants with collection of cardiometabolic factors 
on average 2 months before polyneuropathy screening
definite polyneuropathy
OR (95% C.I.
glycemic state
Diabetes 5.98 (2.11;16.93)
Impaired fasting glucose 2.09 (0.62;7.10)
mets
≥3 criteria of MetS 2.24 (0.84;6.01)
≥4 criteria of MetS 2.99 (1.00;8.95)
5 criteria of MetS 5.16 (1.12;23.78)
Components of mets
Elevated waist circumference 8.55 (1.09;67.05)
Elevated triglycerides 2.49 (0.94;6.58)
Reduced HDL cholesterol 0.96 (0.33;2.79)
Elevated blood pressure 1.12 (0.38;3.31)
Elevated fasting glucose 0.65 (0.25;1.69)
Adjusted for age, sex and height
Analyses involving components of MetS are additionally adjusted for all other components of MetS
No significant effect modification by sex
MetS: metabolic syndrome; HDL: high-density lipoprotein
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High body mass and kidney dysfunction 
relate to worse nerve function, even in 
adults without polyneuropathy
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AbstRACt
Polyneuropathy is a prevalent and disabling disorder. Despite extensive evaluation, 
the cause often remains unknown. Factors that predispose for the development of 
polyneuropathy need to be identified. We investigated the effect of anthropometric and 
metabolic factors on peripheral nerve function in 908 participants of the population-
based Rotterdam Study without any symptoms or signs of polyneuropathy. Participants 
underwent nerve conduction studies of the sural and peroneal nerve. Data on age, 
height, weight, waist circumference, diabetes, lipid levels, hypertension and kidney 
function were collected. Regression analyses were used to investigate determinants 
of nerve action potential amplitudes. The frequency of abnormal sural sensory nerve 
action potential (SNAP) amplitudes increased with age from 1% under 60 years to 23% 
over 80 years. Similarly, the frequency of abnormal peroneal nerve compound motor 
action potential (CMAP) amplitudes increased from 4% to 13%. High weight and BMI 
were independently associated with reduced sural SNAP amplitudes and peroneal 
CMAP amplitudes. Participants with hypertension and kidney dysfunction were more 
likely to have abnormal sural SNAP amplitudes. Older age, high weight, hypertension 
and moderate kidney dysfunction might thus lead to peripheral nerve dysfunction in 
persons yet without symptoms or signs of polyneuropathy.
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intRoduCtion
Polyneuropathy is a common disorder, especially in elderly.1, 2 Due to aging of the popu-
lation, polyneuropathy prevalence will increase and so will the burden on individuals 
and society. Identification of (modifiable) risk factors for polyneuropathy is therefore 
highly important.
The development of polyneuropathy is thought to be gradual, with incremental de-
terioration of peripheral nerve function due to accumulating damage.3, 4 Once a certain 
threshold is passed, nerve function may be considered to be abnormal. When clinical 
symptoms and signs develop, a diagnosis of polyneuropathy can be made.5 A milder, yet 
similar deteriorating process also occurs with advancing age, with a decrease in nerve 
fibers density.6 Consequently, sensory and motor nerve action potential amplitudes, as 
measured with nerve conduction studies (NCS) also decrease with age.7-17 These age-
related morphological and electrophysiological changes to peripheral nerves might 
be considered as a very subtle start of the gradual process towards polyneuropathy, 
eventually leading to clinical symptoms if everyone would live long enough. Some per-
sons however deviate from this subtle process and develop manifest polyneuropathy 
earlier in life. This can often be attributed to co-occurrence of diabetes, end-stage kid-
ney disease, alcohol overuse, and other risk factors.1, 18-21 In a large proportion however, 
polyneuropathy remains idiopathic.1
So far, knowledge on risk factors comes from clinical studies, usually involving 
patients with a diagnosis of polyneuropathy. Far less research focused on factors that 
contribute to nerve damage before overt polyneuropathy develops. Information about 
preclinical changes can be insightful to better understand pathophysiology and per-
haps to identify persons at risk for polyneuropathy, who might benefit from preventive 
strategies. We aimed to investigate the effect of several anthropometric and metabolic 
determinants on peripheral nerve function in a population-based study of older adults 
without clinical symptoms or signs of polyneuropathy.
metHods And mAteRiAls
setting
This study was part of the Rotterdam Study, a prospective, population-based cohort 
study, conducted in a suburb of Rotterdam, the Netherlands.22 In 1990 and in 2000, all 
inhabitants over 55 years of age living in this area were invited to participate. In 2005, the 
study was expanded with persons over 45 years of age, living in the area. Overall, 14926 
individuals agreed to participate (response rate 72%). Every three to four years partici-
pants undergo extensive evaluations to investigate determinants of chronic diseases.
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The Rotterdam Study has been approved by the Medical Ethics Committee of the 
Erasmus MC and by the Ministry of Health, Welfare, and Sports of the Netherlands, 
implementing the “Wet Bevolkingsonderzoek: ERGO (Population Studies Act: Rotterdam 
Study)”. A written informed consent to participate in the study and to obtain information 
from their treating physicians was obtained from all participants.
Assessment of anthropometric and metabolic determinants
Demographic, anthropometric and metabolic determinants that were evaluated includ-
ed age, sex, height, weight, body mass index (BMI), waist circumference, waist-to-hip 
ratio, hypertension, diabetes mellitus, high-density cholesterol and triglyceride levels, 
kidney and liver function, smoking habits and alcohol use. These variables measure 
several factors that have previously been related to polyneuropathy.1, 18-21 Height, weight 
and waist and hip circumference were measured at the research center. BMI was calcu-
lated by dividing weight in kilogram by height in squared meters. A BMI above 25 was 
considered as overweight and above 30 as obese. Waist circumference was dichotomized 
into normal and elevated, at 94 centimeters for males and 80 centimeters for females.23 
Waist-to-hip ratio was calculated by dividing waist circumference by hip circumference. 
Blood pressure was assessed by the mean of two consecutive measurements. Hyperten-
sion was defined as a systolic blood pressure ≥140 mmHg, a diastolic blood pressure 
≥90 mmHg or use of antihypertensive medication. Blood sampling included assessment 
of fasting glucose, high-density lipoprotein cholesterol levels, triglyceride levels, creati-
nine, liver transaminases, bilirubin, alkaline phosphatase, and gamma-glutamyl transfer-
ase. Blood samples were collected as close to the polyneuropathy screening as possible, 
mostly within one year. However, due to logistics of the study blood samples taken at 
a previous visit had to be used in a third of participants (approximately 5 years before 
neuropathy screening). We defined diabetes mellitus as a fasting glucose ≥7.0 mmol/L, 
a non-fasting glucose ≥11.1 mmol/l, use of antidiabetic medication, or a previous diag-
nosis of diabetes (as identified through links with general practitioners’ records).24 The 
Chronic Kidney Disease Epidemiology Collaboration formula was used to calculate the 
estimated glomerular filtration rate (eGFR).25 Participants also collected timed overnight 
urine in which albumin and creatinine were determined. Albuminuria was assessed 
with the albumin-to-creatinine ratio (AC-ratio, mg/g), estimated by dividing albumin by 
creatinine. Kidney function was categorized into three groups: normal eGFR (>60 mL/
min/1.73 m2) and no albuminuria (AC-ratio <30 mg/g); reduced eGFR (<60 mL/min/1.73 
m2) or albuminuria (AC-ratio ≥30 mg/g); and reduced eGFR and albuminuria.26, 27 Smok-
ing habits and alcohol use were assessed by questionnaire.
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Polyneuropathy screening and nerve conduction studies
Details about the polyneuropathy screening have previously been published.28 In brief, 
the screening comprised assessment of symptoms with a questionnaire, neurological 
examination of the lower legs and NCS. The examination involved assessment of tendon 
reflexes, vibration sensation, pin sensibility and muscle strength of the feet. NCS in-
volved bilateral assessment of the sural nerve and unilateral assessment of the peroneal 
nerve. Participants were also asked about a previous polyneuropathy diagnosis, which 
was subsequently checked in medical records. Medical records of all participants with 
any abnormality in the screening were also investigated for a previous diagnosis. An 
expert panel categorized all participants into definite, probable, possible or no polyneu-
ropathy, depending on the estimated likelihood of the diagnosis.
NCS were performed using a Nicolet™ Viking Quest (Natus Medical Incorporated, 
San Carlos, California, USA). Standard techniques of supramaximal stimulation were 
used and examination was performed at room temperature. The nature of our study 
precluded the possibility to preheat the legs. Sural sensory nerve action potential 
(SNAP) amplitudes were measured using antidromic standardized techniques, with a 
recording electrode placed behind the lateral malleolus. Stimulation was applied on the 
calves 14 cm proximal to the recording electrode. In accordance with published norma-
tive values, baseline-peak amplitudes below 4 µV were considered abnormal for this 
middle-aged and elderly population.11 The peroneal nerve was stimulated lateral to the 
tibialis anterior tendon, 8 centimeters proximal to the recording electrode, which was 
placed on the midpoint of the extensor digitorum brevis muscle on the dorsum of the 
right foot. Compound muscle action potential (CMAP) baseline-peak amplitudes below 
1.1 mV were considered abnormal.29
Population for analyses
Between June 2013 and January 2016, 1464 participants successfully underwent the 
polyneuropathy screening. As we were interested in participants yet without poly-
neuropathy, those categorized as probable or definite polyneuropathy were excluded 
(n=196), since per definition these patients had either neuropathic symptoms, signs 
or both. From the remaining participants, we excluded another 198 participants who 
were classified as possible polyneuropathy based on the presence of symptoms or 
signs. Participants with abnormal NCS in the absence of symptoms or signs were not 
excluded, since these are part of the group of interest for this study. Participants with 
impaired vibration sensation on the big toe or reduced or absent ankle tendon reflexes, 
without symptoms or other signs of polyneuropathy were not excluded, since these 
signs may also reflect “normal aging”. Of the remaining 1070 participants, 162 were ex-
cluded because they did not sufficiently undergo nerve conduction studies, or had non-
interpretable results (due to edema, signal disturbance, or other technical problems). In 
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total, 908 participants without symptoms or signs of polyneuropathy were included in 
the analyses.
statistical analyses
Continuous determinants were visually checked for normality and, if necessary, log-
transformed (all were right-skewed distributions). Continuous determinants were 
subsequently standardized to describe associations uniformly per standard deviation. 
Sural SNAP and peroneal CMAP amplitudes were dichotomized into normal and abnor-
mal, using a sural SNAP amplitude of 4 µV and a peroneal CMAP amplitude of 1.1 mV 
according to the discussed normative values. For the sural nerve the side with the high-
est amplitude was used in the analyses. We calculated the frequency of abnormal and 
absent NCS amplitudes with regard to the total sample and by 10-year age categories.
We then performed two sequential analyses. First, logistic regression analyses were 
used to investigate whether anthropometric and metabolic determinants were associ-
ated with abnormal sural SNAP amplitudes and abnormal peroneal CMAP amplitudes. 
Second, we excluded participants with abnormal amplitudes and used linear regression 
analyses to investigate which determinants associated continuously with sural and 
peroneal amplitudes within the normal range. We performed continuous analyses only 
among those that were normal to rule out the possibility that subclinical disease or 
changes could influence the results. Analyses were adjusted for age, sex, height and 
time between blood sampling and neuropathy screening (if applicable) in model 1 (only 
in data supplement), since these variables are known to influence NCS parameters. In 
model 2 we additionally adjusted for the other determinants of interest in this study 
(weight, diabetes mellitus, hypertension, high-density lipoprotein cholesterol, triglyc-
erides, eGFR and AC-ratio, liver enzymes, smoking and alcohol), to investigate whether 
the reported associations were independent. Analyses involving other anthropometric 
measures than weight (BMI, waist circumference and waist-to-hip ratio) were not 
adjusted for weight to avoid over-adjustment. Similarly, analyses involving categorical 
measures of kidney function were not adjusted for the continuous measurements of 
kidney function. In all analyses, effect modification by age and sex was investigated by 
including an interaction term.
As sensitivity analyses we repeated the two sets of analyses while excluding par-
ticipants with limbs <29 degrees Celsius, to avoid cold temperatures influencing NCS 
results. With these analyses, we expect to get an impression of what the result would 
have been were we able to preheat the legs of participants. All analyses were performed 
in SPSS version 21 for Windows (IBM Corp., Armonk, NY).
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Results
The sample consisted of 908 participants, of which 493 (54%) were females. Mean age 
was 69 years. Prevalence of overweight, obesity and elevated waist circumference was 
49%, 17% and 69% respectively. The mean BMI was 26.7 and the mean waist-to-hip 
ratio was 0.9. Diabetes was present in 12% of participants and hypertension in 62% 
(Table 1). Sural SNAP amplitudes were reliably measured in 876 participants. Amplitudes 
table 1. Characteristics of the study sample
Characteristic total population (n=908)
Age, years 69.0 (9.4)
Female sex, n 493 (54.3)
Height, cm 169.5 (9.1)
Weight, kilograms 76.9 (13.0)
Body mass index, kg/m2 26.7 (3.8)
Overweight*, n 447 (49.2)
Obese*, n 154 (17.0)
Waist circumference, cm 92.5 (11.7)
Elevated waist circumference†, n 624 (68.8)
Waist-to-hip ratio 0.9 (0.1)
Diabetes mellitus, n 108 (12.1)
Hypertension, n 563 (62.0)
High-density lipoprotein cholesterol, mmol/L 1.5 (0.4)
Triglycerides, mmol/L 1.2 (1.0-1.7)
eGFR, ml/min/1.73 m2 76.3 (19.9)
Albumin-to-creatinine ratio, mg/g 3.4 (2.0-6.4)
Abnormal AC-ratio or eGFR, n 234 (27.0)
Abnormal AC-ratio and eGFR, n 24 (2.8)
Alanine transaminase, U/L 20.0 (15.0-25.0)
Aspartate transaminase, U/L 24.0 (21.0-28.0)
Bilirubin, µmol/L 8.0 (6.0-11.0)
Alkaline phosphatase, U/L 71.0 (21.4)
Gamma-glutamyl transferase, U/L 23.0 (16.0-33.0)
Smoking Never, n 301 (33.3)
Past, n 474 (52.5)
Current, n 128 (14.2)
Alcohol, drinks per month 21.2 (22.7)
Values represent mean (standard deviation), median (25th - 75th percentile) or number (%)
* Body mass index above 25 was considered as overweight, above 30 as obese
† Waist circumference above 94 centimeters for males, and 80 centimeters for females
n: number; eGFR: estimated glomerular filtration rate; AC-ratio: albumin-to-creatinine ratio; U/L: units per liter
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were abnormal in 87 participants (10%), 60 (7%) of which were absent. Peroneal CMAP 
amplitudes were reliably measured in 833 participants. These were abnormal in 76 
participants (9%), 26 (3%) of which were absent. Of the overlapping 808 participants 
with both nerves reliably measured, 18 (2%) had abnormal amplitudes for both nerves, 
65 (8%) only for the sural, and 57 (7%) only for the peroneal nerve.
Age was strongly related to abnormal values for both the sural SNAP and the 
peroneal CMAP amplitude (Fig. 1). Tall, heavy, (abdominally) obese and hypertensive 
Figure 1. Percentage of abnormal nerve amplitudes by age in participants without clinical suspicion 
on polyneuropathy. The figure shows the percentage of participants with normal (light grey bars) abnor-
mal (dark grey bars) and absent (black bars) sural sensory nerve action potential (SNAP) amplitudes (Panel 
A) and peroneal nerve compound muscle action potential (CMAP) amplitudes (Panel B). An abnormal sural 
SNAP amplitude is defined as an amplitude < 4 µV and an abnormal peroneal CMAP amplitude is defined 
as an amplitude < 1.1 mV.
Figure 2. effect of age on nerve amplitudes in individuals without clinical or electrophysiological sus-
picion on polyneuropathy. Grey circles represent all individual persons with their corresponding age and 
amplitude. Black circles with error bars represent the adjusted mean value, with confidence interval, of the 
specific nerve conduction parameter per five-year age group. Values are adjusted for sex and height.
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participants were more likely to have abnormal sural SNAP amplitudes. Participants with 
chronic kidney dysfunction (reduced eGFR and albuminuria) were also more likely to 
have abnormal sural SNAP amplitudes, independent of other covariates (OR 4.8, 95% 
C.I. 1.4;16.4). Aside from age, a high weight and BMI were associated with abnormal 
peroneal CMAP amplitudes, but waist circumference and waist-to-hip ratio were not. 
Sex, diabetes, lipid levels, liver enzymes, alcohol use and smoking were not related to 
impairment in either sural SNAP or peroneal CMAP amplitude (Table 2). There was no 
effect modification by age or sex in these analyses.
After excluding participants with abnormal amplitudes (87 and 76 participants for 
the sural and peroneal nerve respectively), we still observed a lower sural SNAP and 
peroneal CMAP amplitude with higher age, especially after the age of 70 (Fig. 2). The 
effect of age on the sural SNAP amplitude was stronger in females (-2.64 µV per standard 
deviation increase in age, 95% C.I. -3.14;-2.15) than in males (-1.81 µV, 95% C.I. -2.21;-
1.42). A similar pattern of associations as in the dichotomous analyses was found for 
the sural nerve: being tall, heavy, and (abdominally) obese related to lower sural SNAP 
amplitudes within the normal range (Table 3). These effects were similar in males and 
females. There were no associations with the peroneal CMAP amplitude.
When restricting the analyses to NCS performed in participants with a limb tempera-
ture >29 degrees Celsius, we found a slightly higher percentage of abnormal sural SNAPs 
and peroneal CMAPs of 12.5% (76 out of 606) and 9.6% (61 out of 638) respectively. 
Effect estimates of the logistic and linear regression models were similar to those of the 
main analyses (supplementary tables 1 and 2).
disCussion
In our study of community-dwelling older adults without symptoms or signs of poly-
neuropathy, abnormal sural SNAP and peroneal CMAP amplitudes were found in almost 
10% of participants. Both the sural SNAP and the peroneal CMAP amplitude declined 
with increasing age, especially after the age of 70. Weight, BMI and the presence of obe-
sity, hypertension and kidney dysfunction were also independently related to abnormal 
amplitudes. Most factors were also associated with lower amplitudes within the normal 
range. These results suggest that metabolic factors are related to a decline in peripheral 
nerve function, even before symptoms or signs of polyneuropathy become apparent.
Our study is one of the very few studies that investigates the significance and determi-
nants of abnormal NCS in an unselected older population, utilizing a population-based 
study as source population. This minimizes the chances of selection bias and improves 
the generalizability of the results. Previous clinic-based studies that investigated aging 
effects on NCS also found a decreasing amplitude with increasing age. However, results 
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table 2. Determinants of abnormal nerve conduction parameters in individuals without clinical suspicion 
of polyneuropathy
Abnormal sural
snAP amplitude
OR (95% C.I.)
Abnormal peroneal
CmAP amplitude
OR (95% C.I.)
Age, per SD 1.64 (0.92;2.93) 2.03 (1.20;3.42)
Female sex 2.49 (0.77;8.06) 1.46 (0.45;4.75)
Height, per SD 1.70 (1.08;2.68) 1.25 (0.81;1.91)
Weight, per SD 1.69 (1.16;2.46) 1.59 (1.12;2.25)
Body mass index, SD 1.53 (1.13;2.09) 1.49 (1.11;1.99)
Overweighta 2.46 (1.26;4.78) 1.77 (0.96;3.29)
Obesea 3.01 (1.23;7.40) 2.09 (0.89;4.92)
Waist circumference, per SD 1.64 (1.21;2.23) 1.29 (0.96;1.75)
Elevated waist circumference 2.34 (1.16;4.74) 1.18 (0.64;2.18)
Waist-to-hip ratio, per SD 1.36 (1.01;1.85) 1.15 (0.83;1.58)
Diabetes 0.77 (0.34;1.76) 0.39 (0.13;1.14)
Hypertension 2.14 (1.07;4.27) 0.82 (0.45;1.46)
High-density lipoprotein cholesterol, per SD 0.99 (0.67;1.46) 1.09 (0.75;1.58)
Triglycerides, per SD* 1.04 (0.75;1.44) 1.05 (0.76;1.43)
eGFR, per SD 0.92 (0.55;1.54) 0.93 (0.57;1.54)
Albumin-to-creatinine ratio, per SD* 1.19 (0.93;1.51) 0.99 (0.77;1.26)
Abnormal AC-ratio or eGFRb 1.20 (0.58;2.49) 1.00 (0.49;2.05)
Abnormal AC-ratio and eGFRb 4.80 (1.40;16.41) 2.77 (0.76;10.15)
Alanine transaminase, per SD* 0.76 (0.54;1.08) 0.88 (0.63;1.25)
Aspartate transaminase, per SD* 1.29 (0.89;1.86) 1.20 (0.86;1.67)
Bilirubin, per SD* 0.97 (0.73;1.28) 0.94 (0.72;1.24)
Alkaline phosphatase, per SD 0.98 (0.79;1.22) 1.00 (0.79;1.28)
Gamma-glutamyl transferase, per SD* 0.92 (0.66;1.28) 0.97 (0.71;1.33)
Past smokingc 1.33 (0.73;2.42) 1.19 (0.66;2.15)
Current smokingc 0.97 (0.32;2.91) 2.03 (0.90;4.56)
Alcohol, per SD 0.74 (0.51;1.07) 0.75 (0.53;1.07)
Values represent odds ratios comparing odds on impairment in nerve conduction parameter per SD (con-
tinuous determinants) or per category (categorical determinants).
Adjusted for age, sex, height, weight (if applicable), diabetes mellitus, high-density lipoprotein cholesterol, 
triglycerides, hypertension, eGFR and AC-ratio (if applicable), liver enzymes, smoking, alcohol and time 
between laboratory assessment and NCS (if applicable)
a Compared to body mass index < 25
b Compared to normal eGFR and normal AC-ratio
c Compared to never smokers
* Log-transformed values
SD: standard deviation; eGFR: estimated glomerular filtration rate; AC-ratio: albumin-to-creatinine ratio
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table 3. Determinants of nerve conduction parameters in individuals without clinical or electrophysiological 
suspicion of polyneuropathy
Change in suralsnAP 
amplitude, µV
β (95% C.I.)
Change in peroneal
CmAP amplitude, mV
β (95% C.I.)
Age, per SD -1.81 (-2.45;-1.18) -0.26 (-0.64;0.12)
Female sex -0.31 (-1.82;1.20) -0.38 (-1.29;0.53)
Height, per SD -1.42 (-1.93;-0.90) -0.13 (-0.44;0.18)
Weight, per SD -0.49 (-0.91;-0.07) -0.19 (-0.44;0.06)
Body mass index, per SD -0.42 (-0.77;-0.07) -0.16 (-0.36;0.05)
Overweighta -0.00 (-0.73;0.73) -0.35 (-0.78;0.07)
Obesea -1.44 (-2.45;-0.42) -0.47 (-1.07;0.13)
Waist circumference, per SD -0.48 (-0.85;-0.10) -0.01 (-0.23;0.21)
Elevated waist circumference -0.81 (-1.54;-0.07) -0.27 (-0.71;0.17)
Waist-to-hip ratio, per SD -0.49 (-0.90;-0.09) 0.18 (-0.07;0.42)
Diabetes -0.43 (-1.40;0.55) -0.13 (-0.72;0.46)
Hypertension -0.09 (-0.78;0.59) 0.13 (-0.28;0.54)
High-density lipoprotein cholesterol, per SD 0.32 (-0.11;0.75) -0.10 (-0.35;0.16)
Triglycerides, per SD* 0.31 (-0.07;0.69) 0.05 (-0.17;0.28)
eGFR, per SD -0.16 (-0.82;0.50) 0.16 (-0.23;0.55)
Albumin-to-creatinine ratio, per SD* -0.08 (-0.40;0.23) 0.02 (-0.16;0.21)
Abnormal AC-ratio or eGFRb 0.38 (-0.49;1.25) -0.21 (-0.74;0.32)
Abnormal AC-ratio and eGFRb -0.01 (-2.23;2.20) -0.32 (-1.73;1.09)
Alanine transaminase, per SD* 0.19 (-0.25;0.63) -0.00 (-0.26;0.26)
Aspartate transaminase, per SD* -0.27 (-0.68;0.13) -0.13 (-0.37;0.11)
Bilirubin, per SD* -0.15 (-0.48;0.17) -0.03 (-0.22;0.17)
Alkaline phosphatase, per SD -0.24 (-0.55;0.08) -0.01 (-0.20;0.17)
Gamma-glutamyl transferase, per SD* 0.15 (-0.24;0.53) 0.06 (-0.17;0.29)
Past smokingc 0.06 (-0.64;0.76) 0.26 (-0.15;0.67)
Current smokingc -0.47 (-1.47;0.52) -0.04 (-0.65;0.56)
Alcohol, per SD 0.20 (-0.14;0.55) -0.01 (-0.23;0.20)
Values represent the change in nerve conduction parameter per SD (continuous determinants) or per cat-
egory (categorical determinants) difference of the characteristics shown.
Adjusted for age, sex, height, weight (if applicable), diabetes mellitus, high-density lipoprotein cholesterol, 
triglycerides, hypertension, eGFR and AC-ratio (if applicable), liver enzymes, smoking, alcohol and time 
between laboratory assessment and NCS (if applicable)
a Compared to body mass index < 25
b Compared to normal eGFR and normal AC-ratio
c Compared to never smokers
* Log-transformed values
SD: standard deviation; eGFR: estimated glomerular filtration rate; AC-ratio: albumin-to-creatinine ratio
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concerning the frequency and significance of abnormal NCS amplitudes in otherwise 
healthy elderly have been inconsistent.10-13, 16, 17 One large retrospective study found 
a high percentage of absent NCS responses in old age groups10, while other smaller, 
clinic-based studies found only a few or none participants with unobtainable sural 
SNAP amplitudes.11-13, 15-17 In our study, sural SNAP amplitudes were abnormal in 9.9% of 
participants and absent in 6.8% of participants, and this proportion increased with age. 
We might even have underestimated this proportion: temperature is inversely related to 
NCS amplitudes, it is thus possible that participants with cold feet had artificially high 
amplitudes.30 This is supported by the findings of our sensitivity analyses, showing a 
higher percentage of participants with abnormal values after excluding participants with 
cold feet (<29 degrees Celsius). Given this high frequency of abnormal NCS amplitudes 
in elderly without symptoms or signs of polyneuropathy, the results of such findings 
should be interpreted in combination with other findings of a neurological examination. 
On its own, a reduced sural SNAP amplitude might not be clinically relevant, similar 
to reduced or absent ankle reflexes or distal vibration sensation, which are also quite 
common findings in elderly without polyneuropathy.31 Whether such observations, 
especially in elderly, should even be considered as abnormal is debatable.
Besides age, we found that several measures of body mass were independently related 
to lowered sural SNAP and peroneal CMAP amplitudes. It has been suggested that mea-
suring NCS amplitudes is less reliable in heavy people due to attenuation of amplitudes 
by a thicker layer of subcutaneous tissue.12, 32 An alternative explanation is that these 
lower amplitudes can be an early sign of peripheral nerve dysfunction. Given our findings 
of a relation with especially abdominal obesity (waist circumference and waist-to-hip 
ratio), the latter explanation might be more likely. Obesity has been linked to polyneu-
ropathy and lowered intra-epidermal nerve fiber density in several studies, including our 
own recent study where we investigated the effect of different components of metabolic 
syndrome on polyneuropathy and nerve conduction values.19, 33-36 Therefore, correcting 
NCS values for BMI as a confounding measurement seems not appropriate.12, 14, 32
We found that hypertension and kidney dysfunction independently related to ab-
normal sural SNAP amplitudes, but not with other NCS measures. Around 60-90% of 
patients with end-stage chronic kidney disease who require dialysis have an uremic neu-
ropathy.21 When this neuropathy exactly develops during the course of chronic kidney 
disease is not known, but it has been suggested that neuropathy is limited to patients 
with end-stage kidney disease, which means an eGFR <15 ml/min.21 Interestingly, none 
of the participants in our study had such a low eGFR and only five participants had an 
eGFR below 30 ml/min. Even when excluding these participants, we found a similar 
association of mild to moderate kidney dysfunction with reduced sural nerve action 
potential amplitudes (results not shown). Whether peripheral nerve injury already starts 
in an early stage of kidney dysfunction needs to be further investigated.
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We did not observe associations with lipid levels, smoking, or liver enzymes. Nor did 
we find associations with diabetes and alcohol use, even though excessive alcohol use 
and diabetes are known risk factors for polyneuropathy. There are several explanations 
for these findings. First, there were few participants who were overusing alcohol. Sec-
ond, alcohol use was assessed by self-report, and underreporting of alcohol intake is 
common.37 A surprising finding is that diabetes mellitus in this study did not relate to 
reduced sural SNAP or peroneal CMAP amplitudes. This is likely caused by the selection 
of participants for this study, as those with clinical symptoms or signs of neuropathy 
were excluded, because we were interested in what happened with nerve function prior 
to the onset of clinical polyneuropathy. Diabetics are often screened by their doctors 
and educated about the occurrence of complications like neuropathy. We suspect that 
these individuals are more likely to report symptoms and are more often and early on 
diagnosed with neuropathy, and thus excluded from this study. The remaining diabetics 
in our study sample may have too mild or early diabetes to show a significant effect on 
nerve dysfunction. Unfortunately, we did not have sufficient data to further study this.
The strengths of our study include the population-based design, which led to an 
unselected sample of the general population, the inclusion of a large sample of elderly 
persons, and the prospective and extensive data collection. The main limitation of our 
population-based study is that we could not preheat the legs before performing NCS. 
Although the results of our sensitivity analyses were similar to the main analyses, we 
cannot rule out this has influenced our results. A second limitation is that we had to use 
blood samples taken at a previous visit for a subset of the population. We adjusted the 
analyses for the time between NCS and blood sampling to take this into account, but 
since blood measurements can change over time, this may have influenced our results.
In conclusion, sural and peroneal nerve amplitudes gradually decline with advanc-
ing age. Increased body mass, and obesity are independently associated with reduced 
action potential amplitudes of these nerves. Moderate kidney dysfunction and hyper-
tension might further contribute to impaired functioning of especially sensory nerves. 
These results suggest a gradual decline in peripheral nerve function in the presence 
of these potentially modifiable metabolic factors, even before symptoms or signs of 
polyneuropathy develop. Longitudinal studies are required to investigate whether these 
factors predispose for the development of polyneuropathy.
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supplementary table 1. Determinants of abnormal nerve conduction parameters in individuals without 
clinical suspicion of polyneuropathy in the total sample of participants, and in the sample excluding limbs 
<29 degrees Celsius
Abnormal sural 
nAP amplitude
OR (95% C.I.)
Abnormal peroneal
CmAP amplitude
OR (95% C.I.)
All participants
<29 degrees
excluded
All participants
<29 degrees
excluded
Age, per SD 3.81 (2.77;5.24) 4.01 (2.76;5.83) 1.77 (1.35;2.33) 1.58 (1.16;2.14)
Female sex 1.75 (0.87;3.49) 2.48 (1.14;5.40) 1.26 (0.63;2.54) 1.43 (0.64;3.22)
Height, per SD 1.89 (1.30;2.74) 2.23 (1.46;3.39) 1.49 (1.03;2.14) 1.44 (0.93;2.22)
Weight, per SD 1.62 (1.18;2.21) 1.58 (1.12;2.24) 1.47 (1.10;1.98) 1.56 (1.13;2.17)
Body mass index, SD 1.48 (1.14;1.93) 1.46 (1.09;1.95) 1.39 (1.09;1.78) 1.46 (1.11;1.92)
Overweighta 2.15 (1.20;3.84) 2.23 (1.18;4.23) 1.59 (0.90;2.82) 1.73 (0.90;3.32)
Obesea 2.75 (1.28;5.92) 2.43 (1.04;5.72) 1.95 (0.93;4.08) 1.81 (0.78;4.19)
Waist circumference, per SD 1.51 (1.16;1.95) 1.59 (1.16;2.17) 1.19 (0.92;1.55) 1.22 (0.92;1.62)
Elevated waist circumference 2.18 (1.20;3.93) 2.39 (1.22;4.67) 1.16 (0.67;1.99) 1.35 (0.71;2.55)
Waist-to-hip ratio, per SD 1.35 (1.03;1.78) 1.58 (1.09;2.28) 1.07 (0.79;1.45) 1.11 (0.81;1.51)
Diabetes 0.93 (0.44;1.96) 0.94 (0.42;2.12) 0.40 (0.14;1.15) 0.50 (0.17;1.43)
Hypertension 2.22 (1.23;4.02) 2.16 (1.15;4.03) 1.04 (0.62;1.76) 1.19 (0.66;2.16)
HDL cholesterol, per SD 0.82 (0.62;1.09) 0.85 (0.63;1.16) 0.91 (0.69;1.20) 0.96 (0.71;1.30)
Triglycerides, per SD* 1.11 (0.87;1.42) 1.08 (0.83;1.40) 1.03 (0.81;1.32) 0.95 (0.72;1.26)
eGFR, per SD 0.96 (0.59;1.56) 1.16 (0.67;2.01) 0.94 (0.58;1.52) 0.88 (0.51;1.52)
AC-ratio, per SD* 1.20 (0.95;1.51) 1.22 (0.95;1.56) 1.00 (0.79;1.28) 1.04 (0.80;1.35)
Abnormal AC-ratio or eGFRb 1.17 (0.58;2.36) 1.11 (0.51;2.41) 1.01 (0.50;2.03) 1.06 (0.49;2.28)
Abnormal AC-ratio and eGFRb 5.12 (1.55;16.85) 5.23 (1.48;18.46) 3.08 (0.91;10.44) 3.00 (0.79;11.35)
Alanine transaminase, per SD* 0.89 (0.70;1.14) 0.81 (0.62;1.06) 0.95 (0.74;1.22) 1.02 (0.78;1.34)
Aspartate transaminase, per SD* 1.08 (0.82;1.42) 1.07 (0.80;1.44) 1.05 (0.82;1.36) 1.09 (0.84;1.41)
Bilirubin, per SD* 1.06 (0.82;1.36) 1.04 (0.79;1.37) 0.93 (0.72;1.19) 0.93 (0.70;1.24)
Alkaline phosphatase, per SD 0.97 (0.79;1.18) 0.96 (0.78;1.18) 1.03 (0.84;1.26) 1.00 (0.80;1.27)
Gamma-GT per SD* 0.95 (0.73;1.23) 0.89 (0.66;1.20) 0.95 (0.73;1.24) 0.98 (0.73;1.32)
Past smokingc 1.16 (0.67;1.99) 1.13 (0.62;2.04) 1.13 (0.64;1.99) 1.19 (0.63;2.23)
Current smokingc 0.85 (0.32;2.22) 1.12 (0.41;3.06) 1.90 (0.89;4.04) 1.80 (0.76;4.23)
Alcohol, per SD 1.00 (0.77;1.31) 1.05 (0.80;1.39) 0.77 (0.57;1.03) 0.70 (0.49;1.00)
Values represent odds ratios comparing odds on impairment in nerve conduction parameter per SD (con-
tinuous determinants) or per category (categorical determinants).
Adjusted for age, sex, height and time between laboratory assessment and NCS (if applicable)
a Compared to body mass index < 25
b Compared to normal eGFR and normal AC-ratio
c Compared to never smokers
* Log-transformed values
SD: standard deviation; eGFR: estimated glomerular filtration rate; AC-ratio: albumin-to-creatinine ratio
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supplementary table 2. Determinants of nerve conduction parameters in individuals without clinical or 
electrophysiological suspicion of polyneuropathy in the total sample of participants, and in the sample ex-
cluding limbs <29 degrees Celsius
Change in sural
snAP amplitude, µV
β (95% C.I.)
Change in peroneal
CmAP amplitude, mV
β (95% C.I.)
All participants
<29 degrees
excluded
All participants
<29 degrees
excluded
Age, per SD -2.29 (-2.61;-1.96) -1.85 (-2.20;-1.49) -0.55 (-0.74;-0.36) -0.49 (-0.71;-0.27)
Female sex -0.30 (-1.16;0.56) -0.68 (-1.62;0.25) -0.18 (-0.69;0.33) -0.25 (-0.84;0.34)
Height, per SD -1.63 (-2.07;-1.18) -1.38 (-1.88;-0.89) -0.25 (-0.51;0.02) -0.27 (-0.59;0.05)
Weight, per SD -0.49 (-0.85;-0.13) -0.74 (-1.13;-0.36) -0.08 (-0.29;0.14) -0.09 (-0.34;0.15)
Body mass index, per SD -0.42 (-0.72;-0.12) -0.65 (-0.97;-0.33) -0.07 (-0.24;0.11) -0.08 (-0.28;0.13)
Overweighta 0.10 (-0.55;0.76) -0.21 (-0.92;0.49) -0.19 (-0.57;0.20) -0.22 (-0.66;0.22)
Obesea -1.39 (-2.26;-0.52) -1.98 (-2.91;-1.06) -0.22 (-0.74;0.30) -0.21 (-0.80;0.38)
Waist circumference, per SD -0.43 (-0.74;-0.11) -0.57 (-0.93;-0.22) 0.05 (-0.13;0.24) 0.01 (-0.20;0.22)
Elevated waist circumference -0.79 (-1.42;-0.15) -0.99 (-1.67;-0.30) -0.06 (-0.44;0.32) -0.16 (-0.60;0.28)
Waist-to-hip ratio, per SD -0.43 (-0.78;-0.07) -0.43 (-0.86;0.00) 0.19 (-0.02;0.40) 0.14 (-0.09;0.37)
Diabetes -0.67 (-1.59;0.24) -0.82 (-1.75;0.11) -0.16 (-0.71;0.38) -0.10 (-0.73;0.52)
Hypertension -0.15 (-0.77;0.47) -0.31 (-0.97;0.35) 0.14 (-0.23;0.51) 0.04 (-0.38;0.46)
HDL cholesterol, per SD 0.35 (0.03;0.68) 0.32 (-0.03;0.66) -0.06 (-0.25;0.13) -0.11 (-0.33;0.10)
Triglycerides, per SD* 0.08 (-0.22;0.38) -0.06 (-0.37;0.25) 0.09 (-0.09;0.27) 0.13 (-0.08;0.33)
eGFR, per SD -0.24 (-0.87;0.39) 0.03 (-0.64;0.70) 0.10 (-0.27;0.48) 0.02 (-0.41;0.45)
AC-ratio, per SD* -0.10 (-0.41;0.51) -0.15 (-0.47;0.17) 0.03 (-0.15;0.21) 0.01 (-0.19;0.22)
Abnormal AC-ratio or eGFRb 0.18 (-0.67;1.02) -0.04 (-0.92;0.83) -0.23 (-0.74;0.28) -0.31 (-0.87;0.25)
Abnormal AC-ratio and eGFRb -0.12 (-2.30;2.07) -0.37 (-2.41;1.67) -0.30 (-1.68;1.08) -0.16 (-1.64;1.33)
Alanine transaminase, per SD* 0.04 (-0.26;0.35) 0.18 (-0.14;0.50) -0.04 (-0.22;0.14) -0.04 (-0.24;0.16)
Aspartate transaminase, per SD* -0.06 (-0.37;0.24) 0.10 (-0.22;0.41) -0.10 (-0.28;0.08) -0.09 (-0.29;0.11)
Bilirubin, per SD* -0.02 (-0.33;0.28) -0.05 (-0.37;0.27) -0.03 (-0.21;0.15) -0.03 (-0.25;0.18)
Alkaline phosphatase, per SD -0.26 (-0.56;0.04) -0.20 (-0.49;0.09) 0.01 (-0.17;0.18) 0.05 (-0.14;0.24)
Gamma-GT per SD* 0.13 (-0.19;0.44) 0.22 (-0.12;0.55) 0.03 (-0.15;0.22) -0.00 (-0.22;0.21)
Past smokingc 0.28 (-0.38;0.94) 0.64 (-0.06;1.34) 0.13 (-0.25;0.52) 0.07 (-0.37;0.50)
Current smokingc -0.29 (-1.22;0.65) -0.10 (-1.12;0.92) 0.10 (-0.46;0.65) -0.02 (-0.66;0.61)
Alcohol, per SD 0.29 (-0.02;0.59) 0.32 (-0.02;0.66) 0.01 (-0.17;0.19) -0.04 (-0.58;0.06)
Values represent the change in nerve conduction parameter per SD (continuous determinants) or per cat-
egory (categorical determinants) difference of the characteristics shown.
Adjusted for age, sex, height and time between laboratory assessment and NCS (if applicable)
a Compared to body mass index < 25
b Compared to normal eGFR and normal AC-ratio
c Compared to never smokers
* Log-transformed values
SD: standard deviation; eGFR: estimated glomerular filtration rate; AC-ratio: albumin-to-creatinine ratio
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AbstRACt
objective: To extensively investigate the association of chronic polyneuropathy with 
basic and instrumental activities of daily living (BADL and IADL), falls and gait.
methods: 1445 participants of the population-based Rotterdam Study (mean age 71 
years, 54% women) underwent a polyneuropathy screening involving a symptom ques-
tionnaire, neurological examination and nerve conduction studies. Screening yielded 
four groups: no, possible, probable and definite polyneuropathy. Participants were in-
terviewed about BADL (Stanford Health Assessment questionnaire), IADL (Instrumental 
Activities of Daily Living scale) and frequency of falling in the previous year. In a random 
subset of 977 participants, gait was assessed with an electronic walkway. Associations of 
polyneuropathy with BADL and IADL were analyzed continuously with linear regression, 
and dichotomously with logistic regression. History of falling was evaluated with logistic 
regression and gait changes were evaluated with linear regression.
Results: Participants with definite polyneuropathy had more difficulty in performing 
BADL and IADL than participants without polyneuropathy. Polyneuropathy related to 
worse scores of all BADL (especially walking) and three IADL components (housekeep-
ing, traveling, and shopping). Participants with definite polyneuropathy were more likely 
to fall, and these falls more often resulted in injury. Participants with polyneuropathy 
had worse gait parameters on the walkway, including lower walking speed and cadence, 
and more errors in tandem walking.
Conclusions: Chronic polyneuropathy strongly associates with impairment in the ability 
to perform daily activities and relates to worse gait and an increased history of falling.
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intRoduCtion
The ability to walk and to perform daily activities is an important health indicator that 
strongly relates to the risk of future morbidity and mortality.1, 2 Disability in activities of 
daily living (ADL) can result in loss of the ability to function independently in society, 
which ultimately leads to institutionalization and a reduced quality of life.3, 4
Proper functioning in ADL requires integration of input from various systems. The 
peripheral nervous system plays a key role in this integration by conducting important 
information from all body parts towards the central nervous system and vice versa. In 
persons with polyneuropathy this information throughput is disturbed, typically leading 
to sensory disturbances, balance problems and walking instability. Studies showed that 
polyneuropathy affects mobility and leads to a reduced quality of life.5-11 Additionally, 
persons with polyneuropathy have an increased risk of falling, which is associated with 
significant morbidity, loss of independence and mortality.12-14 It is thus not surprising 
that polyneuropathy can severely reduce a person’s ability to perform ADL.5, 13-16
Still, several knowledge gaps remain. First, ADL consist of physical basic activities of 
daily living (BADL)17, 18, and of cognitively more challenging instrumental activities of 
daily living (IADL)19, each comprising different components that cover more than just 
mobility. Whether polyneuropathy-related impairment extends beyond purely physical 
activities has not been investigated in detail. Second, patients with chronic polyneu-
ropathy have an increased risk of falls, but whether this also relates to an increased risk 
of fall-related injuries is less clear. Moreover, the role of falls in the association of poly-
neuropathy with ADL is undetermined. Third, although it is known that persons with 
polyneuropathy have gait difficulties due to proprioceptive and non-proprioceptive 
sensory loss and motor weakness, there is little data about which specific spatiotemporal 
aspects of gait are predominantly affected. Gait is a complex process, comprising several 
different gait domains, each capturing a certain independent aspect of gait.20 Studies 
have shown different gait domains to be associated with variations in pathology, but the 
link with polyneuropathy is underexplored.
There are a few small studies that addressed some of these issues, but only in selected 
patient groups, mostly consisting of subjects with diabetes mellitus or those receiving 
chemotherapy, precluding generalization to the general population.21-23 Polyneuropathy 
is a common disorder in the general population, especially among elderly.24 Therefore, 
further research is required to address these knowledge gaps. We investigated the 
relation of polyneuropathy with ADL and its individual components. Additionally, we 
studied the relation of polyneuropathy with gait and with falls and related injuries in the 
large population-based Rotterdam Study.
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metHods
study population
This study was embedded in the Rotterdam Study, a prospective, population-based co-
hort study initiated in 1990.25 Participants of this study, individuals over 45 years, reside 
in a specific district of Rotterdam, the Netherlands. Every 3 to 4 years, participants visit 
the (single) research center of the Rotterdam Study where they undergo extensive inter-
views and examinations to facilitate the investigation of epidemiological characteristics 
of chronic diseases. In total, 14926 individuals agreed to participate (overall response 
rate 72%).
From 2013 onwards, a polyneuropathy screening was added to the core protocol 
of the Rotterdam Study. The current study includes all individuals that underwent this 
screening between June 2013 and January 2016. During this period, 1726 participants 
were randomly invited. Ninety-seven participants did not undergo the neuropathy 
screening and 165 participants were excluded because they were not sufficiently 
screened in order to complete the diagnostic process, mainly due to logistic reasons. Of 
the remaining 1464 participants, 19 had missing ADL data. The final study population for 
ADL- and fall-related analyses comprised 1445 participants, including a random subset 
of 977 persons with fully processed gait data.
standard protocol approvals, registrations and patient consents
The Rotterdam Study has been approved by the Medical Ethics Committee of the Eras-
mus MC and by the Ministry of Health, Welfare and Sport of the Netherlands, implement-
ing the “Wet Bevolkingsonderzoek: ERGO (Population Studies Act: Rotterdam Study)”. All 
participants provided written informed consent to participate in the study and to obtain 
information from their treating physicians.
Polyneuropathy screening
A detailed description of the polyneuropathy screening can be found elsewhere.24 In 
brief, the screening consisted of three parts: a symptom questionnaire, neurological 
examination of the legs (vibration and pin sensibility, tendon reflexes, muscle strength), 
and nerve conduction studies (bilateral sural nerve and unilateral peroneal nerve). 
A team of well-trained examiners screened all participants using exactly the same 
protocol. Medical records were scrutinized in case of a self-reported diagnosis of poly-
neuropathy, and in case of an abnormal part of the screening, to identify participants 
who were already diagnosed with polyneuropathy. An expert panel categorized all 
participants case-by-case into no, possible, probable or definite polyneuropathy, de-
pending on the estimated likelihood of the diagnosis. Definite polyneuropathy typically 
required abnormality in all three parts of the screening, or a previously made diagnosis 
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of polyneuropathy by a neurologist (which is considered superior to our screening, since 
this contains a complete work-up according to hospital guidelines). Participants with no 
abnormal parts of the screening were categorized as no polyneuropathy. The remaining 
participants were categorized as possible or probable polyneuropathy, depending on 
the level of abnormality of the screening.24
Assessment of daily functioning
Daily functioning was assessed with questionnaires on BADL and IADL. BADL was 
assessed using the Stanford Health Assessment Questionnaire.17 This questionnaire 
consists of 20 items constituting eight components: dressing and grooming, arising, 
eating, walking, hygiene, grip, reach and activities. Items were scored from 0 to 3, with 
higher scores indicating worse ability (0 = no difficulty, 1 = some difficulty, 2 = much 
difficulty, 3 = unable to). Component scores were calculated as the highest scored item 
per component.17 The BADL score was calculated by summing all components, obtain-
ing a score from 0 to 24. A score of 0 to 8 reflects no to mild impairment, a score above 8 
reflects moderate to very severe impairment.18
IADL was assessed with the Lawton and Brody Instrumental Activities of Daily Liv-
ing scale.19 This scale also consists of eight components: shopping, meal preparation, 
laundry, medication maintenance, management of finances, housekeeping, traveling 
alone and using a telephone. Consistent with BADL, these items were scored from 0 to 
3. If participants reported that they did not perform certain activities, these items were 
scored as non-applicable (5.5% of the IADL variables). To prevent selective loss of data, 
these items were imputed by the mean of five imputations, based on age, sex, all BADL 
items and all other available IADL items. The IADL score was then calculating by sum-
ming the eight components, yielding a score from 0 to 24. Similar to BADL, a score from 
0 to 8 was considered as no to mild impairment, and a score above eight was considered 
as moderate to very severe impairment.
Assessment of falls
Participants were asked whether they fell during the last twelve months. If so, participants 
were subsequently asked whether this (or these) fall(s) ever resulted in serious injuries, 
like fractures, head trauma, severe bruises or lacerations or sustained complaints of pain. 
Falls were dichotomized in no falls or any fall. Additionally, we divided participants who re-
ported at least one fall in the last year into falls with and falls without self-reported injury.
Assessment of gait
Gait was assessed with a 5.79 meter electronic walkway (4.88 meter active area; GAITRite 
Platinum; CIR systems, USA). Details about the gait assessment have been published 
elsewhere.20 In summary, gait was assessed in three walking conditions: normal walk 
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(walking at usual pace), turn (turning halfway) and tandem walk (heel-to-toe walking 
over a line). This assessment yielded 30 different spatiotemporal variables, which we 
summarized using principal component analysis with varimax rotation into seven inde-
pendent domains: Rhythm (temporal variables such as single support time, cadence), 
Variability (variability in length and time among strides), Phases (double support time, 
swing time as a percentage of stride time), Pace (velocity, step length), Base of Support 
(stride width), Turning (turning time, turning step count) and Tandem (errors in heel-
to-toe walking). The seven gait domains were z-standardized and averaged into Global 
gait. Lower values of gait can be considered “worse” gait. Gait data was available for 
participants that visited the research center between June 2013 and June 2015. During 
this period 977 participants underwent this assessment.
Covariates
We collected data about height and weight and we calculated body mass index (weight 
in kilograms divided by height squared in meters). Blood pressure was measured (mean 
of two consecutive readings) and use of antihypertensive and other medications was 
evaluated, including lipid lowering and antidiabetic medication. Blood samples were 
drawn to assess lipid levels and serum glucose. Diabetes mellitus was assessed as a 
fasting glucose ≥7.0 mmol/L, a non-fasting glucose ≥11.1 mmol/L, use of antidiabetic 
treatment or a previous diabetes mellitus diagnoses as identified through a link with 
general practitioner’s records. Smoking was categorized as never, former, or current.
statistical analyses
Associations between polyneuropathy and ADL were investigated in two ways. First, 
we applied linear regression to investigate the association of polyneuropathy with 
continuous BADL and IADL scores, using dummy variables. Second, BADL and IADL 
were dichotomized at a score of 8. Individuals with a score between 0 and 8 were con-
sidered not impaired, and individuals with a score above 8 were considered impaired.26 
Logistic regression was used to investigate the association of polyneuropathy with 
impairment in ADL. These two analyses were repeated after exclusion of participants 
with diabetes mellitus to investigate whether associations were mainly attributable to 
diabetic neuropathy, or were also present in participants with polyneuropathy of other, 
mainly idiopathic, origin.24 Linear and logistic regression were also used to investigate 
associations of polyneuropathy with separate BADL and IADL component scores. For the 
logistic regression, individuals with a score of 0 to 1 were considered not impaired, and 
above 1 impaired.
The association of polyneuropathy with falls and self-reported fall-related injury was 
investigated with logistic regression and we explored to what extent the association 
between polyneuropathy and ADL was affected by a history of falling.
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We investigated the association of polyneuropathy with gait using linear regression. 
Besides Global gait and the seven domains, we also included two of the most studied 
original gait variables (velocity and cadence) into the analyses.
Analyses were adjusted for age, sex, body mass index, diabetes mellitus, blood pres-
sure, antihypertensive medication, triglyceride level, high-density lipoprotein cholesterol 
level, lipid lowering medication and smoking. Analyses involving Tandem were addition-
ally adjusted for step count and step length in tandem walking. All statistical analyses 
were performed using the IBM SPSS statistical package, version 21.0.0.1 for windows.
Results
We included 1445 participants, mean age 70.7 years (standard deviation (SD) 9.7), of 
which 781 (54.0%) were women (Table 1). Possible, probable and definite polyneuropa-
thy were present in 265 (18.3%), 111 (7.7%) and 81 (5.6%) participants respectively. The 
mean BADL score in the total sample was 3.1 (SD 3.3), the mean IADL score was 1.7 (SD 
2.6), 115 (8.0%) participants had impairment in BADL and 46 (3.2%) had impairment in 
IADL. During the last twelve months, 336 (23.3%) participants at least fell once.
table 1. Population characteristics
Characteristic total population (n=1445)
Age, years 70.7 (9.7)
Women, n 781 (54.0)
Polyneuropathy status
 No polyneuropathy, n 988 (68.4)
 Possible polyneuropathy, n 265 (18.3)
 Probable polyneuropathy, n 111 (7.7)
 Definite polyneuropathy, n 81 (5.6)
Diabetes mellitus, n 209 (14.8)
Body mass index, kg/m2 27.0 (3.9)
Systolic blood pressure, mmHg 137.3 (19.5)
Diastolic blood pressure, mmHg 77.6 (11.0)
Antihypertensive medication, n 603 (41.9)
Triglyceride levels, mmol/L 1.4 (0.7)
High-density lipoprotein cholesterol, mmol/L 1.5 (0.4)
Lipid lowering medication, n 423 (29.4)
Current smoking, n 181 (12.6)
Former smoking, n 794 (55.2)
Values represent number (%) or mean (standard deviation). Percentages were calculated without missing 
values.
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Polyneuropathy and activities of daily living
A stronger likelihood of polyneuropathy associated with higher ADL scores (Table 2), 
indicating worse ability to perform these activities. Definite polyneuropathy associated 
with a 2.98 (95% confidence interval (CI) 2.29;3.68) points higher BADL score and 0.82 
(95% CI 0.24;1.41) points higher IADL score than participants without polyneuropathy. 
Polyneuropathy also associated with more ADL impairment (Table 2). With increasing 
diagnostic certainty of polyneuropathy, the association with especially BADL impair-
ment increased likewise. Participants with definite polyneuropathy were 6.41 (95% CI 
3.19;12.88) times more likely to have impairment in BADL and 1.74 (95% CI 0.59;5.10) 
times more likely to have impairment in IADL, though the latter association was not 
statistically significant. After excluding participants with diabetes mellitus, associations 
were similar (Supplementary table 1).
table 3. Association between the presence of polyneuropathy and history of falling
Falls
OR (95% CI)
Fall-related injury
OR (95% CI)
Fall without injury Fall with injury
Possible polyneuropathy 1.14 (0.81;1.60) 0.86 (0.56;1.32) 1.69 (0.72;3.96)
Probable polyneuropathy 1.30 (0.81;2.09) 1.17 (0.67;2.06) 2.30 (0.72;7.32)
Definite polyneuropathy 1.87 (1.10;3.16) 1.64 (0.89;3.02) 3.35 (1.02;10.97)
Values represent the odds ratios of falling (95% confidence intervals) compared to participants with no 
polyneuropathy.
Adjusted for age, sex, body mass index, diabetes mellitus, diastolic blood pressure, systolic blood pressure, 
antihypertensive medication, triglyceride level, high-density lipoprotein cholesterol level, lipid lowering 
medication and smoking
OR: odds ratio; CI: confidence interval
table 2. Association between the presence of polyneuropathy and impairment in activities of daily living
basic activities of daily living instrumental activities of daily living
difference in 
score
(95% CI)
bAdl impairment
OR (95% CI)
difference in 
score
(95% CI)
iAdl impairment
OR (95% CI)
Possible polyneuropathy 1.18 (0.77;1.60) 3.23 (1.92;5.45) 0.79 (0.44;1.13) 1.71 (0.75;3.90)
Probable 
polyneuropathy
1.72 (1.12;2.32) 3.56 (1.83;6.94) 0.63 (0.12;1.13) 2.24 (0.88;5.69)
Definite polyneuropathy 2.98 (2.29;3.68) 6.41 (3.19;12.88) 0.82 (0.24;1.41) 1.74 (0.59;5.10)
Values represent the difference in score or odds ratios of prevalent impairment in BADL or IADL (95% confi-
dence intervals), compared to participants with no polyneuropathy. Higher scores reflect poorer functioning.
Analyses were adjusted for age, sex, body mass index, diabetes mellitus, diastolic blood pressure, systolic 
blood pressure, antihypertensive medication, triglyceride level, high-density lipoprotein cholesterol level, 
lipid lowering medication and smoking
BADL: basic activities of daily living; IADL: instrumental activities of daily living; OR: odds ratio; CI: confi-
dence interval
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Figure 1 shows the association of polyneuropathy with ADL component scores and 
Supplementary table 2 shows the association with impairment in ADL components. 
Polyneuropathy related to higher scores and more impairment in almost all BADL com-
ponents (especially walking and hygiene) and in some IADL components (especially 
housekeeping and shopping).
Polyneuropathy and history of falling
Participants with polyneuropathy were almost two times more likely to have fallen in 
the preceding twelve months (OR 1.87, 95% CI 1.10;3.16, Table 3) and polyneuropathy 
especially related to falls that resulted in injury (OR 3.35, 95% C.I. 1.02;10.97). As with 
BADL, associations were stronger with increasing diagnostic certainty of polyneuropa-
thy. Adjusting the analyses between polyneuropathy and ADL for falls had no effect on 
the associations reported in the previous section.
Polyneuropathy and gait
In the subset of 977 participants with gait data available, 143 (14.6%) had possible 
polyneuropathy, 60 (6.1%) had probable polyneuropathy and 40 (4.1%) had definite 
A. Basic activities of daily living
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Figure 1. Association between polyneuropathy and components of Adl. The symbols represent the 
difference in ADL-scores compared to participants with no polyneuropathy (dotted reference line). A high-
er score indicates poorer functioning. Black circles represent participants with a definite polyneuropathy, 
white triangles represent participants with a probable polyneuropathy and grey squares represent partici-
pants with a possible polyneuropathy. Error bars represent the 95% confidence interval around the differ-
ence. Analyses were adjusted for age, sex, body mass index, diabetes mellitus, diastolic blood pressure, sys-
tolic blood pressure, antihypertensive medication, triglyceride level, high-density lipoprotein cholesterol 
level, lipid lowering medication and smoking. ADL: activities of daily living
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polyneuropathy. Definite polyneuropathy associated with worse Global gait (difference 
in z-score -0.76 95% CI -1.04;-0.48, see Figure 2). Rhythm (difference in z-score -0.46, 
95% CI -0.77;-0.15), Phases (difference in z-score -0.38, 95% CI -0.66;-0.09) and Tandem 
(difference in z-score -0.57, 95% CI -0.90;-0.25) were the gait domains driving this as-
Association between polyneuropathy and gait
Difference in z-score of gait
-1,5 -1,0 -0,5 0,0 0,5
Tandem
Turn
Base of support
Pace
Phases
Variability
Rhythm
Global gait
Velocity
Cadence
Figure 2. Association of polyneuropathy with gait. The symbols represent the difference (per standard 
deviation) in gait domains (bold) or original variables (italic) compared to participants with no polyneurop-
athy (dotted reference line). Negative values indicate worse gait. Black circles represent participants with a 
definite polyneuropathy, white triangles represent participants with a probable polyneuropathy and grey 
squares represent participants with a possible polyneuropathy. Error bars represent the 95% confidence 
interval around the difference. Analyses were adjusted for age, sex, body mass index, diabetes mellitus, dia-
stolic blood pressure, systolic blood pressure, antihypertensive medication, triglyceride level, high-density 
lipoprotein cholesterol level, lipid lowering medication and smoking. Tandem was additionally adjusted for 
step count and step length in tandem walking.
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sociation. Participants with definite polyneuropathy also walked slower (11.3 centimeter 
per second slower, p<0.01) and with lower cadence (4.8 steps/minute less, p<0.01) than 
persons without polyneuropathy.
disCussion
In this prospective population-based study, polyneuropathy strongly related to worse 
activities of daily living scores. Participants with polyneuropathy were six times more 
likely to have moderate to severe impairment in BADL, independent of comorbidities 
and falls. Besides walking difficulty, polyneuropathy also related to difficulty in arising, 
dressing, and even eating, among others. IADL were also affected by polyneuropathy, 
especially components that require much physical activity, like shopping and house-
keeping. Polyneuropathy related to worse gait, mainly by interfering with the gait 
domains Rhythm, Phases and Tandem and participants with polyneuropathy were more 
likely to have fallen during the last twelve months.
Polyneuropathy is common in elderly, and its prevalence is expected to rise in the 
future because of an increased prevalence of diabetes mellitus, obesity and metabolic 
syndrome.24 We showed that polyneuropathy is strongly related to impairment in walk-
ing and the ability to perform ADL, and to a higher probability of falling and related 
injuries. Impairment in the ability to walk and perform daily activities is associated with 
an increased risk of institutionalization.3, 4 Despite the importance of polyneuropathy, 
the disease is often underreported and underdiagnosed.14, 24
A major strength of our study is that we quantified the effect of polyneuropathy on 
ADL, involving components of both basic and instrumental activities of daily living, 
while adjusting for comorbidities and falls. Additionally, our study was implemented 
in a large population-based study, in which all participants underwent an extensive 
polyneuropathy screening. This led to a reliable sample of the general population and a 
valid estimate of polyneuropathy and its effect on ADL. Of note, participants had to be 
able to visit the research center, which might be relatively healthy individuals. This could 
have resulted in an underestimation of the effect of polyneuropathy on ADL. Due to the 
cross-sectional design of our study we were not able to investigate a causal relationship, 
longitudinal studies are required to investigate the relation of polyneuropathy with 
incident ADL impairment.
Chronic axonal polyneuropathy, especially when idiopathic, is often considered a 
relatively mild condition that leads to only minor disability.27 In our study, participants 
with definite polyneuropathy had BADL scores that were more than twice as high as 
participants with no polyneuropathy. Additionally, participants with definite polyneu-
ropathy were more than 6 times more likely to have moderate to severe impairment in 
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BADL. These associations were independent of age, cardiovascular risk factors and falls. 
Associations were similar when excluding participants with diabetes mellitus, indicating 
that associations are not only driven by diabetic neuropathy, but also exists in other, 
mainly idiopathic, polyneuropathies. In our population-based study approximately 
half of the participants with polyneuropathy is newly diagnosed and it is likely that we 
diagnose participants in an earlier stage than in clinic-based studies.24 Therefore, the 
effect of polyneuropathy on ADL might be even stronger in more advances stages of 
the condition. Our findings show that, although the clinical phenotype of (idiopathic) 
polyneuropathy may be relatively mild, patients may still experience much difficulty in 
performing basic daily activities.
We also showed that participants with polyneuropathy had more difficulty in IADL. 
One database-driven study also showed that individuals with polyneuropathy had 
more difficulty in IADL, but different components were not investigated.13 In our study, 
polyneuropathy independently associated with more difficulty in the IADL domains 
shopping, housekeeping and traveling, which are the components that highly rely 
on mobility. Components that depend less on sensorimotor function, like laundry 
and management of finances and medication use, were not affected. Of the BADL 
components, polyneuropathy was also most strongly related with walking. Several 
studies showed that persons with polyneuropathy have impaired balance and motor 
performance, and low physical functioning scores, which probably explains most of 
these associations.5-10, 15, 16, 28-30 However, we also found that polyneuropathy related 
to impairment in BADL components like dressing and grooming, eating and hygiene. 
This indicates that difficulty in performing ADL is not only caused by lower extremity 
dysfunction, but also by impairment in more subtle and precise movements of the up-
per extremities.11
We further investigated the association of polyneuropathy with walking using an 
objective, electronic gait assessment. Participants with definite polyneuropathy had 
worse Global gait, concurring with the self-reported difficulty in walking assessed in 
BADL. Gait domains that were affected most were Rhythm, Phases and Tandem. Ad-
ditionally, participants with polyneuropathy had lower velocity and cadence. Different 
gait domains reflect different abilities, such as balance, physical strength and fine motor 
speed. Physical strength is most strongly related to the domains Rhythm and Pace.26 
Hence, reduced muscle strength, which can occur in polyneuropathy, may lead to worse 
Rhythm and Pace, providing an explanation for the associations with Rhythm, cadence 
and velocity. An alternative explanation is that individuals with polyneuropathy may 
adopt a more conservative gait pattern, with decreased walking speed, cadence and 
an increased double support time (Phases), to feel more secure during walking.31 Bal-
ance and fine motor speed, often altered in polyneuropathy, are more closely related 
to Tandem, explaining the association found between polyneuropathy and Tandem.26
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Chronic polyneuropathy is a disabling disorder that can lead to significant morbidity. 
Recognition of polyneuropathy and associated disability is therefore very important in 
order to inform, support and possibly treat patients, and prevent future falls and depen-
dence in daily functioning.
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supplementary table 1. Association between the presence of polyneuropathy and impairment in activi-
ties of daily living, excluding participants with diabetes mellitus
basic activities of daily living instrumental activities of daily living
Difference in score
(95% CI)
BADL impairment
OR (95% CI)
Difference in score
(95% CI)
IADL impairment
OR (95% CI)
Possible polyneuropathy 1.15 (0.71;1.59) 3.28 (1.83;5.87) 0.61 (0.25;0.97) 1.62 (0.62;4.28)
Probable polyneuropathy 1.68 (1.02;2.33) 3.75 (1.76;8.01) 0.56 (0.02;1.11) 2.64 (0.92;7.57)
Definite polyneuropathy 3.59 (2.75;4.42) 7.95 (3.51;17.96) 1.05 (0.35;1.74) 2.79 (0.82;9.52)
Values represent the difference in score or odds ratios of prevalent impairment in BADL or IADL (95% confi-
dence intervals), compared to participants with no polyneuropathy. Higher ADL scores reflect poorer ADL.
Analyses were adjusted for age, sex, body mass index, diastolic blood pressure, systolic blood pressure, 
antihypertensive medication, triglyceride level, high-density lipoprotein cholesterol level, lipid lowering 
medication and smoking
BADL: basic activities of daily living; IADL: instrumental activities of daily living; OR: odds ratio; CI: confi-
dence interval
supplementary table 2. Polyneuropathy and odds ratios on impairment in activities of daily living
Possible 
polyneuropathy
OR (95% CI)
Probable polyneuropathy
OR (95% CI)
definite 
polyneuropathy
OR (95% CI)
bAdl
Dressing & grooming 2.22 (0.86;5.75) 2.18 (0.61;7.84) 4.66 (1.35;16.01)
Arising 2.84 (1.65;4.88) 3.21 (1.64;6.27) 4.66 (2.25;9.62)
Eating 1.95 (1.07;3.54) 2.79 (1.33;5.84) 2.52 (1.05;6.08)
Walking 2.50 (1.56;4.02) 3.63 (2.02;6.51) 6.64 (3.55;12.39)
Hygiene 2.23 (1.12;4.47) 3.74 (1.68;8.36) 4.98 (2.12;11.69)
Grip 1.95 (0.49;7.74) 4.53 (0.95;21.69) 1.50 (0.15;14.78)
Reach 1.54 (0.83;2.84) 1.92 (0.87;4.27) 3.77 (1.72;8.23)
Activities 2.71 (1.74;4.22) 2.32 (1.26;4.25) 3.77 (1.98;7.19)
iAdl
Shopping 2.79 (1.67;4.67) 3.24 (1.68;6.23) 4.07 (1.99;8.32)
Meal preparation 1.16 (0.69;1.96) 0.99 (0.48;2.02) 1.29 (0.61;2.74)
Laundry 1.19 (0.72;1.96) 0.75 (0.36;1.55) 1.15 (0.55;2.39)
Medication use 2.26 (0.91;5.59) 1.33 (0.35;5.00) 0.71 (0.14;3.52)
Financing 2.06 (1.24;3.43) 1.37 (0.65;2.89) 0.80 (0.30;2.14)
Housekeeping 0.62 (0.22;1.73) 1.59 (0.58;4.33) 1.36 (0.41;4.50)
Traveling alone 2.72 (1.13;6.52) 4.21 (1.58;11.22) 2.73 (0.83;8.99)
Telephone use 1.31 (0.53;3.27) 0.43 (0.09;2.03) 0.54 (0.11;2.78)
Values represent the odds ratios for impairment in specific BADL and IADL components (95% confidence 
intervals) compared to persons with no polyneuropathy.
Adjusted for age, sex, body mass index, diabetes mellitus, diastolic blood pressure, systolic blood pressure, 
antihypertensive medication, triglyceride level, high-density lipoprotein cholesterol level, lipid lowering 
medication and smoking
BADL: basic activities of daily living; IADL: instrumental activities of daily living; OR: odds ratio; CI: confi-
dence interval
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AbstRACt
Aims: To investigate the association of diabetes mellitus and impaired fasting glucose 
with gait in the general middle-aged and elderly population.
methods: We performed a cross-sectional study on 3019 participants from the popu-
lation-based Rotterdam Study (aged >45 years, 54% women). The presence of diabetes 
mellitus and impaired fasting glucose was evaluated by measuring serum glucose levels 
and by documenting anti-diabetic treatment. Participants underwent gait analysis 
using an electronic walkway. Over 30 gait variables were summarized into five inde-
pendent gait domains for normal walking (Rhythm, Variability, Phases, Pace and Base of 
Support), one for turning (Turning) and one for walking heel to toe (Tandem), which were 
averaged into Global Gait. Linear regression analyses were performed to determine the 
association of diabetes, impaired fasting glucose and continuous glucose levels within 
the normal range with gait.
Results: Diabetes mellitus was associated with worse Global Gait (Z-score difference 
-0.19, 95% Confidence Interval (CI) -0.30;-0.07), worse Pace (-0.20, 95% CI -0.30;-0.10) 
and worse Tandem (-0.21, 95% CI -0.33;-0.09), after adjusting for age, sex, height and 
weight. The association with Tandem remained significant after additional adjustment 
for cardiovascular risk factors. Impaired fasting glucose and continuous glucose levels 
within the normal range were not associated with any of the gait domains.
Conclusion: In our population-based study diabetes mellitus was associated with worse 
Global Gait, which was mostly reflected in Pace and Tandem. These associations were 
partly driven by other cardiovascular risk factors, emphasizing the importance of opti-
mal control of cardiovascular risk factor profiles in patients with diabetes.
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intRoduCtion
Diabetes mellitus is common in the elderly population and is a serious threat to an older 
person’s quality of life. Complications such as polyneuropathy, retinopathy and periph-
eral artery disease can already be present at the moment of diagnosis of the disease.1 
This suggests that microvascular as well as macrovascular changes already occur in early 
stages of diabetes and perhaps even in a state before overt diabetes develops, which is 
often referred to as prediabetes.2 These complications directly (neuropathy, peripheral 
artery disease) or indirectly (muscle weakness, ulcerations, cerebrovascular disease) lead 
to walking instability, falls, and fall-related injuries.3-10 To detect the impact of diabetes 
on walking and lower limb performance in an early stage, extensive assessment of gait 
in different walking conditions may be useful.10
Gait is a complex concept that is increasingly recognized as a marker of general 
health.11, 12 Gait is influenced by different organ systems, including the central and periph-
eral nervous system, central and peripheral circulation and the musculoskeletal system, 
all of which can be affected by diabetes mellitus. Dysfunction in any of these systems 
may lead to gait impairment, which in turn is associated with an increased risk of falling 
and higher mortality.13, 14 Gait can be measured using many different spatiotemporal 
variables, which can be summarized into seven independent gait domains (Figure 1): 
Rhythm (cadence, stride time), Variability (variability in stride length and stride time), 
Phases (double support percentage of gait cycle), Pace (stride length, velocity), Base of 
Support (stride width and stride width variability) Tandem (number of side steps in walk-
ing heel to toe) and Turning (number of steps and turning time).12, 13
Previous case-control studies reported lower walking speed and cadence in individu-
als with diabetes10, 15, but population-based data about the relation between diabetes 
and the gait pattern is lacking. In addition, since microvascular pathology can be pres-
ent already early in the course of the disease1, we hypothesized that subtle changes in 
specific gait domains can not only be found in participants with diabetes, but also in 
persons having only impaired fasting glucose or even a glucose level in the high range 
of normal.
Therefore, we aimed to investigate the association of diabetes mellitus and predia-
betes (impaired fasting glucose) with gait and its separate domains in a community-
dwelling population.
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metHods
study setting, study design and study population
The study was embedded in the Rotterdam Study, a population-based cohort in the 
Netherlands that started in 1990. At the start of the study in 1990 and again in 2000, 
all people living in the Ommoord district of Rotterdam, aged 55 years and older were 
selected from the municipal population records and invited to participate in the study. 
In 2006 the cohort was extended with individuals that moved into the study area, aged 
45 years and older. Residential area (ZIP code) and age were the only eligibility criteria 
used for inclusion of participants. In total, 14926 out of 20744 invited persons agreed to 
participate in the study (overall response rate 72%). At baseline and every 3-4 years of 
follow-up, all participants undergo a home interview and extensive medical examina-
tions at the research center.
The Rotterdam Study has been approved by the Medical Ethics Committee of the 
Erasmus MC and by the Ministry of Health, Welfare, and Sports of the Netherlands, 
Rhythm (stride time)
Pace (stride length)
Variability (stride length variability)
Base of Support
(stride width)
Phases (double support)
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21 3
4
5
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Turning
(turning step count)
Tandem
(side steps in walking heel to toe)
Normal walk
Turn
Tandem walk
Figure 1. the three walking conditions. Gait assessment yielded seven gait domains, including five do-
mains for normal walk (Rhythm, Variability, Phases, Pace, and Base of Support), one for the turn (Turning), and 
one for tandem walk (Tandem).
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implementing the “Wet Bevolkingsonderzoek: ERGO (Population Studies Act: Rotterdam 
Study)”. A written informed consent to participate in the study and to obtain information 
from their treating physicians was obtained from all participants.16
From March 2009 onwards, gait assessment was implemented in the core protocol 
of the study. The current study includes all participants that underwent gait assessment 
between March 2009 and March 2012. During this period 3666 persons were invited 
for gait measurements; after exclusion of 600 persons (207 persons were excluded due 
to physical health reasons, 296 because of technical problems, 46 participants did not 
follow or complete the entire protocol, 34 persons had fewer than 16 steps available for 
analyses, 15 had a repeated assessment and 2 persons were excluded for other reasons), 
3066 participants were eligible for the study; 3019 of them had information about dia-
betes mellitus available. These 3019 participants were included in the analyses.
diabetes mellitus and impaired fasting glucose assessment
Presence of diabetes mellitus and impaired fasting glucose was evaluated using labora-
tory data derived from blood sampling performed at the research center and with data 
on medication use. Medication use was assessed by self-report and by going through 
the medication cabinets in the home of the participants during the home interview. 
Diabetes was defined as a fasting glucose level ≥7.0 mmol/L, a non-fasting glucose level 
≥11.1 mmol/L (if fasting samples were not available) or use of anti-diabetic therapy.17 
Impaired fasting glucose was defined according to the ADA 2010 diagnostic criteria as 
a fasting glucose level between 5.6 mmol/L and 6.9 mmol/L in the absence of diabetes.2
gait assessment
Gait was assessed using a 5.79 meter long electronic walkway (4.88 meter of active area; 
GAITRite Platinum; CIR systems, Sparta, NJ, USA), that has been validated before.18-20 
Three walking conditions were recorded: normal walk, turning and tandem walk. In 
normal walk, participants were asked to walk across the electronic walkway at their own 
pace. In the turn, people walked across the walkway, turned halfway, and returned to 
their starting position. In tandem walk, participants walked heel-to-toe over a line vis-
ible on the walkway.
The walkway software was used to generate 30 different spatiotemporal gait vari-
ables; 25 for normal walk, 2 for turning and 3 for tandem walk. Principal components 
analysis (PCA) was used to summarize these 30 gait variables into independent gait 
domains, while capturing the largest amount of variance. Varimax rotation was used 
to make sure that the gait domains were mutually independent. The PCA resulted in 
seven independent domains: Rhythm, Variability, Phases, Pace, Base of Support, Tan-
dem and Turning. Among others, Rhythm represents cadence and stride time; Phases 
represent double support time and double support as a percentage of the gait cycle; 
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Variability represents variability in stride length and stride time; Pace represents velocity 
and stride length; Base of Support represents stride width and stride width variability; 
Tandem represents errors in tandem walking; and Turning represents the number of 
turning steps and turning time (see Supplementary Table 1 and Figure 1). More details 
about the principal component analyses can be found elsewhere.12, 13 These domains 
were standardized and, when necessary, inverted so that lower values indicate “worse” 
gait. Additionally, Global Gait was calculated by averaging the seven independent gait 
domains into one standardized Z-score.
Assessment of covariates
The home interview comprised questionnaires about smoking (current cigarette 
smoking versus non-smoking) and alcohol consumption (converted to grams per day). 
Examinations at the research center included measurement of height (in cm), weight (in 
kg) and mean systolic and diastolic blood pressure from two consecutive measurements 
(in mmHg). Total cholesterol and HDL-cholesterol were measured in serum (mmol/L). 
Use of lipid lowering medication (statins, ezetimibe, or fibrates) and antihypertensive 
medication (diuretics, calcium-channel blockers, ACE-inhibitors or beta-blockers) was 
also documented during the home interview.
statistical analysis
We used multivariable linear regression analyses to investigate the association of 
diabetes with Global Gait and specific gait domains. Next, we performed analyses of 
impaired fasting glucose. Additionally, we investigated the association of continuous 
glucose levels on gait in individuals with a glucose level within the normal range and 
in individuals with a normal or an impaired fasting glucose combined. All analyses 
were performed using two models. The first model was adjusted for age, sex, height 
and weight; the second model was additionally adjusted for cardiovascular risk factors 
and medication use (mean systolic and mean diastolic blood pressure, smoking, alcohol 
use, total cholesterol, HDL-cholesterol, antihypertensive medication and lipid lowering 
medication). Analyses involving Tandem were additionally adjusted for step length 
and step count in the tandem walk.13 Effect modification by sex was tested by adding 
an interaction term into the models. We applied Bonferroni correction for seven tests 
(reflecting the seven independent gait domains) to correct for multiple testing (p-value 
< 0.007). We assessed potential non-linear associations for the continuous glucose levels 
with gait using splines regression in R version 3.2.0. All other reported statistical analyses 
were performed using the SPSS statistical package, version 21 for Windows (IBM Corp., 
Armonk, NY).
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Results
We compared population characteristics between participants and non-participants. 
Results of these analyses can be found in Supplementary Table 2. There were more 
females and more people being treated for hypertension in the non-participants, and 
non-participants were on average older.
In our sample of 3019 participants, 1782 participants (59.0%) had a plasma glucose 
within the normal range, 921 participants (30.5%) had impaired fasting glucose and 316 
participants (10.5%) had diabetes. Participants with normoglycemia were on average 
younger than participants with impaired fasting glucose or diabetes. In the normo-
glycemia group 60.9% was female, while this was 45.2% and 43.4% in the impaired 
fasting glucose and diabetes group respectively. Normoglycemic participants had a 
lower weight and systolic blood pressure and fewer people used lipid-lowering or an-
tihypertensive medication compared to participants with impaired fasting glucose and 
diabetes (Table 1).
Diabetes mellitus was associated with worse Global Gait (difference in Z-score -0.19, 
95% Confidence Interval (CI) -0.30;-0.07) compared to normoglycemic persons after 
adjustment for age, sex, height and weight. Specifically, participants with diabetes had 
table 1. Population Characteristics
Characteristic
normoglycemia
N = 1782
impaired fasting 
glucose
N = 921
diabetes
N = 316
Age, years 66.1 (9.2) 68.6 (8.7)* 70.0 (8.2)*,†
Female sex, n 1085 (60.9) 416 (45.2)* 137 (43.4)*
Height, cm 168.6 (9.3) 169.9 (9.4) 169.5 (9.0)
Weight, kg 75.3 (13.1) 82.0 (14.4)* 84.9 (14.5)*,†
Current cigarette smoking, n 284 (16.0) 135 (14.7) 43 (13.6)
Alcohol, grams per day 6.1 (6.7) 8.1 (8.4)* 5.8 (7.5)†
Diastolic blood pressure, mmHg 82.9 (11.0) 85.4 (11.0)* 84.6 (10.9)
Systolic blood pressure, mmHg 138.2 (21.7) 145.5 (21.9)* 148.2 (21.8)*
Antihypertensive medication, n 502 (28.2) 404 (43.9)* 215 (68.3)*,†
Total cholesterol, mmol/L 5.6 (1.1) 5.5 (1.0) 4.8 (1.1)*,†
HDL-cholesterol, mmol/L 1.5 (0.4) 1.4 (0.4) * 1.3 (0.4)*,†
Lipid lowering medication, n 367 (20.6) 266 (28.9)* 172 (54.6)*,†
Glucose, mmol/L 5.1 (0.4) 6.0 (0.4) * 8.1 (2.3)*,†
Values are mean (SD) or number (%). Percentages were calculated without missing values. Missing values 
occurred in less than 1%.
* p-value < 0.05, impaired fasting glucose and diabetes compared to normoglycemia, age- and sex ad-
justed (if applicable)
† p-value < 0.05, diabetes compared to impaired fasting glucose, age- and sex adjusted (if applicable)
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worse Pace (difference in Z-score -0.20, 95% CI -0.30;-0.10) and Tandem (difference in 
Z-score -0.21, 95% CI -0.33;-0.09) than participants with normoglycemia (Figure 2). After 
additional adjustment for cardiovascular risk factors and medications, only Tandem 
remained worse (difference in Z-score -0.20, 95% CI -0.33;-0.07) in participants with 
diabetes compared to participants with normoglycemia (Figure 2). The attenuation of 
the association with Pace and Global Gait was mainly driven by the inclusion of antihy-
pertensive medication and total cholesterol into the analyses.
Impaired fasting glucose was not associated with Global Gait, nor with any of the 
specific gait domains. However, for several domains the effect estimates for impaired 
fasting glucose were between those of diabetes and normoglycemia. This was especially 
noticeable for the domains Pace and Tandem (Figure 2).
Higher glucose levels were not associated with gait within participants with nor-
moglycemia nor within individuals with normoglycemia or impaired fasting glucose 
combined (Table 2). There were some indications for a non-linear relation of glucose 
with Rhythm, Turning and Global Gait, but these associations did not survive correction 
for multiple testing. We did not observe a consistent pattern of effect modification by 
sex in any of the analyses.
table 2. Difference in Z-score of gait per mmol/L change in glucose level in people without diabetes
gait domains
normoglycemia
(serum glucose <5.6 mmol/L)
N = 1766
normoglycemia and
impaired fasting glucose
(serum glucose <7.0 mmol/L)
N = 2675
Model 1 Model 2 Model 1 Model 2
Global gait 0.05 (-0.06;0.16) 0.04 (-0.07;0.15) 0.02 (-0.04;0.08) 0.01 (-0.06;0.07)
Rhythm 0.05 (-0.06;0.16) 0.03 (-0.08;0.14) 0.03 (-0.03;0.09) 0.02 (-0.05;0.08)
Phases 0.09 (-0.01;0.20) 0.10 (-0.01;0.20) 0.06 (-0.00;0.12) 0.06 (-0.00;0.12)
Variability -0.02 (-0.13;0.09) -0.03 (-0.15;0.08) -0.04 (-0.11;0.03) -0.05 (-0.12;0.02)
Pace -0.07 (-0.17;0.02) -0.10 (-0.20;-0.01) -0.05 (-0.10;0.01) -0.06 (-0.12;-0.01)
Base of Support 0.03 (-0.08;0.14) 0.04 (-0.07;0.16) 0.06 (-0.01;0.13) 0.06 (-0.01;0.13)
Tandema -0.03 (-0.14;0.08) -0.03 (-0.14;0.08) -0.04 (-0.11;0.03) -0.04 (-0.11;0.03)
Turning 0.08 (-0.04;0.20) 0.10 (-0.02;0.22) 0.03 (-0.04;0.10) 0.03 (-0.04;0.11)
Values represent the difference in Z-score of gait with 1 mmol/L change in glucose level
Model 1: age, sex, height, weight
Model 2: model 1+ smoking, alcohol, mean diastolic blood pressure, mean systolic blood pressure, antihy-
pertensive medication, total cholesterol, HDL-cholesterol, lipid lowering medication
None of the results survived Bonferroni adjustment for 7 tests (p-value 0.007)
a Additionally adjusted for step length and step count in tandem walk
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disCussion
In this population-based study diabetes mellitus was associated with worse Global Gait, 
which was mainly accounted for by worse Pace and Tandem. The association for Tandem 
remained significant after adjustment for cardiovascular risk factors. In persons with 
impaired fasting glucose or a glucose level below the threshold for diabetes there was 
no association with gait.
The strengths of our study include the large population-based sample, assessment 
of both diabetes mellitus and earlier stages of diabetes, defined as impaired fasting glu-
cose, and the extensive and objective assessment of gait in different walking conditions 
using an electronic walkway. Our study also has some limitations. The analyses are cross-
sectional, making it difficult to draw firm conclusions on causality. Gait was assessed 
in persons that visited the research center, which might have prevented persons with 
severe physical disability to participate, leading to a relatively healthy study population. 
We did not have data on impaired glucose tolerance, which is also part of the definition 
of prediabetes. Impaired glucose tolerance may be stronger associated with complica-
tions of diabetes, especially neuropathy, than impaired fasting glucose.2 We were not 
able to assess how different diabetes treatment types and diabetes duration would 
affect our results. This would be interesting, since both insulin treatment and diabetes 
duration have been associated with mobility impairment.21 Another limitation is that we 
did not evaluate the presence of polyneuropathy, peripheral artery disease, diabetic feet 
and retinopathy and therefore were not able to assess how these conditions influence 
the associations.
Gait is a complex motor function that depends on the interplay of multiple systems, 
such as intact structure and functioning of the central and peripheral nervous system, 
the vestibular system, intact vascularization of both the brain and the extremities and 
intact functioning of the musculoskeletal system. All of these systems can be affected by 
diabetes. We found that participants with diabetes had significantly worse Global Gait, 
Pace and Tandem compared to persons with normoglycemia. Previous, smaller stud-
ies that investigated the association of diabetes with spatiotemporal variables of gait 
found an association with a decrease in cadence (constituting the domain Rhythm)15, 22, 23 
and with lower gait velocity and shorter stride length (both constituting the domain 
Pace).6, 7, 9, 10, 15, 23-27 In our study, we also found an association with Pace, which might 
result from damage to the vasculature of the legs or feet or be due to damage of the pro-
prioceptive system in case of neuropathy. After adjusting for cardiovascular risk factors 
the association with Pace attenuated, mainly due to inclusion of total cholesterol and 
antihypertensive medications. Adjusting for cardiovascular risk factors also attenuated 
the association of diabetes with Global Gait, suggesting that a large part of the effect of 
diabetes on gait is due to vascular comorbidity.
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Our study is among the first to investigate the effect of diabetes mellitus on tandem 
walk in a community-dwelling population. We found a strong independent association 
of diabetes with errors in tandem walking. Tandem walk represents a complex heel-to-
toe type of walk that requires very fine and precise motor function, preserved balance 
and integration of various other systems, including the eyes, in order to be performed 
correctly. Even subtle changes in the feet and lower limbs, as well as ocular pathology 
that can occur due to diabetes mellitus may affect successful performance in tandem 
walk.
In our study, there was no association of diabetes with Rhythm. The most likely expla-
nation for this is that in our study cadence (Rhythm) is made independent from stride 
length (Pace) with the principle component analysis. Hence, associations with cadence 
in previous studies may have been (partly) driven by an association with stride length, 
which in our study is a component of Pace. Moreover, we adjusted the analyses for several 
cardiovascular risk factors, which is not performed in most studies that found an effect 
on cadence (part of the domain Rhythm). The results of these studies might have been 
due to confounding. We did not find an association of diabetes with Variability, which 
is the domain from the normal walk that is most strongly related to falls.12, 13 Previous 
studies that reported this association could only find an effect while walking in chal-
lenging circumstances or on irregular surface, which makes comparison with our study 
difficult.10, 15 A perhaps surprising result was the inverted association of diabetes with 
Phases, even though it did not survive correction for multiple testing. Post-hoc analysis 
revealed that this was possibly due to overadjustment for weight, which is a strong 
determinant of both diabetes and Phases. Indeed, if we ran models without weight 
as covariate, the effect size of diabetes for Phases was -0.17 (95% CI -0.29;-0.04). This 
suggests that the association of diabetes with “better” gait was likely a spurious result. 
Whether our findings of gait impairment are specific to diabetes, or specific to certain 
complications of diabetes such as polyneuropathy, needs to be further investigated.
Since microvascular pathology occurs early in the development of diabetes we hy-
pothesized that this already leads to subtle changes in gait characteristics in patients 
with earlier stages of diabetes. However, in our study gait was not significantly different 
in participants with impaired fasting glucose than in participants with normoglycemia, 
though we did find a pattern of the strength of the associations with impaired fast-
ing glucose being in between those of normoglycemia (reference) and diabetes. This 
suggests an early decline in gait when moving away from the normal glucose range 
and was especially noticeable in the domains Pace and Tandem. Yet, a counterargument 
against this reasoning is the finding that a glucose level within the normal range was not 
associated with gait domains when investigated continuously.
To conclude, in our community-dwelling population, the presence of diabetes 
mellitus was associated with worse Global Gait, Pace and Tandem. This relationship is 
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mainly mediated by cardiovascular risk factors. Impairment in gait seems to occur early 
in the process of developing diabetes mellitus. It may be beneficial to detect and treat 
abnormal fasting glucose levels and diabetes in early stages in order to prevent future 
gait impairment in middle-aged and elderly people. Furthermore, within diabetes care, 
tight regulation of blood pressure and cholesterol levels might be important to prevent 
or reduce the development of gait problems.
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supplementary table 1. Correlation of all gait variables with their corresponding gait domain
gait domain gait variable Correlation mean (sd)
Rhythm
Single Support Time, s -0.958 0.42 (0.04)
Swing Time, s -0.958 0.42 (0.04)
Step Time, s -0.943 0.55 (0.05)
Stride Time, s -0.943 1.10 (0.10)
Cadence, steps/min 0.939 109.58 (9.64)
Stance Time, s -0.837 0.68 (0.08)
Phases
Single Support (%GC) 0.973 38.60 (1.91)
Swing (%GC) 0.973 38.60 (1.91)
Stance (%GC) -0.972 61.40 (1.91)
Double Support (%GC) -0.969 23.03 (3.83)
Double Support Time, s -0.851 0.26 (0.06)
Variability
Stride Length SD -0.877 4.58 (1.68)
Step Length SD -0.865 2.85 (0.95)
Stride Velocity SD -0.861 5.90 (1.98)
Stride Time SD -0.767 0.03 (0.02)
Step Time SD -0.749 0.02 (0.01)
Stance Time SD -0.761 0.03 (0.02)
Swing Time SD -0.650 0.02 (0.01)
Single Support Time SD -0.650 0.02 (0.01)
Double Support Time SD -0.512 0.02 (0.01)
Pace
Stride Length, cm 0.857 130.43 (18.52)
Step Length, cm 0.856 65.02 (9.27)
Velocity, cm/s 0.718 118.96 (20.48)
Base of Support
Stride Width SD -0.734 2.40 (0.85)
Stride Width, cm 0.663 10.34 (4.05)
Tandem
Sum of Feet Surface -0.914 0.33 (0.65)
Sum of Step Distance -0.904 9.68 (17.28)
Double Step -0.563 0.07 (0.30)
Turning
Turning Step Count, steps -0.921 4.95 (0.91)
Turning Time, s -0.851 2.84 (0.63)
Factors were inverted so that lower values represent “worse” gait. The numbers shown represent correla-
tions after the inversion.
SD: standard deviation; %GC: as a percentage of the gait cycle time, the cycle time equals the stride time.
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supplementary table 2. Population characteristics of participants and non-participants
Participants non-participants P-value
Age, years 67.3 (9.1) 73.3 (10.3) <0.01
Female sex, n 1638 (54.3) 385 (59.5) 0.01
Height, cm 169.1 (9.3) 167.0 (9.6) 0.69
Weight, kg 78.4 (14.2) 77.5 (14.6) 0.03
Current cigarette smoking, n 462 (15.3) 64 (12.0) 0.56
Alcohol, grams per day 6.7 (7.4) 5.9 (7.2) 0.70
Diastolic blood pressure, mmHg 83.8 (11.0) 83.8 (11.0) 0.16
Systolic blood pressure, mmHg 141.5 (22.2) 146.0 (22.5) 0.06
Antihypertensive medication, n 1121 (37.1) 274 (52.4) 0.01
Total cholesterol, mmol/L 5.5 (1.1) 5.3 (1.1) 0.06
HDL cholesterol, mmol/L 1.5 (0.4) 1.4 (0.4) <0.01
Lipid lowering medication, n 805 (26.7) 166 (25.7) 0.50
Glucose, mmol/L 5.7 (1.2) 5.8 (1.3) 0.89
Diabetes, n 316 (10.5) 71 (14.8) 0.13
Impaired fasting glucose, n 921 (30.5) 143 (29.8) 0.19
Values represent number (%), or mean (SD). P-values are age- and sex adjusted (if applicable).
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This thesis focusses on the epidemiology of chronic axonal polyneuropathy. The main 
aims were to describe the prevalence of chronic (idiopathic) axonal polyneuropathy in 
the general population, to study the impact of chronic polyneuropathy on a person’s daily 
life, and to describe the effect of known and new risk factors for chronic polyneuropathy 
and for chronic idiopathic axonal polyneuropathy (CIAP) in particular. In this chapter, the 
main findings of the studies described in this thesis will be outlined and discussed with 
regard to previous studies. Subsequently, methodological considerations regarding the 
work described in this thesis and potential clinical implications will be discussed. Finally, 
directions for future research will be provided.
mAin Findings
screening methods for polyneuropathy
Polyneuropathy is a common disease in both general and neurological practice.1 Yet, 
large, comprehensive epidemiological studies investigating this disease are scarce, 
hence the exact prevalence in the population is unknown. The first step in the investiga-
tion of the prevalence of a disease is to develop a screening protocol that can accurately 
detect the disease. Herein probably lies the main reason why large epidemiological 
studies on chronic polyneuropathy are lacking. Polyneuropathy is a heterogeneous 
disease and there is not one gold standard test for polyneuropathy. In neurological 
practice, polyneuropathy usually is a clinical diagnosis that can be made after careful 
history taking and neurological examination, which can be further complemented 
with nerve conduction studies (NCS) and electromyography (EMG).2 Besides NCS and 
EMG, there are several other laboratory tests that can aid the diagnostic process, such 
as computerized sensory testing instruments and skin- or nerve biopsies. These tests 
have often been criticized to be too time-consuming, invasive or costly, and therefore 
inappropriate and not feasible for utilization in large epidemiological field studies.3-9 
Several simplified methods have been developed to be able to estimate the prevalence 
of polyneuropathy.9-20 These simplified methods are reviewed in chapter 2.1. In this 
literature overview, questionnaires, scoring systems for neurological signs and scoring 
systems that combined both symptoms and signs, all developed with the aim to detect 
polyneuropathy in high-risk patient groups, such as in patients with diabetes mellitus, 
are summarized. Although these tools can be useful to screen high-risk individuals in 
clinical practice, it is unknown whether these techniques also produce accurate preva-
lence estimates when used in a general low-risk population. Moreover, the diagnostic 
accuracy, as measured with the sensitivity and specificity, of these simplified screening 
methods is often suboptimal. Likewise, estimating the prevalence of polyneuropathy 
with a single simple test, such as a monofilament or a tuning fork is also inaccurate.21, 22 
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Screening procedures that combine symptoms with a neurological examination focused 
on sensory alterations seem to have the best discriminative ability for chronic axonal 
polyneuropathies.9 Motor symptoms are often only present in more advanced stages of 
polyneuropathy, and are therefore less sensitive for screening. Therefore, when initiat-
ing an epidemiological study focused on chronic polyneuropathy it is important to not 
only use symptoms, but also incorporate an assessment of at least sensory modalities 
into the screening protocol.
In chapter 2.2 we further examined the discriminative ability of individual symptoms 
of polyneuropathy and we described the development of a new simple questionnaire 
that may aid the diagnosis of polyneuropathy. Numbness and tingling sensations in the 
feet were the most sensitive symptoms (87% and 85% respectively), as these symptoms 
were experienced by most polyneuropathy patients. Allodynia (pain due to a stimulus 
that normally does not provoke pain) and a feeling as if walking on cotton wool had 
the highest specificity (90% and 77% respectively). These four symptoms, together with 
balance problems and tingling hands were included in the new, validated Erasmus 
Polyneuropathy Symptom Score (E-PSS), a tool that can be used to discriminate persons 
with polyneuropathy from persons without polyneuropathy. This 14-point scoring 
system was based on a logistic regression model and incorporated the frequency of 
occurrence of each symptom (never, sometimes, and (almost) continuously), as well as 
the individual diagnostic value of each of the six symptoms. The discriminative ability, 
as assessed by the area under the receiver operating characteristics curve, of this score 
was very good (0.92), but further studies are required to assess the utility of this score in 
clinical practice. As with the other questionnaires that have been discussed in chapter 
2.1, the Erasmus Polyneuropathy Symptom Score may have to be complemented with 
other tests to further improve the diagnostic accuracy.
Prevalence of polyneuropathy
Most of the scoring systems have been used to investigate the prevalence and incidence 
of polyneuropathy in high-risk groups, in particular in patients with diabetes mellitus. 
The amount of studies investigating the prevalence of polyneuropathy in a low-risk, 
general population is very limited. In chapter 3.1, data from studies that report on the 
prevalence of polyneuropathy in the general population are reviewed. These studies 
differed greatly in study design, study size, age distribution of the study population, 
employed methodology and polyneuropathy definitions. None of these studies used 
an extensive-in person screening that included assessment of symptoms, signs and 
nerve conduction. Some studies defined polyneuropathy as the presence of merely one 
bilateral neurological deficit (such as numbness or abnormal ankle reflexes), while in 
other studies only persons with electrophysiology confirmed polyneuropathy (based on 
medical records in database studies) were included in the case definition. Consequently, 
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prevalence estimates across these studies also differed substantially, ranging from 0.1% 
to 12.6% when considering the total adult population23, 24, and from 1.9% to 30.9% when 
only considering an elderly population.25, 26 Based on this literature review, we estimated 
the prevalence of chronic polyneuropathy (in developed countries) at approximately 1% 
in the total population, and at approximately 7% in elderly. Further population-based 
studies had to confirm these estimates.
Chapter 3.1 also delineates the most common risk factors for chronic polyneuropathy. 
This data was extracted from hospital-based studies, as population-based data was not 
available. Hospital-based studies identified diabetes mellitus, toxic factors (like alcohol 
abuse and chemotherapy), inflammatory factors and systemic diseases as the most 
common risk factors for polyneuropathy. Despite extensive diagnostic investigations, 
in approximately 25% of polyneuropathy cases no known risk factor can be identified. 
These cases are diagnosed with CIAP. We did not identify studies that described the 
prevalence of CIAP in the general population.
Prevalence of chronic polyneuropathy in the Rotterdam study
We developed an extensive in-person screening protocol for polyneuropathy which we 
implemented in the population-based Rotterdam Study. This screening protocol con-
sists of three parts: 1) a questionnaire that evaluates the presence of neuropathic symp-
toms; 2) a neurological examination with a focus on sensory modalities; and 3) nerve 
conduction studies, which were focused on distal action potential amplitudes of the 
peroneal (motor) and sural (sensory) nerve (Table 1). All participants of the Rotterdam 
Study undergo this screening procedure. Among 1310 middle-aged and elderly partici-
pants the prevalence of ‘definite’ polyneuropathy, a relatively strict definition requiring 
table 1. Polyneuropathy screening in the Rotterdam Study
symptom questionnaire neurological examination nerve conduction studies
Tingling/prickling feet Bilateral assessment of: Bilateral assessment of:
Burning feet - Pin prick (wooden pin) - Sural nerve (sensory)
Walking on cotton-wool feeling - Vibration (Rydel-Seiffer tuning fork) Unilateral assessment of:
Muscle cramps in legs or feet - Knee and ankle tendon reflexes - Peroneal nerve (motor)
Muscle pain in legs or feet - Muscle strength (dorsiflexion feet)
Stabbing pain in legs or feet - Ability to walk on heels
Muscle weakness in legs or feet
Numb feet
Tightness of the legs
Allodynia in legs or feet
Polyneuropathy screening used in the population-based Rotterdam Study. All collected data from each 
individual participant is discussed by an expert panel. The panel categorizes each participant into no, pos-
sible, probable or definite polyneuropathy.
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abnormality in all three parts of the screening (questionnaire, neurological examination 
and nerve conduction studies) or a previous neurologist’s diagnosis of polyneuropathy, 
was 5.5% (chapter 3.2). Applying a less strict definition, requiring abnormality in only 
two parts of the screening protocol (‘probable’ and ‘definite’ polyneuropathy combined), 
yielded a prevalence of 13.1%. These estimates fall in the same range as those reported 
in the literature review described in chapter 3.1 (polyneuropathy prevalence in elderly 
ranging from 1.9% to 30.9%). Since we used a rigorous definition of polyneuropathy in 
a large and random sample of the general population (only selected on residential area 
and age), our estimates likely are the most accurate to date.
Prevalence of definite polyneuropathy was slightly higher in males than in females 
(6.7% compared to 4.5%) and drastically increased with age from 1.2% in persons aged 
50-60 years to 13.2% in persons aged 80 years and over. To take the age distribution of 
our study sample into account, we age-standardized the prevalence to the population 
of the Netherlands. This yielded a standardized (definite) polyneuropathy prevalence 
of 4.0%, indicating that elderly were slightly overrepresented in our sample. Assum-
ing polyneuropathy under the age of 50 years (the lower limit of our age-range) is 
relatively uncommon, this prevalence translates to approximately 260 000 persons in 
the Netherlands suffering from chronic polyneuropathy.27 If age-specific prevalence of 
polyneuropathy does not change in the future, this number will rise to approximately 
400 000 persons in 2040, purely due to aging of the population.27 However, given the 
worldwide increase in the prevalence and incidence of risk factors for polyneuropathy 
such as diabetes mellitus, obesity, chronic kidney disease and cancer (with its related 
treatments), it may be unlikely that the (age-specific) prevalence of polyneuropathy will 
remain stable.28-34 Therefore, this projection is likely underestimating the true burden 
that polyneuropathy will pose in the future.
In chapter 3.2 the presence of putative causes of polyneuropathy was also described. 
Diabetes mellitus was present in about a third of all definite cases, which corresponds 
with the findings from hospital-based studies.35-37 In contrast, the proportion of par-
ticipants with definite polyneuropathy with no known risk factor (these persons are 
diagnosed with CIAP in clinical practice) was higher in our population-based study than 
in previous hospital-based studies: 46% in our study compared to approximately 25% 
in hospital-based studies. This indicates that, on population level, CIAP is much more 
prevalent than was previously estimated, translating to roughly 120 000 persons in the 
Netherlands.27 There are at least three reasons that may explain this discrepancy. First, 
the probability of finding an underlying etiology when a person is diagnosed with poly-
neuropathy decreases with age.35 The study population consisted of middle-aged and 
elderly participants, with an age range from 50 to 95 years, and we slightly oversampled 
elderly, as discussed earlier. Therefore the proportion of elderly with polyneuropathy 
is probably higher in our study than in hospital-based studies. Second, it is likely that 
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we detected cases of polyneuropathy in persons who are only mildly affected. These 
persons may be less likely to visit their general practitioner or be referred to a neurolo-
gist, especially when symptoms are not very bothersome and the disease course is slow. 
Hence, these mildly affected persons are missed in hospital-based studies. Since chronic 
idiopathic axonal polyneuropathy (CIAP) often is a relatively mild disease, these mildly 
affected persons may more often have idiopathic polyneuropathy.38 Third, although the 
presence of several known risk factors (diabetes mellitus, vitamin deficiencies (B1 and 
B12), thyroid dysfunction and monoclonal gammopathies) was routinely evaluated in 
patients with definite polyneuropathy, we did not routinely investigate for very unlikely 
causes of chronic axonal polyneuropathy, we had to rely on medical records for a history 
of systemic diseases, we did not have information about a possible family history of 
hereditary neuropathies and we might have been unable to distinguish mild forms of 
inflammatory neuropathies such as chronic inflammatory demyelinating polyneuropa-
thy. However, since hereditary and demyelinating neuropathies are rare in the general 
population, this probably only marginally influenced our estimates.39, 40
A last, but also important finding described in chapter 3.2 is the finding that 49% of 
polyneuropathy cases was not yet diagnosed. This emphasizes that underreporting or 
underdiagnosing is a common problem in polyneuropathy. An even higher proportion 
(85%) was reported by a previous population-based study, conducted in Italy, approxi-
mately 20 years ago.4 Apparently, there has been some improvement in the awareness 
and recognition of polyneuropathy during the last decades, but polyneuropathy still is 
an underacknowledged disease.
emerging cardiovascular and metabolic risk factors of polyneuropathy
Diabetes mellitus is present in about a third of polyneuropathy cases. This makes 
diabetes mellitus the most frequently identified, and most important risk factor for 
polyneuropathy, especially since its prevalence is reaching epidemic proportions 
worldwide.29, 33 However, although diabetes mellitus can cause polyneuropathy, it does 
not cause polyneuropathy in all diabetic patients as approximately 50% will eventually 
develop neuropathy during the course of the disease.41 Apparently, some individuals are 
more susceptible to the effects of diabetes mellitus on peripheral nerves than others. 
According to Rothman’s theory of causation, a sufficient cause inevitably leads to dis-
ease in everyone in whom this cause is present.42 Since diabetes mellitus does not lead 
to polyneuropathy in all patients, by definition it cannot be considered as a sufficient 
cause of polyneuropathy. This indicates that other factors, or component causes, are 
likely also required to cause polyneuropathy. This is further supported by the observa-
tion that strict glucose control is not efficacious in reducing the development of poly-
neuropathy in patients with type 2 diabetes.41 Factors that have been associated with 
the development or the presence of polyneuropathy in patients with diabetes mellitus 
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include cardiometabolic factors such as obesity, dyslipidemia and hypertension.41, 43-46 
These factors may be the other component causes that are required to form a complete 
causal mechanism in patients with diabetes mellitus. See Figure 1 for an illustration of 
this theory of causation.
There are several mechanisms through which these cardiometabolic factors may pro-
mote the development of polyneuropathy. In diabetes mellitus, hyperglycemia causes 
enhanced formation and deposition of advanced glycation end products that initiate 
inflammatory pathways that generate oxidative stress, impair the biological function 
of cellular proteins and increase the rate of atherosclerosis which can lead to occlusion 
of vessels and thus to hypoxia of peripheral nerves.41, 47 Hyperglycemia and insulin 
resistance also lead to dysregulation of several metabolic pathways that result in mito-
chondrial dysfunction, inflammation and further oxidative stress. All these processes can 
eventually lead to nerve ischemia and cytotoxicity.41 Dyslipidemia can further enhance 
neuronal damage via several mechanisms. First, free fatty acids can injure Schwann cells 
directly, and also promote inflammatory pathways that lead to oxidative stress. Second, 
high levels of oxidized low-density lipoprotein can also trigger mitochondrial dysfunc-
tion and increase oxidative stress. Abdominal obesity plays an important role in these 
processes since it leads to increased concentrations of free fatty acids and systemic 
inflammation, which further contributes to insulin resistance and nerve ischemia.41, 47, 48
An increasing body of evidence implicates the same cardiometabolic factors in the 
pathophysiology of chronic idiopathic axonal polyneuropathy (CIAP), but population-
based evidence in unselected samples was required to further strengthen this hypoth-
esis.48-52 In chapter 4.1 the role of diabetes mellitus, prediabetes and metabolic syndrome 
Diabetes
Genetics
B
Diabetes
Dyslipidemia
?Obesity
Hypertension
A
Diabetes
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?
?
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single
component 
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Figure 1. Causal mechanisms for polyneuropathy in persons with diabetes mellitus. The figure shows 
three hypothetical causal mechanisms (sufficient causes) through which diabetes mellitus can cause poly-
neuropathy. Diabetes mellitus itself is not a sufficient cause: there is no causal pie that only includes diabe-
tes as component, it needs other (unknown) component causes to lead to polyneuropathy. Pie A illustrates 
an example that includes cardiometabolic factors, which have been associated with polyneuropathy in 
patients with diabetes mellitus, and a yet unknown, perhaps genetic component. Genetic susceptibility 
may also be the only extra component that is necessary to form a sufficient cause in diabetics (pie B). It is 
likely that there are more causal mechanisms that include yet unknown components (pie C).
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in relation to polyneuropathy was investigated. Metabolic syndrome refers to a clustering 
of interrelated risk factors for cardiovascular diseases.53 These factors include hyperten-
sion, abdominal obesity, elevated triglyceride levels, reduced high-density lipoprotein 
cholesterol levels and elevated glucose levels. In the study described in chapter 4.1, we 
found that participants with diabetes mellitus were three times more likely to have poly-
neuropathy than participants without diabetes mellitus. Participants with metabolic syn-
drome were two times more likely to have polyneuropathy and this relation was stronger 
as more factors of metabolic syndrome were present. Abdominal obesity and elevated 
triglycerides were the most important individual factors contributing to this association. 
The associations with metabolic syndrome, especially abdominal obesity, were present 
in the total study sample, as well as in the non-diabetic sample. This strengthens the 
hypothesis that these cardiometabolic factors are not only important in the pathophysi-
ology of polyneuropathy in patients with diabetes mellitus, but indeed also in persons 
without diabetes mellitus, of which the vast majority is diagnosed with chronic idiopathic 
axonal polyneuropathy (as described in chapter 3.2). In contrast to some other, mostly un-
controlled studies, our findings do not support the hypothesis that prediabetes is related 
to polyneuropathy, but our study likely was underpowered to show a small effect.3, 54-56
The important role of these conventional cardiovascular risk factors in the patho-
physiology of polyneuropathy is further supported by the finding that in patients with 
type 2 diabetes, polyneuropathy is related to an increased risk of cardiovascular events 
(myocardial infarction, transient ischemic attack, stroke), which is probably explained 
by the shared etiology.57, 58 Similarly, in a case-control study of patients with chronic 
idiopathic axonal polyneuropathy (CIAP), cases had more often experienced a transient 
ischemic attack or stroke and more often had ischemic heart disease than controls.59 
Investigating the association between polyneuropathy and vascular diseases in the Rot-
terdam Study yielded similar results (Table 2). Participants with polyneuropathy more 
table 2. Polyneuropathy and vascular disease
Clinical cerebrovascular 
disease
mRi defined brain infarcts Coronary heart disease
% OR (95% CI) % OR (95% CI) % OR (95% CI)
No PNP 5.5 1.00 7.9 1.00 6.6 1.00
Possible PNP 10.0 1.37 (0.79;2.40) 11.4 1.15 (0.69;1.90) 8.1 0.97 (0.54;1.76)
Probable PNP 13.3 1.60 (0.80;3.18) 15.3 1.09 (0.55;2.17) 12.6 1.35 (0.67;2.72)
Definite PNP 19.5 2.75 (1.39;5.45) 20.3 1.92 (0.98;3.77) 17.1 1.66 (0.79;3.48)
Odds ratios (OR) with 95% confidence intervals (CI) comparing the presence of clinically defined cerebral 
vascular disease (stroke or transient ischemic attack), imaging defined brain infarcts (lacunar or cortical in-
farcts on magnetic resonance imaging, MRI) and coronary heart disease (myocardial infarction or coronary 
revascularization) between participants with possible, probable or definite polyneuropathy (PNP), com-
pared to participants with no polyneuropathy. Odds ratios are adjusted for age and sex
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often had cerebrovascular disease (both by a clinical definition of stroke or transient 
ischemic attack and by an imaging-based definition of lacunar or cortical infarcts) and 
coronary heart disease (history of myocardial infarction or coronary revascularization) 
than participants with no polyneuropathy. However, not all associations were statisti-
cally significant, which is probably due to a lack of power. Nonetheless, these findings 
support the hypothesis of a shared underlying etiology.
Preclinical changes in peripheral nerves
In chapter 4.1 we provided further support for a potential causal role of cardiometa-
bolic factors in the development of polyneuropathy, by showing that the presence of 
these factors also related to impaired peripheral nerve function in persons yet without 
polyneuropathy. Participants with metabolic syndrome had lower sural sensory nerve 
action potential (SNAP) amplitudes and lower peroneal nerve compound muscle action 
potential (CMAP) amplitudes than persons without metabolic syndrome. Moreover, 
this association was stronger when more factors of metabolic syndrome were present. 
This association was even stronger in participants without diabetes mellitus than in the 
total sample of participants. This again emphasizes that these factors may not only be 
important for the development of polyneuropathy in persons with diabetes mellitus, 
but also in persons without diabetes mellitus.
The effect of demographic, anthropometric and other metabolic determinants on 
peripheral nerve function in participants without polyneuropathy is described in chap-
ter 4.2. In order to study the deteriorating effect of these factors on peripheral nerve 
function, it is first important to understand normal aging effects on peripheral nerve 
function. Therefore, the relation between age and sural SNAP and peroneal CMAP am-
plitudes was investigated first. Both the sural SNAP and the peroneal CMAP amplitude 
linearly declined with increasing age. Furthermore, even in participants (yet) without 
polyneuropathy, abnormal amplitudes were a common finding, especially in old age 
groups. Sural SNAP amplitudes were abnormal in 1% of participants under 60 years, 
compared to 23% of participants over 80 years. Similarly, the proportion of abnormal pe-
roneal CMAP amplitudes increased from 4% to 13%. These are important findings, which 
show that age must be taken into account when interpreting nerve conduction studies. 
It is possible that once these persons with impaired nerve function live long enough, 
they will eventually develop a chronic polyneuropathy. Aside from age, a person’s height 
also was an important determinant of nerve action potential amplitudes, with a taller 
height relating to a lower amplitude. Potentially modifiable factors that related to espe-
cially worse sural SNAP amplitudes, were increased values of body weight (total weight, 
body mass index, waist circumference, waist-to-hip ratio) and chronic kidney dysfunc-
tion. Interestingly, none of the persons with chronic kidney disease that participated in 
our study met the criteria for end-stage kidney disease. Generally, polyneuropathy is 
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only described in patients with end-stage kidney disease.60 Our results however suggest 
that changes in peripheral nerves already occur in an earlier stage of mild to moderate 
kidney dysfunction. This is an interesting observation that requires further investigation.
Polyneuropathy related disability
As already mentioned, polyneuropathy poses a large burden on society. In chapter 5 the 
impact of polyneuropathy on an individual is discussed. Besides bothersome complaints 
of numbness and pain, previous studies showed that polyneuropathy can lead to mo-
bility impairment and a reduced quality of life.61-63 In chapter 5.1 we further described 
the impact polyneuropathy has on an individual by investigating the effect of polyneu-
ropathy on the ability to perform daily activities, history of falls, and the gait pattern. 
Persons with polyneuropathy were much more likely to experience difficulty in several 
complex mobility related tasks, such as walking, housekeeping and shopping, but even 
in very basic, simple tasks involving eating, hygiene, dressing and grooming. Partici-
pants with polyneuropathy were also more likely to fall, and these falls often resulted in 
injury, which in turn can further contribute to disability. The ability to perform activities 
of daily living is very important in order to function independently in society. Loss of 
this ability may lead to institutionalization.64 With advancing age the ability to perform 
daily activities already decreases, until a point is reached where institutionalization may 
be necessary. Population aging will thus considerably increase the demand on health 
care.65 This process will be further enhanced by a growing prevalence of age-related 
diseases that also affect daily functioning, such as polyneuropathy. Chronic polyneu-
ropathy thus poses a large burden on both the society and the individual patient, which 
makes polyneuropathy an important health concern.
In chapter 5.1 we also discussed how gait patterns of participants with polyneuropathy 
differed from participants without polyneuropathy. Participants with polyneuropathy 
walked with lower gait velocity and lower cadence. This may be a direct consequence 
of polyneuropathy, for example due to muscle weakness or balance problems, but may 
also be because these participants adopt a more conservative gait pattern to achieve 
greater stability. Polyneuropathy also associated with more errors in tandem walking, 
which illustrates the problems with stability, balance and coordination. Importantly, 
errors in tandem walking is strongly related to an increased risk of falling, which may 
partly explain the increased risk of falling associated with polyneuropathy. In chapter 
5.2, gait patterns of participants with diabetes mellitus were compared to gait patterns 
of participants without diabetes mellitus. This study showed similar findings as discussed 
in chapter 5.1. Diabetes mellitus associated with worse Pace (constituting velocity and 
step length), and also with more errors in tandem walking. Besides polyneuropathy, pe-
ripheral arterial disease may be another potential cause of gait disturbances in persons 
with diabetes mellitus. Peripheral arterial disease is characterized by pain that occurs 
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during walking (intermittent claudication), which may lead to gait alterations. A previ-
ous study showed that peripheral arterial disease leads to similar spatiotemporal gait 
abnormalities as polyneuropathy.66 These changes in gait could already be observed be-
fore the onset of pain, suggesting other mechanisms than pain are involved. Proposed 
mechanisms involve myopathy and axonal polyneuropathy secondary to mitochondrial 
dysfunction and chronic ischemia.66 It is therefore not surprising that changes in gait 
observed as a consequence of peripheral arterial disease are similar to that observed 
in polyneuropathy. Unfortunately, data on polyneuropathy was not available for the 
participants of the study described in chapter 5.2 and no data was collected about 
peripheral arterial disease.
metHodologiCAl ConsideRAtions
study design
The studies discussed in this thesis were conducted in the Rotterdam Study, a large, 
longitudinal population-based cohort study, designed to study determinants and prog-
nosis of chronic diseases in the elderly.67 One of the major advantages of this study is the 
repeated measurement and wide collection of data on numerous different exposures 
and outcomes, resulting in a wealth of data that enables in-depth cross-sectional and 
longitudinal analyses. The polyneuropathy screening protocol was only implemented 
in the beginning of 2013 and before this date, information about polyneuropathy was 
not available. Therefore, the amount of screened individuals is still relatively limited, and 
no repeated measurements have yet been performed. This prevents the investigation 
of potential small associations due to a lack of power, and restricts the investigation of 
potential risk factors to cross-sectional analyses. Results of these cross-sectional analy-
ses should be interpreted cautiously with respect to causality. Hopefully, longitudinal 
studies will follow in the future.
Another major advantage of the Rotterdam Study over hospital-based studies is the 
population-based study design, in which participants can be considered as a random 
sample of the general middle-aged and elderly population. This greatly reduces the pos-
sibility of selection bias and therefore improves the generalizability of the results. Still, 
the population of this study is relatively homogeneous, mostly consisting of middle-
class Caucasians, so results may therefore only be generalizable to similar populations. 
One other form of selection bias, known as the healthy volunteer effect, may still have 
been present in this study. Participation in the study is voluntary and participants have 
to visit the research center to complete the assessment of most exposures. This may 
prevent frail, disabled, or otherwise less healthy persons to participate. Polyneuropathy 
is a disease that results in mobility limitations, hence prevalence of polyneuropathy 
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may have been higher among these non-participants. Additionally, cardiovascular risk 
factors and diseases may have been more prevalent among non-participants. Therefore, 
the prevalence of polyneuropathy reported in chapter 3.2, as well as the associations 
with cardiovascular risk factors described in chapter 4 and with impairment in daily life 
reported in chapter 5, might have been underestimated.
misclassification of polyneuropathy status
The diagnosis of polyneuropathy cannot be made by a single test. Several tests need 
to be combined in order to make a reliable polyneuropathy diagnosis. As discussed in 
chapter 3.1, there is a large inter-study variation with respect to the prevalence of poly-
neuropathy, which was mainly due to differences in methodology. In several studies there 
probably was a large amount of misclassification due to inaccurate screening methods. 
In our study, we tried to minimize misclassification of polyneuropathy status by apply-
ing a rigorous polyneuropathy definition which involved the presence of symptoms, 
bilateral abnormalities on neurological examination of the legs and bilaterally abnormal 
nerve conduction studies, but we cannot rule out that some misclassification remained, 
since it is not a full neurological and neurophysiological examination. The Rotterdam 
Study is an extensive population-based study involving multiple medical specialties. 
Therefore, there were several limitations we had to take into account when designing 
the screening protocol, especially concerning time, costs, invasiveness and burden for 
participants. The screening had to be a non-invasive protocol that could be performed 
within 20 minutes, was minimally cumbersome for participants, and could be executed 
by trained personnel working at the research center. Still, this protocol needed to result 
in reliable information about symptoms, signs (especially sensory, see chapter 2.1), and 
preferably also nerve conduction studies, since these greatly adds to the specificity.68
These limitations somewhat restricted the completeness of the diagnostic work-up 
and may have resulted in some bias due to misclassification of disease status. Misclassi-
fication could have occurred in any of the three components of the screening (question-
naire, examination, nerve conduction studies), but for each part we tried to minimize this 
possibility. First, instead of a live interview, polyneuropathy symptoms were evaluated 
using a questionnaire. The use of a questionnaire prevents the possibility to distinguish 
polyneuropathy-related symptoms from symptoms that result from diseases that may 
resemble some of the complaints of polyneuropathy (i.e. osteoarthritis, radiculopathy, 
fibromyalgia). Additionally, there is the possibility of recall bias. However, given that we 
assessed the presence of symptoms over the last three months, and given that these 
symptoms are often experienced daily, recall bias probably is very limited. Second, as 
polyneuropathy usually is a length-dependent disease that starts distally in the feet, 
the neurological examination was purely focused on the lower legs and consisted of 
assessment of vibration sensation on the big toes (large fibers), pin prick of the lower 
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legs (small fibers), reflexes of both the knee and Achilles tendons, and muscle strength 
of the feet. Besides polyneuropathy, these modalities can also be affected by other 
(neurological) disorders, such as radiculopathies and mononeuropathies. To reduce 
misclassification, all items were assessed bilaterally, and only when multiple items were 
bilaterally abnormal, the neurological examination was considered abnormal. Still, we 
did not conduct a full neurological examination and for example did not assess sensation 
of touch, coordination and joint position sense. These items normally are included in the 
neurological examination of a patient who is suspected of polyneuropathy. However, we 
do not expect that information about these items would have led to important different 
conclusions. Third, although nerve conduction studies were performed according to 
internationally used guidelines, we were unable to preheat the legs of the participants. 
Cold feet may yield artificially high action potential amplitudes, possibly leading to 
a (false) classification of normal.69 This might have led to an underestimation of the 
prevalence of polyneuropathy. Additionally, our nerve conduction studies were limited 
and did not include the full range of diagnostic tests that are advised for the diagnosis 
of polyneuropathy.68 The sural and peroneal nerve taken together are the most sensi-
tive for detecting a polyneuropathy, but these may not be very specific.68 As shown in 
chapter 4.2, abnormal nerve conduction amplitudes also occur in elderly without poly-
neuropathy, indicating the necessity to combine nerve conduction studies with other 
tests to make a final diagnosis of polyneuropathy.70, 71 Therefore, we used all three parts 
of the screening when forming an overall polyneuropathy conclusion. To further reduce 
bias in the polyneuropathy definition, an experienced expert panel categorized each 
participants into one of 4 groups (no, possible, probable and definite polyneuropathy), 
reflecting the diagnostic uncertainty. The amount of misclassification in the group of 
participants classified as definite polyneuropathy is therefore most likely very minimal.
interpretation of associations
In this thesis several associations of cardiometabolic factors with polyneuropathy or 
peripheral nerve dysfunction and of polyneuropathy with impairment in gait and daily 
functioning are described. Aside from being true effects, these associations may also be 
introduced by selection bias, information bias (misclassification) and confounding. As 
already discussed in this chapter, selection bias is probably not much of an issue in our 
population-based studies and misclassification of polyneuropathy status is likely also 
minimal. Misclassification of cardiometabolic determinants due to measurement error 
may have been present in chapter 4. Similarly, misclassification may have occurred when 
assessing daily functioning in chapter 5. Daily functioning is assessed with question-
naires, and although validated, questionnaires are subjective and therefore more prone 
to information bias, either participant-related, such as recall bias and response bias, or 
researcher-related, such as interviewer bias. However, this misclassification is not directly 
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related to the presence of polyneuropathy and is therefore probably non-differential 
and thus not affecting the associations of interest or, if any, leading to an underestima-
tion of the true effects. Finally, associations may be due to confounding. We tried to 
minimize this confounding by using multivariable modeling, thus adjusting for several 
potential confounding factors, but we cannot rule out that there is residual confounding 
that influenced some of our results. Much is unknown about polyneuropathy, so it is 
likely that other, unknown and unmeasured factors played a role in several associations.
Proportion of cases attributable to certain risk factors
In chapter 3.1 and chapter 3.2 the presence of putative causes in participants with 
polyneuropathy was described. In the study described in chapter 3.2, twenty-two par-
ticipants (31%) with definite polyneuropathy had diabetes mellitus. In clinical practice, 
but also in most polyneuropathy-related research, a person who has both diabetes mel-
litus and a chronic distal polyneuropathy is considered to have diabetic polyneuropathy. 
Although this is clinically useful, from an etiological point of view this is not fully correct. 
This assumption ignores the fact that some patients with diabetes mellitus develop 
polyneuropathy irrespective of the presence of diabetes mellitus, and that a patient 
with diabetes mellitus also requires other (component) causes to give rise to the disease 
(as discussed before, see also Figure 1). Therefore, it is incorrect to state that 31% of 
polyneuropathy cases is due to diabetes mellitus. An alternative, more appropriate way 
to describe the proportion that can be attributed to a certain risk factor is by calculat-
ing the population attributable fraction.72 The population attributable fraction can be 
calculated with the following formula:
Population attributable fraction = P(E|D)
(RR − 1)
RR
In this formula P(E|D) denotes the proportion of persons with the disease exposed to the 
risk factor, and RR denotes the relative risk of the disease associated with the exposure. 
In our study, the proportion of participants with polyneuropathy exposed to diabetes 
mellitus was 33% (22 out of 67 participants with data about diabetes mellitus available) 
and the relative risk, as estimated using the odds ratio, of definite polyneuropathy 
(compared to no polyneuropathy as reference) associated with diabetes mellitus was 
3.3. Introducing these numbers in the formula yields an attributable fraction of 23%. 
This means that 23% of polyneuropathy cases can ‘truly’ be attributed to diabetes 
mellitus and can theoretically be prevented by completely eliminating this risk factor 
from the population. This computation also shows that there is a proportion of persons 
with diabetes mellitus and polyneuropathy, in which diabetes itself is not the cause of 
the polyneuropathy, but just a bystander. This example is a simple computation using 
the crude estimation of the relative risk, but this formula can also be applied using 
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adjusted odds ratios, and several statistical programs are capable of calculating popula-
tion attributable fractions. The age and sex-adjusted population attributable fraction 
for diabetes mellitus is 20%. Similarly, for metabolic syndrome (which includes diabetes 
mellitus among others) the age- and sex-adjusted population attributable fraction is 
32%. This method preferentially should be used more often in polyneuropathy research. 
For proper use however, it requires extensive data collection on exposures among both 
cases and controls and also a large sample size. Currently, the sample size of our study 
is still relatively small and therefore yields wide confidence intervals, hampering us to 
study the population attributable fraction of the described risk factors in detail.
CliniCAl imPliCAtion And FutuRe PeRsPeCtiVes
In this thesis, we described the prevalence of polyneuropathy in the general population, 
risk factors for polyneuropathy and the impact of polyneuropathy on daily functioning. 
There are several areas of health care in which this data is very useful.
Knowledge about the frequency of the disease is necessary to assess the burden 
of the disease on society (which is important for policy makers and funding agencies 
among others), but is also necessary in clinical practice. The prevalence determines the 
prior probability (before any testing has been done) that someone suffers from a specific 
disease. This is not only important for neurologists, but also and perhaps especially for 
general practitioners. A general practitioner has to think about polyneuropathy when 
a patient presents with numb feet or even when a patient presents with nonspecific 
leg complaints, purely because polyneuropathy is so common, especially in elderly. In 
our study, a large proportion of participants, although these participants had clinically 
overt polyneuropathy, was not previously diagnosed with this disease. Hopefully, the 
data described in this thesis will contribute information that will lead to an improved 
recognition and awareness of this disease.
This thesis also provided evidence that traditional cardiovascular risk factor may play 
an important role in the development of polyneuropathy, but longitudinal studies are 
required to further strengthen the hypothesis that this association is indeed causal. 
Besides assessment of diabetes mellitus, vascular factors are not routinely investigated 
in the diagnostic work-up of polyneuropathy. It may be recommended that future poly-
neuropathy guidelines implement measurement of lipid levels and blood pressure 
and encourage weight reduction when appropriate. However, it is currently unknown 
whether patients who are already diagnosed with polyneuropathy may benefit from 
treatment of these risk factors. Even if such treatments are able to halt progression, it will 
probably not cure the disease since irreversible damage may already have accumulated 
over a period of years. Therefore prevention may be most important. Unfortunately, 
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we performed a cross-sectional observational study and were not able to investigate 
whether such an intervention indeed helps. Trials are necessary to investigate the true 
potential of strict treatment of these factors on the development and progression of 
polyneuropathy. When designing a clinical trial that evaluates the effect of such an 
intervention, knowledge about the impact of polyneuropathy on daily life and the 
risk of falls is very important, especially when deciding on the appropriate outcome 
measures.73 Information about the impact of polyneuropathy on daily life is also very 
useful for clinical practice. Clinicians can use this data to inform and counsel patients 
with polyneuropathy at diagnosis and during follow-up.
This thesis provides important information about chronic axonal polyneuropathy, 
but much of the etiology of this disease remains unknown. Currently, the Rotterdam 
Study is one of the very few population-based studies focusing on chronic axonal poly-
neuropathy. This is unfortunate, since collaborative consortia greatly increases sample 
size, and thus increases the chance to find small effects. This would especially also be 
useful for the investigation of genetic polymorphisms in polyneuropathy. Still, when 
more participants of the Rotterdam Study have been screened, we will hopefully be able 
to further elucidate at least a part of the genetic background of chronic – yet idiopathic 
– axonal polyneuropathy. Besides the discussed cardiovascular risk factors and genetic 
factors, the search for other risk factors of (idiopathic) polyneuropathy still continues. 
Other interesting topics for new research include the investigation of inflammatory fac-
tors and markers of small vessel disease. As discussed before, inflammation, hypoxia and 
ischemia likely play an important role in the pathophysiology of polyneuropathy. One 
way to further study this association can be to study the association between changes 
in easily accessible vessel beds, such as the microvasculature of the retina, and poly-
neuropathy. Retinal vessels can be visualized non-invasively, and are thought to be a 
representative reflection of systemic microvasculature.74, 75 The eyes can also be used to 
study peripheral nerves non-invasively, using optical coherence tomography or corneal 
confocal microscopy, both relatively new and promising techniques that may be able 
to detect neurodegenerative changes already at an early stage.76 The potential of these 
new techniques requires further investigation.
In conclusion, in this thesis, in which we described the first results of a study on polyneu-
ropathy in the Rotterdam Study, we found that chronic (idiopathic) axonal polyneuropa-
thy is a common, disabling, but underdiagnosed disease, that disproportionately affects 
elderly. Aside from diabetes mellitus, other cardiometabolic factors, especially dyslipid-
emia, obesity and kidney dysfunction, are important in chronic axonal polyneuropathy, 
including chronic idiopathic axonal polyneuropathy. Future studies are necessary to 
investigate whether optimal prevention and treatment of these risk factors leads to a 
reduction in incidence or progression of chronic polyneuropathy.
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summARy
Chronic axonal polyneuropathy is the most common age-related disease of the periph-
eral nervous system. The disease is characterized by slowly progressive symmetrically 
distributed sensory disturbances such as numbness, tingling and neuropathic pain, and 
motor symptoms, such as cramps and muscle weakness. Initially, most symptoms are re-
stricted to distal body parts, but symptoms may ascend during the course of the disease, 
which is mostly over a period of several years. The symptoms are caused by irreversible 
length-dependent axonal degeneration of peripheral nerves. The most common cause 
of this axonal degeneration is diabetes mellitus. Other known causes of axonal poly-
neuropathy include alcohol abuse, nutritional deficiencies, hereditary factors, systemic 
diseases and use of certain medications, such as chemotherapy. Despite an extensive 
diagnostic work-up, the cause of axonal polyneuropathy remains unknown in 25-30% 
of cases. These patients are diagnosed with ‘chronic idiopathic axonal polyneuropathy’, 
or CIAP.
Due to the complexity of the diagnosis of chronic polyneuropathy, which includes as-
sessment of symptoms, signs, and nerve conduction, little population-based data about 
the prevalence and risk factors of chronic axonal polyneuropathy, and in particular CIAP, 
was available. The scientific work described in this thesis addressed these knowledge 
gaps. The aims of the studies were to describe the prevalence of chronic (idiopathic) 
axonal polyneuropathy in the general population, to investigate the (early) effects of 
known risk factors on polyneuropathy and peripheral nerve function and to identify 
new risk factors for polyneuropathy. Most studies in this thesis were embedded in the 
Rotterdam Study, a large prospective population-based study among people 45 years of 
age and older, residing in Ommoord, a district of Rotterdam, the Netherlands.
In chapter 2 several screening methods for chronic polyneuropathy are described. 
Chapter 2.1 outlines screening questionnaires and scoring systems for neurological ex-
amination that have previously been developed especially for the detection of polyneu-
ropathy in high-risk individuals, such as persons with diabetes mellitus. A screening that 
combines the assessment of symptoms with an evaluation of sensory modalities has 
the best discriminative ability for polyneuropathy. Scoring systems that only assess the 
presence of symptoms perform less well. Several questionnaires include multiple non-
specific symptoms such as fatigue, muscle pain, or cramps and most do not incorporate 
the frequency of occurrence of these symptoms into the questionnaire, although this 
may contribute important information about the likelihood of the disease. Therefore, it 
is likely that the diagnostic accuracy of a questionnaire can be optimized. In the study 
described in chapter 2.2, we extensively interviewed polyneuropathy patients about 
their complaints, to investigate which symptoms are most informative for the presence 
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of a polyneuropathy. The six most informative symptoms – numb feet, tingling feet, allo-
dynia of the feet (pain due to a stimulus that normally does not provoke pain), a feeling 
as if walking on cotton wool, balance problems and tingling hands – were included in 
a new symptom scoring tool: the Erasmus Polyneuropathy Symptom Score (E-PSS). This 
tool proved to be highly accurate in detecting the presence of a polyneuropathy across 
several populations. The practical utility of this tool for the use in research settings and 
in clinical practice needs to be further investigated.
Chapter 3 focuses on the prevalence of polyneuropathy in the general population. 
Chapter 3.1 first summarizes previous studies that have attempted to report on the 
prevalence of polyneuropathy. Because of the complexity of the diagnostic procedure 
and the lack of a simple standard test to diagnose chronic polyneuropathy, there was a 
large inter-study variation with regard to the applied methodology to diagnose poly-
neuropathy. Consequently, the reported prevalence among elderly ranged from around 
2% to over 30%. Most studies had several limitations and most importantly, none used 
a rigorous screening that involved both assessment of symptoms and signs together 
with nerve conduction studies, which is recommended for the diagnosis of this disease.
In order to provide a more reliable estimate of the prevalence of chronic polyneu-
ropathy, we implemented an extensive screening protocol for polyneuropathy in the 
population-based Rotterdam Study, that aside from assessment of symptoms and signs, 
also included nerve conduction studies. Among 1310 participants, the crude prevalence 
of polyneuropathy was 5.5%, and the age-standardized prevalence to the population of 
the Netherlands was 4.0%. (chapter 3.2) This translates to approximately 260 000 persons 
in the Netherlands with chronic polyneuropathy. In almost half (46%) of the participants 
of the Rotterdam Study with polyneuropathy no known risk factor was present (CIAP), 
a proportion that is much larger than was estimated based on hospital-based studies 
(25-30%). Additionally, almost half (49%) of the participants with polyneuropathy were 
not previously recognized as having polyneuropathy. These results show that chronic 
polyneuropathy, and in particular CIAP, is a common, but underdiagnosed health prob-
lem, that deserves more public attention.
In chapter 4, potential risk factors of chronic (idiopathic) axonal polyneuropathy and 
peripheral nerve dysfunction are described. Chapter 4.1 focuses on the presence of 
diabetes mellitus and metabolic syndrome, a clustering of interrelated risk factors for 
cardiovascular diseases. The presence of thee out of five risk factors (abdominal obesity, 
elevated triglycerides, reduced high-density lipoprotein cholesterol, hypertension, and 
elevated fasting glucose) defines the presence of metabolic syndrome. Participants with 
diabetes mellitus were three times more likely to have polyneuropathy. Similarly, par-
ticipants with metabolic syndrome were two times more likely to have polyneuropathy, 
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independent of the presence of diabetes mellitus. The presence of more components of 
metabolic syndrome related to a higher probability of having polyneuropathy. Abdomi-
nal obesity and elevated triglycerides contributed most to this association.
The important role of these cardiometabolic risk factors was further emphasized by 
showing that the presence of metabolic syndrome also related to worse peripheral nerve 
function (lower sural sensory nerve action potential amplitude and lower peroneal com-
pound muscle action potential amplitude) in participants yet without polyneuropathy. 
Additionally, in chapter 4.2 we show that a high weight, obesity and the presence of 
moderate kidney dysfunction also relate to worse peripheral nerve function in persons 
without any symptoms or signs of polyneuropathy. These results suggest that the pres-
ence of cardiometabolic risk factors and kidney dysfunction leads to a gradual decline in 
peripheral nerve function and may predispose for the development of polyneuropathy.
Chapter 5 of this thesis is dedicated to the impact of polyneuropathy on daily life. In 
chapter 5.1 the effect of polyneuropathy on the ability to perform daily activities was 
investigated. Participants with polyneuropathy were much more likely to experience 
difficulty in performing basic activities, such as walking, eating, dressing and arising, 
and also in more complex activities such as housekeeping and shopping. Additionally, 
gait pattern, as assessed with an electronic walkway, of participants with polyneuropa-
thy showed a lower gait velocity, lower cadence, and a longer double support time. 
Moreover, participants with polyneuropathy made more errors when walking heel-to-
toe over a line visible on the walkway. Especially the latter finding might predispose to 
an increased risk of falls in patients with polyneuropathy. In our study, we found that 
participants with polyneuropathy were two times more likely to fall, and these falls often 
resulted in injury, such as fractures, head trauma or severe bruising. In chapter 5.2 we 
investigated the gait pattern of participants with diabetes mellitus. Here we found that 
participants with diabetes mellitus exhibit similar gait abnormalities as participants with 
polyneuropathy. This is a logical observation, since polyneuropathy is a very common 
complication of diabetes mellitus.
The final chapter (chapter 6) provides an extensive discussion of the main findings, 
methodological considerations, clinical implications and future directions.
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Chronische axonale polyneuropathie is de meest voorkomende leeftijdsafhankelijke 
aandoening van het perifere zenuwstelsel. Het ziektebeeld wordt gekenmerkt door 
langzaam progressieve symmetrische klachten van het gevoel, zoals doofheid, tintelin-
gen en neuropathische pijn, en klachten van de motoriek, zoals kramp en spierzwakte. 
Aanvankelijk bevinden deze klachten zich vooral in de voeten, maar later in het beloop 
van de aandoening, meestal over een periode van meerdere jaren, kunnen deze klach-
ten opstijgen in de benen en ook ontstaan in de handen en armen. De klachten worden 
veroorzaakt door irreversibele axonale degeneratie van perifere zenuwen. De meest 
voorkomende oorzaak van deze axonale degeneratie is diabetes mellitus (suikerziekte). 
Andere bekende oorzaken van axonale polyneuropathie zijn alcohol misbruik, tekorten 
aan bepaalde voedingsmiddelen, erfelijke factoren, systeemziekten en het gebruik van 
bepaalde medicijnen zoals chemotherapie. Ondanks uitgebreid aanvullend onderzoek 
blijft de oorzaak van polyneuropathie onbekend in 25-30% van alle polyneuropathie ge-
vallen. Deze patiënten worden gediagnosticeerd met ‘chronische idiopathische axonale 
polyneuropathie’, ook wel CIAP.
Doordat het stellen van de diagnose chronische polyneuropathie een complexe pro-
cedure betreft, bestaande uit een evaluatie van symptomen, een neurologisch onderzoek 
en een zenuwgeleidingsonderzoek, zijn er erg weinig populatie studies naar de prevalen-
tie (voorkomen) en de risicofactoren van chronische axonale polyneuropathie, en in het 
bijzonder CIAP, verricht. De studies die zijn beschreven in dit proefschrift richten zich op 
dit hiaat in de wetenschappelijke kennis. Het doel van deze studies was te beschrijven hoe 
vaak chronische (idiopathische) axonale polyneuropathie in de algemene bevolking voor-
komt, te onderzoeken wat het effect is van bekende risicofactoren op polyneuropathie en 
perifere zenuw functie, en om nieuwe factoren te kunnen identificeren die betrokken zijn 
bij het ontstaan van polyneuropathie. De meeste studies die beschreven zijn in dit proef-
schrift zijn verricht in de Rotterdam Studie, een groot prospectief bevolkingsonderzoek 
onder inwoners van de wijk Ommoord in Rotterdam, van 45 jaar en ouder.
In hoofdstuk 2 worden verschillende screeningsmethoden voor chronische polyneuro-
pathie beschreven. In hoofdstuk 2.1 zijn vragenlijsten en score instrumenten voor het 
neurologisch onderzoek samengevat die in eerdere studies zijn gebruikt om polyneuro-
pathie op te sporen bij mensen met een hoog risico op polyneuropathie, zoals mensen 
met diabetes mellitus. Een screening protocol dat de aanwezigheid van klachten, in 
combinatie met sensibele stoornissen evalueert lijkt het meest geschikt om mensen 
met polyneuropathie te kunnen onderscheiden van mensen zonder polyneuropathie. 
Het gebruik van een vragenlijst alleen is minder accuraat, mogelijk omdat in de meeste 
vragenlijsten ook naar de aanwezigheid van verschillende aspecifieke klachten wordt 
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gevraagd, zoals moeheid, kramp en spierpijn. Daarnaast wordt vaak niet meegenomen 
hoe vaak klachten optreden, wat wellicht belangrijke informatie geeft over de waar-
schijnlijkheid van de diagnose. Mogelijk kunnen deze vragenlijsten dus verder worden 
geoptimaliseerd. In de studie beschreven in hoofdstuk 2.2 hebben we patiënten met 
polyneuropathie uitgebreid ondervraagd over het optreden van hun klachten, om zo 
te onderzoeken welke symptomen het meest informatief zijn voor de diagnose poly-
neuropathie. De zes meest informatieve symptomen – dove voeten, tintelende voeten, 
overgevoeligheid van de voeten, het gevoel op watten te lopen, balans problemen en 
tintelende handen – hebben we opgenomen in een nieuw score instrument voor symp-
tomen van polyneuropathie: de “Erasmus Polyneuropathy Symptom Score” (E-PSS). Dit 
instrument was erg accuraat in het detecteren van de aanwezigheid van polyneuropa-
thie in verschillende populaties. De bruikbaarheid van dit instrument voor wetenschap-
pelijk onderzoek en in de klinische praktijk moet nog verder worden onderzocht.
Hoofdstuk 3 richt zich op het voorkomen van polyneuropathie in de algemene bevol-
king. In hoofdstuk 3.1 worden eerder verrichtte studies naar de prevalentie van polyneu-
ropathie samengevat. Wegens de complexe diagnostische procedure en de afwezigheid 
van een simpele test om de diagnose chronische polyneuropathie te stellen, is er een 
grote variatie tussen deze studies met betrekking tot de toegepaste methodiek om de 
diagnose te stellen. Dit heeft als gevolg dat ook de resultaten erg uiteenlopen, variërend 
van een prevalentie onder ouderen van rond de 2% tot boven de 30%. De meeste van 
deze studies hadden verschillende beperkingen, en geen van alle studies gebruikte een 
strenge definitie van polyneuropathie, bestaande uit de combinatie van symptomen, 
afwijkingen bij het neurologisch onderzoek en afwijkingen bij het zenuwgeleidingson-
derzoek, wat wel aanbevolen wordt bij het stellen van de deze diagnose.
Om een meer betrouwbare schatting van de prevalentie van polyneuropathie te ver-
krijgen, hebben we een uitgebreid polyneuropathie screening protocol geïmplemen-
teerd in de Rotterdam Studie. Dit protocol bestaat uit een evaluatie van symptomen, 
afwijkingen bij neurologisch onderzoek en een zenuwgeleidingsonderzoek. Van de 
1.310 onderzochte deelnemers had 5.5% een polyneuropathie (hoofdstuk 3.2). Wan-
neer we dit vertalen naar de Nederlands bevolking was dit 4.0%. Dit betekent dat er 
in Nederland ongeveer zo’n 260.000 mensen een chronische polyneuropathie hebben. 
In ongeveer de helft (46%) van de deelnemers aan de Rotterdam Studie waarbij er een 
polyneuropathie werd vastgesteld, kon geen bekende risicofactor gevonden worden 
(CIAP). Dit is een stuk vaker dan eerder werd geschat op basis van studies verricht in 
ziekenhuizen (25-30%). Bovendien vonden we dat bijna de helft (49%) van deze mensen 
nog niet eerder was gediagnosticeerd met polyneuropathie. Deze resultaten laten zien 
dat chronische polyneuropathie, met name ook CIAP, erg vaak voorkomt, maar vaak niet 
goed wordt herkend. Er moet dus meer aandacht komen voor polyneuropathie.
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In hoofdstuk 4 zijn potentiele risicofactoren voor chronische (idiopathische) axonale 
polyneuropathie en dysfunctie van perifere zenuwen onderzocht. In hoofdstuk 4.1 is 
het verband tussen de aanwezigheid van diabetes mellitus, het metabool syndroom en 
polyneuropathie beschreven. Het metabool syndroom is een benaming voor de aanwe-
zigheid van een combinatie van meerdere risicofactoren voor hart- en vaatziekten. Bij de 
aanwezigheid van drie van vijf factoren (abdominale obesitas, verhoogde triglyceride, 
verlaagd HDL-cholesterol, hoge bloeddruk en verhoogd nuchter glucose) spreekt met 
van metabool syndroom. Deelnemers met diabetes mellitus hadden drie keer zo vaak 
een polyneuropathie. Deelnemers met metabool syndroom hadden twee keer zo vaak 
een polyneuropathie en dit was onafhankelijk van de aanwezigheid van diabetes mel-
litus. De kans op polyneuropathie was groter wanneer er meer factoren van metabool 
syndroom aanwezig waren. Abdominale obesitas en verhoogde triglyceride waarden 
droegen het meeste bij aan dit verband.
De belangrijke rol van deze cardio-metabole risico factoren werd verder benadrukt 
door aan te tonen dat de aanwezigheid van metabool syndroom gerelateerd was aan een 
slechtere perifere zenuwfunctie (verlaagde amplitudes bij zenuwgeleidingsonderzoek) 
bij mensen bij wie de diagnose polyneuropathie niet kon worden gesteld. Daarnaast 
laten we in hoofdstuk 4.2 ook zien dat een hoog gewicht, obesitas en de aanwezigheid 
van gematigd nierfalen gerelateerd zijn aan een verminderde zenuwfunctie bij mensen 
zonder symptomen of andere klinische kenmerken van polyneuropathie. Hieruit kun-
nen we concluderen dat de aanwezigheid van deze cardio-metabole factoren mogelijk 
leidt tot een geleidelijke afname van perifere zenuwfunctie, en mogelijk het risico op 
het ontwikkelen van een polyneuropathie vergroot.
Hoofstuk 5 van dit proefschrift gaat over de impact van polyneuropathie op het dage-
lijks leven. In hoofdstuk 5.1 is het effect van polyneuropathie op de mogelijkheid tot 
het uitvoeren van allerlei dagelijkse activiteiten onderzocht. Deelnemers met polyneu-
ropathie bleken veel vaker moeilijkheden te hebben met het uitvoeren van simpele 
activiteiten zoals lopen, eten, aankleden, opstaan, maar ook met het uitvoeren van meer 
complexe activiteiten zoals boodschappen doen en het huishouden doen. Met behulp 
van een elektronische loopmat vonden we dat mensen met polyneuropathie een ander 
looppatroon hadden dan mensen zonder polyneuropathie: ze liepen langzamer en met 
een lagere cadans. Daarnaast maakten mensen met polyneuropathie meer zijstappen 
wanneer zij voetje-voor-voetje over een lijn moesten lopen. Deze bevindingen spelen 
een belangrijke rol bij het risico op vallen. Wij vonden dat mensen met polyneuropathie 
twee keer zo vaak vielen dan mensen zonder polyneuropathie. Een dergelijke val leidde 
ook vaker tot verwondingen zoals botbreuken, hoofdwonden, of kneuzingen. In hoofd-
stuk 5.2 wordt het looppatroon van mensen met diabetes mellitus beschreven. In deze 
studie vonden we dat het looppatroon bij mensen met diabetes op dezelfde manier is 
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veranderd als bij mensen met polyneuropathie. Dit is een logische bevinding, aangezien 
polyneuropathie een veel voorkomende complicatie van diabetes mellitus is.
In het laatste hoofdstuk (hoofdstuk 6) worden in een uitgebreide discussie de belangrijk-
ste resultaten, methodologische overwegingen, klinische implicaties en onderwerpen 
voor toekomstig onderzoek beschreven.
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Inmiddels zijn er ruim vier jaar verstreken sinds ik begon aan mijn promotie onderzoek. 
Deze tijd is voorbij gevlogen en heeft geresulteerd in het proefschrift dat nu voor u ligt. 
Via dit dankwoord wil ik graag iedereen bedanken die mij heeft gesteund, geholpen, 
begeleid of anderszins heeft bijgedragen aan de totstandkoming van dit proefschrift. 
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tijds in het Sint Franciscus Gasthuis en raakte enthousiast van de verschillende studies 
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Intussen maak ik zelf deel uit van deze leuke groep en daar ben ik erg trots op. Ik wil 
je bedanken voor het overbrengen van jouw enthousiasme voor dit onderzoek, voor 
wetenschap in het algemeen en voor het werken in de kliniek. Ook wil ik je bedanken 
voor je vertrouwen, je goede begeleiding en voor de gezelligheid tijdens de congres-
sen, zeiluitjes, etentjes en borrels waar ik gedurende deze periode onderdeel van ben 
geweest. Ik hoop nog veel van je te kunnen leren tijdens mijn werkzaamheden in de 
kliniek. Beste Arfan, aanvankelijk was je als co-promotor mijn dagelijkse begeleider. 
Inmiddels ben je professor en hoofd van de afdeling. Ondanks de extra taken die dit 
ongetwijfeld met zich meebracht kon ik altijd even langskomen voor een advies. Ik 
bewonder je epidemiologische kennis en heb in onze gesprekken veel van je geleerd, 
over de epidemiologie en over het schrijven van een wetenschappelijk artikel: onder 
andere het stroomlijnen van een introductie, en het verbuigen van zinnen en stukken 
tekst zodat ze lekkerder lezen en er ook nog voor zorgen dat het uiteindelijke artikel 
wel binnen de maximale woordenlimiet past. Hopelijk kunnen we onze samenwerking 
voortzetten als er een opvolger van het project kan worden aangesteld.
Ook wil ik de leden van mijn promotiecommissie hartelijk bedanken voor het willen 
uitwisselen van gedachten over mijn proefschrift. Speciale dank gaat uit naar de leden 
van de leescommissie: professor Peter Koudstaal, professor Oscar Franco, en dr. Nico-
lette Notermans, voor de bereidheid deel te nemen aan deze commissie en de tijd te 
nemen het proefschrift kritisch door te lezen. Daarnaast wil ik alle coauteurs bedanken 
voor hun bijdrage aan mijn publicaties. Marieke, bedankt voor het meeschrijven aan 
de subsidie aanvraag, het starten van het vragenlijst onderzoek en je deelname aan de 
eerste consensusbesprekingen. Dr. Notermans en Dr. Vrancken, bedankt dat we voor 
het vragenlijst onderzoek ook gebruik mochten maken van jullie trouwe CIAP patiënten 
groep.
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Judith, bij het voorbereiden, verkrijgen, verwerken en interpreteren van alle data ben 
jij werkelijk onmisbaar geweest. Heel hartelijk bedankt voor de duizenden EMG’s die jij 
bekeken hebt, je technische ondersteuning bij storingen, je bijdrage aan de consensus-
besprekingen en input voor publicaties. Ik ben onder de indruk van jouw KNF-kennis en 
hoop dat ik daar tijdens mijn KNF-stage verder van kan profiteren.
Vervolgens wil ik een woord van dank uiten aan alle deelnemers van de Rotterdam 
Studie. Zonder hen geen gegevens, wetenschappelijke publicaties of promoties. Ook 
alle medewerkers van het ERGO-centrum die elke dag klaar staan om de verschillende 
testen af te nemen of uit te voeren wil ik hartelijk bedanken voor hun inzet. Speciale 
dank gaat hierbij uit naar een aantal mensen die voor het polyneuropathie project erg 
belangrijk zijn. Aanvankelijk Lydia, Pauli, Charlotte, Marja, Dilan en Hanan voor de eerste 
1000 deelnemers en later het studententeam (Merel, Nadine, Jessica, Anna, Débora en 
Michiel) voor de volgende 1000, ik wil jullie heel erg bedanken voor het screenen van 
alle deelnemers. Ook Anne-Monique, Marlies en natuurlijk Jolande wil ik bedanken voor 
hun harde werk om alle huisartsgegevens te doorgronden. Ik wil hier ook graag Frank 
van Rooij bedanken voor het verwerken en beheren van alle data en het beantwoorden 
van mijn talloze data-verzoeken. Ook wil ik Nano bedanken voor zijn computertechni-
sche ondersteuning.
Jacqueline en Gabriëlle, bedankt voor het inplannen van alle afspraken in de drukke 
agenda’s van mijn promotoren en de hulp bij het regelen van allerlei zaken, invullen van 
formulieren of het verkrijgen van een handtekening.
Zoals ik aan het begin van dit dankwoord al aangaf, de tijd is voorbij gevlogen. Dit komt 
mede door de goede sfeer en gezelligheid op de Epidemiologie afdeling. Ik wil alle me-
depromovendi en masterstudenten die daaraan bijdroegen dan ook hartelijk bedanken. 
Met name de collega’s van de Neuro-Epi wil ik bedanken voor de leuke gesprekken, 
uitjes en discussies: Frank, Hazel, Sanaz, Saloua, Ben, Eline, Unal, Pinar, Lotte, Renée, 
Tavia, Sirwan, Jasper, Pauline, Ana, Marileen, Hoyan, Jory, Saira, Thom, Sylvan, Liselotte, 
Vanja, Hieab, Daniel, Vincent, Liz, Meike, Sonja en Sven. Ook een bijzonder woord van 
dank aan de voetbalteams van ERGO en GenR, de vele uren die we aan de voetbaltafel(s) 
hebben versleten waren soms bijzonder welkom!
Natuurlijk wil ik Lotte en Renée extra bedanken voor de tijd die we samen op 28-07 
hebben doorgebracht. Bedankt voor alle leuke gesprekken, grappen, en andere gezel-
lige (en soms ook moeilijke) momenten die we samen hebben gedeeld. Ik had me geen 
betere roommates kunnen wensen dan jullie. Renée, ik vond het een eer jouw paranimf 
te mogen zijn en vind het erg leuk dat we nu weer collega’s zijn bij de neurologie. Lotte, 
mijn buddy, het grootste deel van mijn promotie zat jij aan mijn zijde, het kan dan ook 
niet anders dan dat jij wederom aan mijn zijde staat tijdens mijn promotie. Bedankt dat 
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je mijn paranimf wil zijn. Ik hoop dat ik je nog veel ga zien, ook na mijn promotie. Jasper, 
Sirwan en Tavia, jullie waren ook aangenaam gezelschap op de kamer! Tavia, you are the 
coolest Welsh person I’ve ever met ;-)
Lotte, Hazel, Shiro en Joost, bedankt voor alle gezelligheid en grappen tijdens de 
master-meuk borreltjes en alle courses van de NIHES master. Deze waren soms bijzonder 
nodig om door de taaie stof van sommige skill courses heen te komen. Tavia, Frank en 
Daniel, bedankt voor de goede gesprekken en gezellige avondjes met hamburgers, 
spare-ribs, drankjes, fifa of beerpong! Vincent, bedankt voor de tijd die je voor me uit-
trok in mijn eerste maanden, om me op weg te helpen toen ik nog op de 22e in het 
oude gebouw zat, en later om me dingen bij te brengen over ADL en over gait. Frank 
en Sirwan, bedankt voor de gezelligheid tijdens onze trip door de bergen van Canada 
aansluitend op de AAN. Ook mijn collega’s van de neuromusculaire onderzoeksgroep 
heel erg bedankt voor jullie input en gezelligheid tijdens de wekelijkse lunches (bedankt 
Marieke!) en etentjes. Willem-Jan, Bianca, Christine, Joyce, Carina, en Marieke, bedankt 
voor alle lol tijdens onze avonturen op verschillende congressen. Ik kijk uit naar juli, dan 
kunnen we het nog een keer overdoen!
Lieve vrienden, Joris, Niels, Kelly en Jeff. Sinds de brugklas zijn er over de jaren heen 
regelmatig mensen komen aanwaaien en weer verdwenen, maar wij zijn de harde 
kern van onze groep. Op jullie kan ik altijd bouwen, eigenlijk zijn jullie gewoon familie. 
Bedankt voor de welkome afleidingen tijdens mijn promotie zoals borreltjes, etentjes, 
feestjes, en weekendjes weg. Daniël, Hulya, Cigdem, Gijs en Deniz, ook jullie bedankt 
voor al het plezier dat we hebben beleefd in café de Waard en de tijd daarna. Jammer dat 
we elkaar niet zo vaak meer zien, daar moeten we wat aan veranderen! Henri, bedankt 
voor de tochtjes samen op de racefiets. Jammer dat je nu zo ver weg woont. We moeten 
nog steeds een nieuwe fietstocht plannen. Daphne en Paul, ook al zien we elkaar niet 
meer zo vaak, de jaarlijkse Sinterkaasfondue blijft altijd erg gezellig, bedankt daarvoor!
En dan, niet te vergeten, mijn familie. Papa en mama, al mijn hele leven staan jullie voor 
me klaar en hebben jullie ervoor gezorgd dat ik alles kon doen wat ik wilde doen. Jul-
lie steunen mij in alles wat ik doe en proberen altijd een helpende hand te bieden. Ik 
ben jullie heel erg dankbaar voor alles en het doet mij deugd om jullie nog meer trots 
te maken dan dat jullie al waren. Lauri en Wouter (en Evy!), bedankt voor de gezellige 
avondjes Wie is de Mol, etentjes, spelletjes en andere welkome afleidingen tijdens mijn 
onderzoeksperiode. Lauri, samen verhuisden we naar Rotterdam en studeerden we 
Geneeskunde. Ik vind het mooi om deze promotie toch ook nog een beetje samen te 
kunnen doen met jou als mijn paranimf. Bedankt voor alles.
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Gerard, Mariet en Joris, bedankt dat jullie mij zo warm hebben ontvangen in jullie 
familie en bedankt voor de interesse die jullie toonden in de voortgang van mijn on-
derzoek.
Tenslotte, Mirjam, bedankt dat je ruim twee jaar geleden voor mij naar Rotterdam 
bent verhuisd en dat je er altijd voor mij bent. Dank je dat jij mij gelukkig maakt, elke 
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